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The central molecule in this thesis is the diterpene glycoside Fusicoccin (FC). FC is produced 
by the fungus Phomopsis amygdali (formerly known as Fusicoccum amygdali Del.) from 
which more than 19 fusicoccin derivatives have been isolated up to now (Muromtsev, 
Voblikova, et al., 1994; Sassa, Tajima, et al., 2002; Tajima, Nukina, et al., 2004). The fungus 
infects peach and almond trees, in which the secreted FC stabilizes the complex formed 
between the C-terminal tip of the plasma membrane H
+
-ATPase and a 14-3-3 protein 
(Korthout and De Boer, 1994; Baunsgaard, Fuglsang, et al., 1998; Wurtele, Jelich-Ottmann, et 
al., 2003). This irreversibly activates the H
+
-ATPase and opens the stomata, resulting in 
uncontrolled water loss and the wilting of the tree. Although the fungus is host specific, FC is 
not. Furthermore, FC is not only active on all higher plants, but on other organisms as well as 
it has also been shown to randomize the left-right asymmetry early during the Xenopus laevis 
embryonic development (Bunney, De Boer, et al., 2003). 
In this thesis we analyzed the affect of FC on cancer cells. In general, we studied the effect 
of FC on cancer cell growth, determined its general mode of action and tried to identify the 
cellular receptor of FC. 
In chapter 1 the importance of protein-protein interactions (PPIs) are described together 
with the potential of their targeting by small molecules as a new therapeutic approach in 
cancer therapy. Mode-III 14-3-3 targets are put forward as potential new therapeutic targets, 
as their interaction leaves an empty cavity in the 14-3-3 binding groove that can be targeted 
by small molecules. For some mode-III 14-3-3 interactions it is already known that this cavity 
can be filled up by small molecules like Fusicoccin (FC), and FC together with other 
fusicoccanes (molecules with the same core structure) belong therefore to a group of small 
molecules with a potential as new anticancer drugs. 
In chapter 2 we study the effect of the natural occurring fusicoccanes Fusicoccin-A (FC), 
Ophiobolin-A (OPH-A) and Ophiobolin-I (OPH-I) on various tumor cell lines, and show that 
both FC and OPH-A inhibit tumor cell growth efficiently. The efficacy of FC can be 
enhanced by combining it with the cytokine Interferon-α (IFNα) and IFNα primes the tumor 
cells for apoptosis induction by FC, in which DR4 and the TRAIL pathway plays an 
important role. Furthermore, healthy cells (HUVECs, Human Umbilical Vein Endothelial 
Cells) are far less sensitive to IFNα/FC treatment, what indicates that the IFNα/FC treatment 
is a promising new cancer therapy, especially when IFNα and FC are used sequentially.  
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Chapter 3 analyzes the ion channels present in the OVCAR3 ovarian carcinoma cell 
membrane by whole cell patch clamping. These cells mainly express K
+
 channels, although a 
small Na
+
 current was identified as well. The K
+
 current is sensitive to the extracellular Ca
2+
 
and Mg
2+
 concentration and pH, what indicates that OVCAR3 cells functionally express 
TASK K
+
 channels. When mannitol based buffers are used, we observe a current composed of 
different kinetic characteristics that can be divided into an instantaneous current component, a 
time dependent activating current component, and large voltage-dependent single channel 
openings with a slope conductance of 93 pS. 
Chapter 4 focuses on the TASK/14-3-3 interaction and the effect of FC on this interaction. 
We show that TASK proteins are able to interact with 14-3-3 proteins when their penultimate 
S is phosphorylated and that FC enhances the affinity of this interaction up to 7 times. 
Expression analysis shows that TASK1 (and possibly TASK5) is expressed in OVCAR3 cells 
and we identified a TASK-like current in OVCAR3 cells. In one batch of OVCAR3 cells, FC 
inhibits most of this TASK current (in a 14-3-3 dependent manner) and in IFN  treated cells 
FC inhibits an extra K
+
 current as well, what can explain the apoptosis induction and the 
IFN /FC synergy described in Chapter 2. 
Because the FC receptor involved in the apoptosis induction is not known we used a 
proteomics approach to identify it in chapter 5. FC-coated beads (FC-Beads) were used to 
pull-down the FC receptor from a whole cell lysate from MCF7 and OVCAR3 cells. Mass 
spectrometry analysis identified many proteins, both on the FC-Beads and eluted by the R18 
peptide, amongst which are 21 proteins with a C-terminal tip that should allow for               
FC receptor complex formation. None of these 21 proteins has been shown before to interact 
with 14-3-3 proteins by their C-terminal tip but interesting candidates are amongst others 
PMCA1 (a Ca
2+
-ATPase known to interact with 14-3-3 proteins by an N-terminal motif), 
PABPC1 and STAT1 based on their cellular functions. 
Chapter 6 explores the estrogen receptor  (ER ) as FC receptor in ER
+
 MCF7 breast 
cancer cells. We show that the extreme C-terminal tip of ERα interacts with 14-3-3 proteins, 
involving a mode-III 14-3-3 binding motif. A T
594
A mutation that prevents 14-3-3 binding 
and enhances the estradiol induced ERα dimerization as well as the transcriptional activity of 
the receptor. Moreover, FC stabilizes the ERα/14-3-3 interaction, binds endogenous ERα and 
14-3-3 from MCF7 cells and reduces the estradiol induced ERα activity in vivo. This study 
thereby provides a mechanism underlying the role of the F-domain in regulating receptor 
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dimerization and activity and offers a novel treatment option for ER
+
 breast cancer by using 
FC. 
Finally all the results described in this thesis are summarized in an English summary and a 
Dutch samenvatting. 
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Abstract 
 
Protein-protein interactions (PPIs) regulate almost every cellular process, and form thereby an 
important group of targets for the development of new anticancer therapies. We propose the 
stabilisation of C-terminal mode-III based 14-3-3 PPIs by active small molecules belonging to 
the fusicoccane family. Several fusicoccanes are known to selectively modify PPIs and some 
have already been shown to hamper cancer cell growth. Most human fusicoccane targets are 
unknown, but are likely to involve mode-III containing 14-3-3 targets and may have great 
potential as targets for the development into new anticancer treatments, as they play key roles 
in many important cellular processes. 
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Targeting Protein-Protein Interactions (PPIs) as therapeutic strategy against cancer 
Protein-protein interactions (PPIs) are involved in the regulation of all cellular processes and 
many diseases, including cancer. Several research groups therefore suggested that the 
selective targeting/modulation of PPIs could be a promising new strategy for anticancer 
therapies. Some suggest to inhibit PPIs, while others postulate the potential of stabilizing PPIs 
as a therapeutic approach (Berg, 2003; Zinzalla and Thurston, 2009). Various new search 
programs, like iPred and ANCHOR, have been developed over the last couple of years to 
identify targetable PPIs (Meireles, Domling, et al., 2010; Geppert, Hoy, et al., 2011). Others 
combined (existing) programmes and aim at the identification of targetable PPIs together with 
the small molecules that can be used for the targeting (Davis and Sali, 2010; Davis, 2011). In 
general, most programs focus on the identification of amino acids or ‘hotspots’ in a protein 
sequence that are located on the PPI interface and are crucial for the PPI (Ofran and Rost, 
2007; Geppert, Hoy, et al., 2011), while some others aim at the identification of ‘anchor sites’ 
or drugable pockets in the PPI surface based on PDB protein complexes (Fuller, Burgoyne, et 
al., 2009; Meireles, Domling, et al., 2010). Both methods identify sites that can be targeted by 
small molecules to selectively interfere with PPI formation. However, to successfully prevent 
a PPI the targeting of a single ‘hotspot’ or ‘anchor site’ is most often not enough as they 
frequently lack sufficient secondary structure or a large enough cavity to be successfully 
targeted by small molecules. To overcome this problem most compounds therefore 
simultaneously target several important residues/sites that are located in close proximity of 
each other, adding another challenge to the identification of targetable PPIs. 
When the search for targetable PPIs is coupled to the identification of small molecule 
inhibitors/stabilizers, there are some extra limitations for the now available search programs. 
Not only is the use of a reliable search algorithm challenging, but also the availability of 
existing compounds in drug libraries is limiting. There is a large structural variety in available 
natural compounds, but the existing drugs and compounds in drug libraries are structurally 
rather similar and leave a large group of compounds/structures underrepresented and therefore 
inaccessible for most screens (Bauer, Wurst, et al., 2010). It has even been estimated that 
about 83% of the unique core ring scaffolds present among natural products is completely 
absent from the available databases (Hert, Irwin, et al., 2009), and it is therefore difficult to 
rely only on search programs for the identification of targetable PPIs and their modifiers in 
general. 
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Natural small molecules and their use as anticancer drug 
Some small molecules that are used in preclinical as well as clinical studies influence PPIs of 
the Bcl-2 protein family of anti-apoptotic proteins (Azmi and Mohammad, 2009). Several 
compounds have been identified that target the hydrophobic binding pocket, which forms the 
BH3 binding site in Bcl-2, and prevent thereby the hetero-dimerization of Bcl-2 with         
pro-apoptotic members and thereby the induction of apoptosis. Another well known example 
are the nutlins (cis-imidazoline analogs) that target the p53/MDM2 interaction (Vassilev, Vu, 
et al., 2004). These compounds bind selectively to MDM2 and prevent thereby the interaction 
with p53 and enhance the activity of the p53 pathway. Interestingly, healthy wild-type p53 
cells retained their viability when treated with these nutlins, while wild-type p53 expressing 
cancer cells are killed (Vassilev, Vu, et al., 2004; Dudkina and Lindsley, 2007). Besides these 
examples many other small molecules are known that prevent PPIs that are beneficial in the 
treatment of cancer (Fletcher and Hamilton, 2007). However, so far not many small molecules 
are known that affect cancer cells by stabilizing PPIs. 
In recent years several reviews have been published about the isolation of (novel) natural 
compounds and active small molecules with an anticancer activity from various sources 
(Desai, Qazi, et al., 2008; Mayer and Gustafson, 2008; Kinghorn, Chin, et al., 2009; Mothana, 
Kriegisch, et al., 2011). Plants supplied several of these compounds while other anticancer 
drugs have been isolated from marine organisms and microorganisms, like fungi. Although 
the working mechanism of many active small molecules is not yet (completely) clarified, 
most new compounds have been shown to belong to diverse structural classes, including 
polyketides, terpenoids, terpenes, alkaloids, and steroids (Mayer and Gustafson, 2008; 
Bishayee, Ahmed, et al., 2011; Mothana, Kriegisch, et al., 2011) and to influence PPIs. 
Furthermore, many drugs (> 60%) that are currently used in cancer treatment are derived from 
natural occurring small molecules, either directly or indirectly. Paclitaxel (taxol) is, for 
instance, isolated from the bark of the Pacific yew tree Taxus brevifolia (Schiff and Horwitz, 
1980) and the vinca alkaloids vinblastine and vincristine are isolated from the Madagascar 
periwinkle Catharanthus roseus (Cragg and Newman, 2005). 
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Fusicoccanes, an interesting group of active small molecules 
Fusicoccanes are a large group of active small molecules that belong to the terpenoids. They 
have a typical dicyclopenta[a,d]cyclooctane skeleton (5-8-5 core ring structure), to which 
various side chains are linked (Muromtsev, Voblikova, et al., 1994). They are found 
throughout nature and are amongst others produced by various fungi, higher plants, 
liverworts, and even insects. A number of biological effects have been described for 
fusicoccanes on both plants and other organisms (De Boer and De Vries-van Leeuwen, 2012), 
and several of them are caused by the selective targeting of a particular protein or PPI. Some 
well-studied fusicoccanes are Fusicoccin-A (FC), Cotylenin-A (Cot-A), and Ophiobolin-A 
(OPH-A) (Figure 1). 
Fusicoccin-A was first described in 1964 by Ballio et al. (Ballio, Chain, et al., 1964), and is 
produced by the fungus Phomopsis amygdali (formerly known as Fusicoccum amygdali Del.) 
from which more than 30 fusicoccin derivatives have been isolated, among which at least     
16 natural derivatives (Figure 2) (Ballio, Demichelis, et al., 1981; Ballio, Federico, et al., 
1981; Muromtsev, Voblikova, et al., 1994; Priede, Krasnopolskaya, et al., 1997; Sassa, 
Zhang, et al., 1999; Sassa, Tajima, et al., 2002; Tajima, Nukina, et al., 2004). The fungus 
infects peach and almond trees, in which the secreted FC stabilizes the complex formed 
between the C-terminal tip of the plasma membrane H
+
-ATPase and a 14-3-3 protein 
(Korthout and De Boer, 1994; Baunsgaard, Fuglsang, et al., 1998; Wurtele, Jelich-Ottmann, et 
al., 2003). This stabilization irreversibly activates the H
+
-ATPase, what drives the opening of 
Figure 1. Chemical structure of Fusicoccin-A, Cotylenin-A and Ophiobolin-A. 
Fusicoccanes as potential anticancer drugs by targeting mode-III based 
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stomata, resulting in uncontrolled water loss and the wilting of the tree. Although the only 
known FC target in plants is the H
+
-ATPase, at the cell and organ level FC affects a range of 
different processes, like opening the stomata, breaking seed dormancy, inducing an apoptotic 
like cell death in sycamore cells (Malerba, Cerana, et al., 2003; Malerba, Crosti, et al., 2003), 
and reducing the hydrogen peroxide and nitric oxide production in guard cells (She, Huang, et 
al., 2010; She, Li, et al., 2010). Many of these processes can be (in)directly explained by the 
activation of the H
+
-ATPase while others suggest the presence of another FC target. FC is not 
only active on all higher plants, but on other organisms as well. It randomizes, for instance, 
the left-right asymmetry early in the Xenopus laevis embryonic development (Bunney, De 
Boer, et al., 2003) and induces apoptosis in cancer cells derived from different origins, for 
which the efficacy of FC can be enhanced by combining it with the cytokine interferon  
(IFNα) (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). 
Cotylenin-A was first described by Sassa, who discovered it in a fungal culture filtrate of 
Cladosporium sp. and described its growth enhancing effect on plant cotyledons (Sassa, 
1970). The structure of Cot-A is rather similar to that of FC, and comparisons made on their 
effects in plants show that both molecules have similar physiological effects (Muromtsev, 
Voblikova, et al., 1994). In some cases FC is more potent (e.g. induction of seed germination 
and wilting of tomato cuttings), while Cot-A is more effective in others (e.g. stomatal opening 
and cotyledon elongation). Besides this, Cot-A has been shown to induce differentiation in 
human myeloid leukemia cells (Asahi, Honma, et al., 1997) and inhibits the growth of various 
tumor types both in vitro and in vivo when combined with IFNα or rapamycin (Honma, Ishii, 
et al., 2003; Honma, Kasukabe, et al., 2005; Kasukabe, Okabe-Kado, et al., 2005). 
Ophiobolins (OPHs) are produced by plant pathogenic fungi belonging to the Bipolaris 
species. Currently 23 analogs have been identified, to which various biological activities are 
ascribed that are all damaging to plants either directly or indirectly (Au, Chick, et al., 2000). 
Besides being harmful for plants, OPHs also possess anti-microbial activities as well as a 
toxicity towards animals and even cancer cells (Shen, Krasnoff, et al., 1999). The working 
mechanism of most OPHs is not completely clear and probably differs per analog. OPH-A, 
however, has been shown to mainly function through the specific inhibition of calmodulin, an 
important signalling molecule (Leung, Taylor, et al., 1984; Au and Leung, 1998). 
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Figure 2. Chemical structure of most natural Fusicoccin derivatives. 
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Anticancer effects have been described for several fusicoccanes, including FC, Cot-A and 
OPH-A (Shen, Krasnoff, et al., 1999; Au, Chick, et al., 2000; Honma, Ishii, et al., 2003; 
Honma, Kasukabe, et al., 2005; De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). All 
show a clear growth reduction at relatively low concentrations (IC50-value mostly in the μM 
range, depending on the cell line). Although the tumor selectivity differs per molecule, with 
some being relatively cancer selective while others are indiscriminate and kill healthy cells as 
well as cancer cells, fusicoccanes form an interesting group of potentially new anticancer 
compounds. The working mechanism of most fusicoccanes in inhibiting the cancer cell 
growth is not yet clear. OPH-A most likely acts through the selective inhibition of calmodulin 
by binding covalently to calmodulin with its C7-aldehyde group (Au, Chick, et al., 2000). FC 
and Cot-A both lack this aldehyde group, suggesting that these compounds function through a 
different cellular target. When combined with IFN , FC and Cot-A both induce apoptosis by 
the induction of the TRAIL pathway (Honma, Ishii, et al., 2003; De Vries-van Leeuwen, 
Kortekaas-Thijssen, et al., 2010), however, this is most likely the final effect of the combined 
treatment and the primary target of both compounds is therefore still unknown. 
 
14-3-3 based PPIs are regulated by fusicoccanes 
Taking the targeting of the plant H
+
-ATPase by fusicoccanes as a lead (Wurtele, Jelich-
Ottmann, et al., 2003; Ottmann, Weyand, et al., 2009) we hypothesize that these compounds 
also target PPIs in which 14-3-3 proteins are involved in humans. 14-3-3 proteins are a family 
of homologous adapter proteins present in all eukaryotic organisms. They interact with over 
300 human proteins (Meek, Lane, et al., 2004; Pozuelo Rubio, Geraghty, et al., 2004; Asher, 
Khan, et al., 2010) and regulate thereby several important cellular functions, ranging from cell 
cycle regulation, apoptosis induction and prevention, to protein synthesis and trafficking 
(Aitken, 2006; Morrison, 2009). Most 14-3-3 targets interact through a phosphorylated 
internal mode-I (R/KXXpS/pTXP) or mode-II (R/KXXXpS/pTXP) binding motif, while some 
other targets interact with a C-terminally located mode-III binding motif (pS/pTX1-2-COOH) 
(Aitken, 2006; Coblitz, Wu, et al., 2006). The potential of 14-3-3 PPI stabilisation by small 
molecules as an anticancer treatment was already suggested in 2003 (Hermeking, 2003) and 
especially mode-III targets form a group of interesting proteins, as their interaction leaves an 
empty cavity in the 14-3-3 binding groove that can be targeted by fusicoccanes. 
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The best known example of a mode-III 14-3-3 target interaction that can be stabilized by 
fusicoccanes is the interaction described afore of the plant plasma membrane H
+
-ATPase with 
14-3-3 proteins. FC fits in the 14-3-3 binding groove next to the ultimate C-terminal tip of the 
H
+
-ATPase and enhances the H
+
-ATPase/14-3-3 affinity thereby 90-times (Wurtele, Jelich-
Ottmann, et al., 2003). This enhanced 14-3-3 binding eventually causes the wilting of the tree, 
what indicates that the selective stabilisation of a 14-3-3 based PPI by a small molecule can 
have a dramatic affect on an organism as a whole. 
 
 
 
 
 
Human mode-III 14-3-3 interactions: putative cancer therapy targets 
Not only the plant H
+
-ATPase/14-3-3 interaction is enhanced by FC, but also the interaction 
between 14-3-3 proteins and a human mode-III target: the glycoprotein Ib  subunit of the 
glycoprotein Ib-IX-V complex in human platelets (Du, Fox, et al., 1996; Camoni, Di Lucente, 
et al., 2011). In this, FC again enhances the binding affinity of 14-3-3 protein with the 
glycoprotein Ib  subunit, and stimulates thereby platelet aggregation and their adhesion to 
von Willebrand factor (vWF), an important step in hemostasis. This suggests that the 
stabilisation of mode-III 14-3-3 interactions is most likely a general mode of action for FC. 
Other human mode-III 14-3-3 targets include the cyclin-dependent kinase inhibitor p27
Kip1
, 
the TASK1 and TASK3 K
+
 channels, and the G protein-coupled receptor GPR15. p27
Kip1
 
interacts with 14-3-3 proteins when phosphorylated at its ultimate threonine (T
198
) by Akt or 
the p90 ribosomal protein S6 kinase (Fujita, Sato, et al., 2002; Fujita, Sato, et al., 2003). This 
interaction enhances the cytoplasmic localization of p27
Kip1
 and stimulates thereby cell cycle 
progression. 14-3-3 binding to the C-terminal tip of TASK1 and TASK3 is necessary for the 
Table 1. Effect of FC on known mode-III 14-3-3 targets. 
Positively charged amino acids are indicated in bold; n.d. = not determined. 
Fusicoccanes as potential anticancer drugs by targeting mode-III based 
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forward transport of these K
+
 channels from the endoplasmatic reticulum (ER) to the plasma 
membrane (O'Kelly, Butler, et al., 2002; Rajan, Preisig-Muller, et al., 2002). In this, the      
14-3-3 binding is phosphorylation dependent and overrules ER retention by preventing the 
interaction of -COP with a di- or tribasic motif (KR or KRR), present in the C-terminus of 
the TASK proteins (O'Kelly, Butler, et al., 2002; Zuzarte, Heusser, et al., 2009). 14-3-3 
binding to GPR15 has been linked to an enhanced surface expression of GPR15 as well 
(Chung, Okamoto, et al., 2009; Okamoto and Shikano, 2011). Again, a phosphorylation 
dependent 14-3-3 interaction releases GPR15 from the ER, for which the activation of the 
PI3K/Akt pathway has been shown to significantly enhance 14-3-3 binding and the GPR15 
cell surface expression. 
Interestingly, p27
Kip1
, TASK1, TASK3 and GPR15 all have 2 or more positively charged 
amino acids in their 14-3-3 interaction motif (indicated in bold in Table 1). These proteins 
thereby contain an interaction motif that is a combination between a mode-I/II and a mode-III 
motif. The H
+
-ATPase and glycoprotein Ib  have no charged residues in their interaction 
motif, but an interesting difference between them is that the conserved YTV-tip of the        
H
+
-ATPase is a HSL-tip in glycoprotein Ib  (Table 1). In plants the YTV-tip is conserved in 
all P-type H
+
-ATPases that are located at the plasma membrane as well as between species. 
Only AHA10 (in Arabidopsis or its homolog in Petunia) contains an HTV-tip and is located 
at the vacuolar membrane. Whether AHA10 is also controlled by 14-3-3 interaction, like all 
plasma membrane localized pumps, is not known. Since the main difference in the C-terminal 
tip of AHA10 is the histidine at the -3 position (instead of the tyrosine) we analyzed the effect 
of a Y to H mutation in a barley plasma membrane H
+
-ATPase (AHA3) and showed that this 
mutation abrogates the 14-3-3 binding of both barley 14-3-3B and human 14-3-3  (Figure 3). 
This indicates that a histidine at the -3 position in the plant ATPases is not compatible with 
14-3-3 binding (both plant and human). Intriguingly, glycoprotein Ib  also has a histidine at 
the -3 position, but does interact with 14-3-3 proteins and responds to FC (Camoni, Di 
Lucente, et al., 2011). Apparently, a histidine at -3 position can have different effects on 
different mode-III/14-3-3 targets. 
 
Putative human mode-III 14-3-3 interaction as new targets in cancer therapy 
Besides known mode-III target proteins, there is also a large group of human proteins      
(5770 proteins) that contain a putative mode-III motif (S/T at penultimate position). A further 
selection for putative mode-III targets that should allow for FC to fit in the 14-3-3 binding 
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groove (S/T at the penultimate position combined with a V, L or I at the ultimate position 
(Wurtele, Jelich-Ottmann, et al., 2003)) limits the number to potential targets to 873 proteins. 
Of these, 41 proteins (Table 2) contain an R at the -5 position as well; the presence of which 
should enhance the phosphorylation of the penultimate S/T necessary for 14-3-3 binding and 
also the affinity of the 14-3-3 interaction (Coblitz, Wu, et al., 2006; Smith, Daut, et al., 2011). 
Of these 41 proteins, 32% (13 proteins, including TASK1, TASK3 and GPR15) function at 
the plasma membrane. 
 
 
 
 
Especially the K
+
 channels form a group of interesting putative FC targets for the selective 
modulation in cancer therapy. In general, K
+
 channels are involved in the regulation of many 
cellular processes. They play important roles in controlling normal tissue homeostasis by 
regulating both cell growth and apoptosis and since they are deregulated in many diseases, 
including cancer, they are being acknowledged as potential therapeutic targets (Kunzelmann, 
2005; Lawson and McKay, 2006). When K
+
 channels interact with 14-3-3 proteins and FC, 
this can either activate or inactivate the channel. The enhanced 14-3-3 interaction caused by 
FC that is observed for TASK1 (Chapter 4) will most likely enhance the forward transport of 
TASK1 from the ER to the plasma membrane resulting in an enhanced TASK1 current and 
thereby an enhanced K
+
 efflux. In contrast, FC has been shown to inhibit an outward-
rectifying K
+
 channel in barley embryonic root cells (Van den Wijngaard, Sinnige, et al., 
2005). Although this are two different species, it indicates that FC can potentially both 
Figure 3. Interaction of the C-terminal domain of the plasma membrane H
+
-ATPase 
with barley 14-3-3-B and human 14-3-3- , as measured in a yeast two-hybrid assay. 
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activate and inhibit K
+
 channels. Changes in the K
+
 channel activity will affect the ion 
homeostasis of a cell in general, resulting in instable cells and most likely cell death. For 
TASK3, for instance, it has been observed that over-expression can both enhance cell survival 
as well as induce apoptosis (Pei, Wiser, et al., 2003; Patel and Lazdunski, 2004). In this, the 
cellular context seems to determine the outcome of the TASK3 over-expression, indicating 
that the final result of the change in activity caused by FC will also be dependent on the 
cellular context. As the cellular context often differs between cancer and healthy cells this 
difference could allow for the selectivity of the anticancer therapy. 
Besides the ion channels, other mode-III/FC targets are potentially interesting as well, 
because the selective modification of their function will most likely also affect the delicate 
cellular balance resulting in instable cells. Furthermore, FC is most likely not able to stabilize 
all mode-III 14-3-3 interactions. p27
Kip1
, for instance, possesses a 14-3-3 interacting             
C-terminal tip but does not contain any of the ultimate amino acids that support FC binding 
(Table 1, tip: LRRRQpT). The presence of different amino acids at the ultimate position 
(other than V, L or I) might allow for the modification/stabilization of these PPIs by 
fusicoccanes or small molecules other than FC A similar observation has, for instance, already 
been made for Cot-A which is also able to stabilize the interaction between 14-3-3 proteins 
and a mode-I peptide derived from Raf1 kinase (Ottmann, Weyand, et al., 2009). FC is not 
able to stabilize this interaction due to the presence of an OH-group at the C12 position of FC, 
which causes sterical hindrance with the +2 amino acid (Pro). This thereby expands the 
repertoire of PPIs that can be targeted by fusicoccanes, and supports the rational of the search 
for fusicoccanes that can be utilized to selectively modify PPIs in the therapeutic strategy 
against cancer. However, the wider spectrum of 14-3-3 PPIs that can be stabilized by some 
fusicoccanes will cause a reduced specificity in view of the large number of known mode-I/II 
targets, and the selectivity of the active small molecules therefore needs to be evaluated 
carefully. 
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Table 2. Putative human FC targets. 
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Conclusion 
 
Protein-protein interactions (PPIs) form a group of interesting targets for the development of 
new anticancer therapies by small molecules, as they are involved in the regulation of many 
important cellular processes. However, there are several limitations regarding the 
identification of targetable PPIs and small molecules by the currently available search 
programs and it is therefore necessary to rationally select PPIs that can be targeted in new 
cancer therapies. We propose here the potential of targeting mode-III 14-3-3 interactions by 
active small molecules that belong to the fusicoccane family. Fusicoccanes have already been 
shown to be able to selectively modify PPIs and some also hamper cancer cell growth. 
Several interesting (putative) mode-III 14-3-3 targets are present in humans, of which some 
have a high potency to be selectively targeted by fusicoccanes in new anticancer treatments. 
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Abstract 
 
Ion channels are involved in the regulation of many cellular processes. They are not only 
important for excitable cells, but also play an important role in controlling cell growth, 
development and apoptosis of other cell types through the regulation of the ion homeostasis. 
A de-regulation of ion channels can result in numerous diseases, including cancer, and due to 
their role in regulating tissue homeostasis they are being acknowledged as attractive targets 
for the development of therapeutic drugs. Here we made an inventory of the ion channels 
present in OVCAR3 ovarian carcinoma cells by whole cell patch clamping. These cells 
mainly express K
+
 channels with various different current characteristics/kinetics, although a 
small Na
+
 current was identified as well. The K
+
 current is, in general, enhanced by a 
reduction in the extracellular Ca
2+
 and Mg
2+
 concentration ([Ca
2+
/Mg
2+
]) and subsequently 
reduced upon lowering the extracellular pH, indicating the presence of acid sensitive channels 
of the TASK family. With mannitol based buffers a stable current was observed that contains 
an instantaneous current component, a time dependent activating component, and large 
voltage dependent single channel openings. All of which are affected by changes in the 
extracellular [Ca
2+
/Mg
2+
] and pH. Based on this analysis we conclude that OVCAR3 cells 
contain active TASK channels together with other K
+
 channels, with voltage dependent and 
large single channel characteristics, which we could not identify yet. 
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Introduction 
 
Ions are not uniformly distributed in cells, but concentration gradients exist between        
intra- and extracellular compartments. The major ion gradients across the plasma membrane 
are the gradients of potassium (K
+
), sodium (Na
+
), calcium (Ca
2+
) and chloride (Cl
-
) (Franco, 
Bortner, et al., 2006). The maintenance of these gradients depends on both (secondary) active 
and passive transport of ions. Primary active transport involves the pumping of ions against 
their concentration gradient using energy from ATP, whereas secondary active transport    
(co-transport) is coupled to another ion in a transporter and is driven by the electro-chemical 
potential difference of that ion. The transport of ions through ion channels is considered 
passive transport, where diffusion of the ions is driven by their electrochemical gradient. This 
gradient is made up by the concentration difference of the ion and the electrical membrane 
potential of the cell (Franco, Bortner, et al., 2006). Ion channels control the membrane 
potential (Vm) of a cell and regulate thereby several other important cellular parameters, like 
the cytosolic pH, the cell volume, the intracellular ion concentration, and even cell 
proliferation and apoptosis (Kunzelmann, 2005; Burg, Remillard, et al., 2006). 
Most cells have a high resting membrane permeability for K
+
 and this, together with the 
outwardly directed K
+
 gradient, results in the maintenance of a negative Vm close to the 
electrochemical equilibrium of K
+
 (Franco, Bortner, et al., 2006). K
+
 channels belong to a 
diverse class of ion channels. They can be divided into five main families, Kv, KCa, KIR, KATP, 
and K2P channels, and each of these families can be divided in sub-families based on their 
structure, regulation, and other general characteristics (Wang, 2004; Burg, Remillard, et al., 
2006). 
- Kv channels are voltage sensitive K
+
 channels that open upon membrane depolarization 
and can be blocked by 4-aminopyridine (4-AP). They are divided in 12 subfamilies and 
display diverse current characteristic caused by the association of a pore forming α-subunit 
with a modulatory β-subunit, as well as alternative splicing (Burg, Remillard, et al., 2006). 
- KCa channels are regulated by changes in the intracellular Ca
2+
 concentration and can be 
sub-classified based on their single channel conductance and pharmacological properties. 
Large conductance KCa channels (BKCa or maxi-KCa; > 200 pS) are regulated by direct 
Ca
2+
 binding to their intracellular C-terminal tail and are voltage dependent, like              
Kv channels. However, their voltage dependence is regulated by the intracellular [Ca
2+
] 
(Burg, Remillard, et al., 2006). Intermediate conductance KCa channels (IKCa; 50-200 pS) 
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and small conductance KCa channels (SKCa; 2-15 pS) are only weakly voltage dependent 
and require calmodulin binding to their C-terminal tail to regulate their Ca
2+
 sensitivity. 
- KIR channels are inwardly rectifying K
+
 channels, that are activated upon Vm 
hyperpolarization and elevated external [K
+
] (Doupnik, Davidson, et al., 1995).              
KIR channels can be divided into 7 subfamilies based on their sensitivity to endogenous 
signals. Some KIR channels are ATP sensitive (KIR1, KIR4, and KIR6) or gated by             
G-proteins (KIR3), while others (KIR2) are constitutively active (Doupnik, Davidson, et al., 
1995; Burg, Remillard, et al., 2006). 
- KATP channels are voltage independent K
+
 channels that are inhibited by intracellular ATP 
and activated by nucleotide diphosphates. They can be subclassified as intermediate        
(5-50 pS) or large (≥ 130 pS) conductance K+ channels. The ion-conducting part of KATP 
channels is the KIR6 subunit, which is linked to a sulfonylurea receptor (SUR) subunits to 
regulate the ATP sensitivity (Ho, Nichols, et al., 1993; Inagaki, Gonoi, et al., 1995). 
- K2P channels are K
+
 channels characterized by the presence of two pore domains and four 
transmembrane segments. Fifteen K2P channels have been identified so far, that can be 
divided into 6 subfamilies based on sequence similarity and functional resemblance (Burg, 
Remillard, et al., 2006; Enyedi and Czirjak, 2010). They are open at the resting Vm and are 
therefore also referred to as background or leak K
+
 channels. 
K
+
 channels have been shown to play important roles in the regulation of proliferation as well 
as apoptosis (Kunzelmann, 2005; Burg, Remillard, et al., 2006). The expression level of 
several K
+
 channels has been correlated to different stages of the cell cycle. Kv channels from 
the ether à go-go (EAG) family, for instance, are highly expressed in the early G1 phase 
(Wang, 2004; Kunzelmann, 2005), while the large (BKCa) and intermediate (IKCa) 
conductance KCa channel expression is enhanced in the late G1 and S phase (Ouadid-
Ahidouch, Roudbaraki, et al., 2004a; Ouadid-Ahidouch, Roudbaraki, et al., 2004b). This 
differential expression of K
+
 channels with different regulatory mechanisms results in Vm 
fluctuations that are necessary for cell cycle progression (Kunzelmann, 2005). The K
+
 channel 
activation causes an initial Vm hyperpolarisation that, amongst others, enhances the uptake of 
Ca
2+
 what results in a subsequent Vm depolarisation. In general, actively dividing cells, 
including cancer cells, have a depolarized Vm compared to terminally differentiated cells in 
the G0 phase (Kunzelmann, 2005). An enhanced K
+
 channel activity has also been linked to 
the induction of apoptosis. The increased K
+
 efflux is in this case thought to be followed by 
an efflux of Cl
-
 and water, resulting in an apoptotic volume decrease (AVD), which is one of 
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the first characteristics of apoptosis (Maeno, Ishizaki, et al., 2000; Burg, Remillard, et al., 
2006). The loss of intracellular K
+
 also allows for the activation of caspases and nucleases, 
that are needed for the progression of apoptosis (Montague, Bortner, et al., 1999). A reduction 
of the cell volume after K
+
 channel activation is observed during proliferation as well. 
However, here the volume decrease seems to be controlled and is observed after an initial cell 
swelling, facilitating a regulatory volume decrease (RVD) instead of AVD (Wang, 2004; 
Kunzelmann, 2005). Although the exact role of K
+
 channels in both proliferation and 
apoptosis is not completely understood, the K
+
 efflux observed during apoptosis largely 
exceeds the efflux during proliferation. Moreover, some K
+
 channels seem to have context 
dependent cellular functions. The K2P channel TASK3, for instance, has been shown to be 
over-expressed in various cancers and enhances thereby the oncogenic potential (Mu, Chen, et 
al., 2003), whereas its expression in other cells induces apoptosis (Lauritzen, Zanzouri, et al., 
2003; Patel and Lazdunski, 2004). This suggests that the oncogenic potential and exact role of 
TASK3, as well as other K
+
 channels in cells, is dependent on the cellular context (Wang, 
2004). 
Because of the accumulating evidence that tumor cells possess various types of                
K
+
 channels and the reports that K
+
 channels play important roles in the regulation of both 
(tumor) cell proliferation as well as apoptosis, they are attracting increasing interest as 
potential targets for cancer therapy or as biomarkers for diagnostic purposes (Wang, 2004; 
Lawson and McKay, 2006). In view of the induction of apoptosis in OVCAR3 cells by the 
small molecule ligand Fusicoccin (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010), 
and the reported effects of Fusicoccin on K
+
 channels in plant cells (Blatt and Clint, 1989; 
Van den Wijngaard, Sinnige, et al., 2005; MacRobbie and Smyth, 2010), we here first made 
an inventory of the ion channels present in the plasma membrane of the OVCAR3 ovarian 
carcinoma cell line by whole cell patch clamping. This showed that most of the OVCAR3 
current is outward and carried by K
+
 channels. Different total current characteristics were 
observed, with a clear contribution of a K
+
 current that is inhibited by high extracellular    
Ca
2+
 and Mg
2+
 concentration ([Ca
2+
/Mg
2+
]) and an acidification of the medium (pH 6.2). 
These responses are characteristic for TASK channels from the K2P family. Besides this, we 
observed large single channel events and a voltage sensitive time-dependent activating 
current, which were both also sensitive to extracellular [Ca
2+
/Mg
2+
] and pH changes. 
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Results 
 
Total membrane current of OVCAR3 cells at a glance 
With whole cell patch clamping the total plasma membrane current of OVCAR3 cells was 
analyzed. At first buffers were used that allow for the transport of the main ions of a cell;    
K
+
, Na
+
, and Cl
-
 as well as Ca
2+
 and Mg
2+
 (Table 1). In this configuration we mainly observed 
an instantaneously activated current (Figure 1A). At positive holding potentials above        
+30 mV ionic currents observed as well as below -70 mV. The I/V-plot of this total OVCAR3 
current shows an outward current at positive potentials and a smaller inward current at 
negative potentials (Figure 1B). Based on the Nernst potential (Vrev) and the ions present in 
the buffers the positive current is likely to be carried by a K
+
 efflux or Cl
-
 influx while the 
negative current is most likely carried by a Na
+
 influx or Cl
-
 efflux. However, part of the 
current might also be caused by a leak current, carried by “leak-channels” and/or the seal 
between measuring pipette and the membrane. Due to the high seal resistance (> G ) of all 
measurements included in the patch clamp analysis the contribution of the leak current is 
expected to be relatively low. However, it is hard to discriminate between the leak current and 
the current of instantaneous channels no leak correction has been applied. Therefore, part of 
the observed current in all measurements might be caused by a leak current. 
 
 
 
 
 
Table 1. Complete pipette and bath buffer composition     
(in mM), including Na
+
 free bath buffer. 
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Several ion channels, especially K
+
 channels, are affected by changes in the extracellular 
Ca
2+
 or Mg
2+
 concentration [Ca
2+
/Mg
2+
]. To see whether the OVCAR3 current responds to 
changes in the extracellular [Ca
2+
/Mg
2+
], the concentration of these divalent cations was 
reduced from 2 and 1 mM respectively to 0.1 mM in the bath buffer (low [Ca
2+
/Mg
2+
]). This 
reduction especially enhanced the current at a positive Vm (Figure 1C). Whereas the current 
activated instantaneously in the standard buffer, a (small) time dependent inactivation was 
observed for the low [Ca
2+
/Mg
2+
] buffer, which becomes more pronounced at higher 
potentials (Figure 1A). The observed ionic curents at positive holding potentials does not 
seem to be affected by the low [Ca
2+
/Mg
2+
] buffer, but no detailed/further analysis of this has 
been made. Nonetheless, these data demonstrate that low [Ca
2+
/Mg
2+
] activated channels are 
present in OVCAR3 cells. 
 
 
 
 
 
 
OVCAR3 cells possess active Na
+
 channels, but hardly a significant Cl
-
 current 
As indicated before, several K
+
 channels are affected by changes in extracellular [Ca
2+
/Mg
2+
]. 
However, before focusing on K
+
 channels we fist addressed whether active Na
+
 and Cl
-
 
channels are present in OVCAR3 cells and tried to determine their contribution to the total 
current as measured in Figure 1. To study the presence of Na
+
 channels we switched from the 
standard bath buffer to a Na
+
 free bath buffer, in which the NaCl was replaced by NMDG-Cl 
Table 2. NMDG-Gluconate pipette and bath buffer 
composition (in mM). 
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to only remove the Na
+
 ions and keep the amount of Cl
-
 ions constant (Table 1). This 
significantly reduced the inward current, especially at negative holding potentials (Figure 2A 
and 2B), indicating that Na
+
 channels are active in OVCAR3 cells and can be responsible for 
the observed negative/inward current. 
 
 
 
 
Some of the current traces with the total buffers showed large time-dependent inactivating 
currents (Figure 2C), resembling the kinetics of Volume-Sensitive Outwardly Rectifying 
(VSOR) channels. VSOR channels are swelling activated Cl
-
 channels that are involved in 
AVD, observed upon the induction of apoptosis (Jiao, Xu, et al., 2006; Okada, Shimizu, et al., 
2006). These channels show time dependent inactivating currents at holding potentials above 
+50 mV, which inactivate such that the total current hardly increases when analyzed for more 
than 600 ms. VSOR channels are inhibited by DIDS as well as other general Cl
-
 channel 
inhibitors, like tamoxifen and NPPB (Dick, Kong, et al., 1999; Okada, Shimizu, et al., 2006). 
Figure 1. OVCAR3 current analysis with complete bath and pipette buffer. (A) Representative whole 
cell current traces of the complete standard and low [Ca
2+
/Mg
2+
] bath buffer. (B) I/V-plot of the 
whole cell current observed with complete standard bath and pipette buffer (n = 8; average ± S.E.). 
Current was analyzed by stepping from -85 mV to +75 mV with 10 mV increments from a -65 mV 
holding potential. (C) Left: I/V-plot of the whole cell current observed with the complete standard 
(●) and low [Ca2+/Mg2+] ( ) bath buffer (n = 8; average ± S.E.), using the protocol of (B). Right: 
Low [Ca
2+
/Mg
2+
] activated current in OVCAR3 cells (= low [Ca
2+
/Mg
2+
] current - standard current). 
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However, the use of these inhibitors, or combinations thereof, did not block the total current 
significantly (data not shown). Therefore, the inactivating currents are not likely to be carried 
by VSOR channels, despite their resemblance in kinetics with the observed current. 
 
 
 
 
 
Figure 2. Whole cell Na
+
 and Cl
-
 current analysis. (A) Representative whole cell current traces of 
the complete standard and [Na
+
] free bath buffer. (B) Left: I/V-plot of the whole cell current 
observed with the complete standard (●) and [Na+] free ( ) bath buffer (n = 2; average ± S.E.). 
Current was analyzed by stepping from -90 mV to +80 mV with 15 mV increments from a            
-65 mV holding potential. Right: Na
+
 current in OVCAR3 cells (= standard current - [Na
+
] free 
current). (C) Whole cell current of the complete standard buffer, displaying a large                 
time-dependent inactivating current. 
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Analyzing the OVCAR3 K
+
 current 
To get an impression of the K
+
 channels that are active in OVCAR3 cells we changed our 
buffer compositions, omitting most of the Cl
-
 and all Na
+
, to allow almost exclusively for the 
transport of K
+
 (Table 2). With this NMDG-Gluconate buffer we observed several different 
types of currents (Figure 3A). Some cells displayed instantaneous currents while others had 
time dependent currents, which could both be time dependent activating or inactivating. 
Furthermore, some cells showed large single channel activity noticeable at positive potentials, 
while others did not. Part of this variation was dependent on the cell culture conditions as 
more cells with (fast) inactivating currents were, for instance, observed upon very regular 
passing, but also the exact buffer composition and the compound used to balance the 
osmolarity with influenced the observed current. Balancing the osmolarity with mannitol 
(Table 3) resulted in more stable currents, and cells measured with these buffers diplayed time 
dependent activating currents with large single channel openings at a positive Vm         
(Figure 3B). 
 
 
 
 
 
 
 
Table 3. Mannitol pipette and bath buffer composition 
(in mM). 
* For the low pH (6.2) buffer the pH was adjusted by HCl. 
Less NMDG Cl was used to compensate for the extra Cl
-
. 
Ion channels in OVCAR3 ovarian cancer cells 
 
 
 
61 
 
The I/V-plots of these K
+
 measurements show mainly an outward current for both the 
NMDG-Gluconate (Figure 4A) as well as the mannitol (Figure 4B) based buffers. Again a 
reduction of the extracellular [Ca
2+
/Mg
2+
] to 0.1 mM enhances the outward current, indicating 
that the low [Ca
2+
/Mg
2+
] activated channels in the total buffer (Figure 1C) are most likely    
K
+
 channels. However, no clear change in current characteristic was observed upon changing 
the extrcellular [Ca
2+
/Mg
2+
], like for the total buffers (data not shown). 
As different whole cell currents were observed with the NMDG-Gluconate buffers, in 
contrast to the mannitol based buffers, we subsequently only used the mannitol buffers. 
 
 
 
 
 
Figure 3. Whole cell K
+
 current observed with different buffers. (A) Representative example of 
the different whole cell K
+
 current types observed with the NMDG-Gluconate standard buffer.  
(B) Representative example of the whole cell K
+
 current observed when mannitol was used to 
balance the osmolarity (mannitol standard buffer). 
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Some K
+
 channels that are activated by low extracellular [Ca
2+
/Mg
2+
] are the TASK 
channels (e.g. TASK1 and TASK3), from the K2P family. These channels are amongst others 
also regulated by other divalent cations, volatile anesthetics and changes in the extracellular 
pH within the physiological range; pH reduction reduces the channel activity (Duprat, Lesage, 
et al., 1997; Talley and Bayliss, 2002; Bayliss, Sirois, et al., 2003). TASK1 has a pK of 
7.3~7.6 and TASK3 of 6.5~6.7, although these values differ depending on the extracellular K
+
 
concentration (Morton, O'Connell, et al., 2003). To test if TASK channels underlie the low 
[Ca
2+
/Mg
2+
] activated current in OVCAR3 cells we analyzed the effect of an extracellular pH 
reduction to pH 6.2 on the low [Ca
2+
/Mg
2+
] activated current. The low pH buffer completely 
abrogated the low [Ca
2+
/Mg
2+
] activated current (Figure 4B), suggesting that TASK channels 
are active in OVCAR3 cells. An expression analysis confirmed the presence of TASK1 (and 
TASK5) mRNA as well as the TASK1 protein in OVCAR3 cells (Chapter 4, Figure 4). 
However, no TASK3 transcript or protein could be detected, indicating that TASK1 can cause 
the low [Ca
2+
/Mg
2+
] and pH sensitive current. 
 
Single K
+
 channel analysis 
Besides TASK1 other K
+
 channels have to be present in OVCAR3 cells as well. This because 
TASK1 is known to be an instantaneously activating channel while we also observe an 
activating current component and since part of the K
+
 current is not blocked at pH 6.2, while 
TASK1 is almost completely blocked at pH 6.2 (Duprat, Lesage, et al., 1997; Rajan, Preisig-
Muller, et al., 2002). To get an impression about other K
+
 channels that can be present in 
OVCAR3 cells we examined the current in the mannitol buffer more closely. The whole cell 
current contains different kinetic characteristics. It can be divided in an instantaneous 
component, a time dependent (activating) component and large single channel openings 
(Figure 3B). I/V-plots of these separate components show that the instantaneous current 
component is almost linear while the time dependent current component is slightly rectifying 
and voltage gated, as it is only present at a depolarized Vm (Figure 5A). Both the 
instantaneous and the time dependent components are activated by a reduction of the 
extracellular [Ca
2+
/Mg
2+
] and blocked by a subsequent pH reduction. However, the low 
[Ca
2+
/Mg
2+
] induced current increase of the time dependent component is almost 3 times      
(± 2.8x increase), while the instantaneous component is not even doubled (± 1.6x increase). 
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The large single channel openings are voltage dependent as well, and only observed at a 
positive Vm (≥ 0 mV). An increase in Vm increases the open state frequency, as does a 
reduction of the extracellular [Ca
2+
/Mg
2+
] (Figure 5B). A subsequent reduction of the 
extracellular pH again counteracts the low [Ca
2+
/Mg
2+
] induced activation and lowers the 
open state frequency back to the level of the standard buffer. The low [Ca
2+
/Mg
2+
] buffer does 
not influence the voltage dependence, nor does the low pH (6.2) buffer. The single channel 
Figure 4. Analysis of the K
+
 current with observed with NMDG-Gluconate and mannitol based 
buffers. (A) Left: I/V-plot of the whole cell current observed with the NMDG-Gluconate standard 
(●) and low [Ca2+/Mg2+] ( ) bath buffers (n = 11; average ± S.E.). Currents were analyzed by 
stepping from -97 mV to +69 mV with 15 mV increments from a -77 mV holding potential. Right: 
Low [Ca
2+
/Mg
2+
] activated current. (B) Left: I/V-plot of the whole cell current observed with the 
mannitol standard (●, n=7), low [Ca2+/Mg2+] ( , n=7), and low pH (6.2) (■, n=5) bath buffers 
(average ± S.E.). Currents were analyzed by stepping from -102 mV to +78 mV with 20 mV 
increments from a -82 mV holding potential. Right: Low [Ca
2+
/Mg
2+] activated current (●), and 
low pH (6.2) inhibited current ( ; = low [Ca
2+
/Mg
2+
] current - low pH (6.2) current). 
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activity has a slope conductance of 93 pS (± 1.7, Figure 5C), which is not significantly 
affected by changes in the extracellular [Ca
2+
/Mg
2+
] or pH (data not shown). 
 
 
 
 
 
Figure 5. Detailed analysis of the different currents observed with the mannitol buffers. (A) I/V-plot 
of the instantaneous current component (left), and time dependent activating current component 
(right) observed with the mannitol standard (●), low [Ca2+/Mg2+] ( ), and low pH (6.2) (■) bath 
buffers. Currents were analyzed as described for Figure 4B. The instantaneous current component 
represents the average current in the first 0.5 ms of the each pulse after the capacitance peak. The 
time dependent activating current component is the average current increase observed from 
instantaneous current to the last 10 ms of each pulse, excluding the single channel current.              
(B) Representative single channel recording observed with the mannitol standard (●),                     
low [Ca
2+
/Mg
2+
] ( ), and low pH (6.2) (■) bath buffers at +58 mV, including amplitude histogram at   
+18 mV and +58 mV. (C) I/V-plot of the single channel current with the mannitol standard bath 
buffers from -2 to +58 mV. The calculated slope conductance is 93 pS (±1.7). 
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Discussion 
 
K
+
 channels are not only important in excitable cells, but also play an important role in the 
survival and functioning of non-excitable cells. They control the membrane potential (Vm) 
and thereby cell proliferation and apoptosis as indicated before. A dysfunctioning of            
K
+
 channels has been linked to many diseases, including cancer, although the exact role of 
most of these channels is not known. Nevertheless, ion channels, and in particular                
K
+
 channels, are attracting increasing attention as therapeutic target. Their modulation by 
selective agents would change the ion balance of a cell, and thereby the stability of the cell 
itself (Lawson and McKay, 2006). The use of K
+
 channel modulators, for instance, has shown 
that voltage dependent Kv channels are important for the proliferation of ovarian carcinoma 
cell lines (Zhanping, Xiaoyu, et al., 2007; Asher, Khan, et al., 2010) and a knockdown of 
KIR2.2 expression induces a growth arrest in several cancers from different origins (Lee, Park, 
et al., 2010). Our analysis of the ion channels present in OVCAR3 ovarian carcinoma cells 
showed that K
+
 conducting channels are prominently present. A small Na
+
 current is observed 
as well, but no significant Cl
-
 current was detected. The K
+
 current is enhanced by a reduction 
of the extracellular [Ca
2+
/Mg
2+
], which is a known characteristic of several K
+
 conducting 
channels, like the TASK channels and TRPV3 (Musset, Meuth, et al., 2006; Xiao, Tang, et 
al., 2008). TASK channels are acid sensitive background K
+
 channels, as indicated before. 
They show an outward rectification (dependent on the extracellular [K
+
]), are voltage 
independent and characterized by an (almost) instantaneous channel activation (Lopes, 
Gallagher, et al., 2000; Bayliss, Sirois, et al., 2003). Our analysis indicates that these channels 
(most likely TASK1 channels) are active in OVCAR3 cells and are likely responsible for 
most of the [Ca
2+
/Mg
2+
] and pH sensitive part of the K
+
 current. 
When mannitol based buffers were used we observed a current with several different 
kinetic characteristics, which can be divided in an instantaneous current component and a 
time dependent activating component, besides large voltage dependent single channel 
openings. These single channel openings have a slope conductance of 93 pS (± 1.7). This 
conductance is much larger than the conductance reported for TASK1 (14-19 pS) or TASK3 
(27-29 pS), although especially the TASK3 conductance is [Ca
2+
] dependent and can increase 
up to 100-120 pS in a [Ca
2+
] free solution (Rajan, Wischmeyer, et al., 2000; Bayliss, Sirois, et 
al., 2003; Musset, Meuth, et al., 2006). However, no TASK3 transcript or protein could be 
detected in the OVCAR3 cells and at our [Ca
2+
] the TASK3 conductance should maximally 
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be 80 pS (Musset, Meuth, et al., 2006). Furthermore, the TASK3 conductance has also been 
reported to be reduced by the extracellular pH, while we did not observe any change. We 
therefore conclude that TASK1 and TASK3 are not responsible for the single channel 
activity, also because they are both voltage independent. It might be that TASK5 is 
responsible for the single channel activity, as we could detect TASK5 transcript. However, 
TASK5 is only linked to TASK1 and TASK3 based on sequence homology, and it has not 
been possible to functionally express this channel in heterologous systems or determine its 
current characteristics up to now (Ashmole, Goodwin, et al., 2001; Kim and Gnatenco, 2001). 
Besides TASK other K
+
 channels must be present in OVCAR3 cells as well, as they cannot 
explain the voltage dependence and large single channel openings and as only part of the     
K
+
 current is affected by changes in the extra cellular [Ca
2+
/Mg
2+
] and pH. The nature of these 
channels remains to be determined, and the use of various K
+
 channel inhibitors is probably 
necessary to establish the identity of these channels. 
 
 
 
Material and methods 
 
Cell culture. The OVCAR3 cell line was maintained in DMEM medium (PAA Laboratories) 
supplemented with 10% FBS (PAA Laboratories), 100 units/ml penicillin and 100 μg/ml streptomycin 
(both Lonza), and grown in a 37°C humidified growth chamber containing 5% CO2 in air. 
For patch clamping the cells were counted and plated at 50,000 cells/well in a 6 well plate in          
2 ml/well. The next day the medium was removed and replaced by fresh medium. The cells were 
incubated again at 37°C and used after 2 or 3 days of culturing. 
 
Whole cell patch clamping. After culturing the OVCAR3 cells were trypsinized and transferred to a 
glass coverslip in the recording chamber. They were allowed to settle for 30 min at 37°C before 
starting the perfusion at RT at about 1 ml/min. Patch pipettes were made from thin wall borosilicate 
glass without filament (Clark Electromedical Instruments), coated with sylgard (Dow Corning), and 
fire-polished before use. The pipette resistance was 1.5-2.5 MΩ when filled with pipette buffer. Whole 
cell currents were recorded at 10 kHz with an Axopatch-200A patch-clamp amplifier (Molecular 
Devices) using the pClamp-8 software; low-pass filter set at 2 kHz. The pipette and membrane 
capacitances were compensated as much as possible. The currents were analyzed using the Clampfit-9 
software by averaging the currents recorded in the last 65 ms of each pulse, unless indicated 
differently. The holding potentials were corrected for the liquid junction potential (calculated with JP 
Calc, pClamp-8), but no leak subtraction was performed. The used bath buffer and corresponding 
pipette buffer compositions are given in Table 1, Table 2 and Table 3. 
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Abstract 
 
Combined IFN /FC treatment induces apoptosis in various cancer cell lines. The cellular 
target of FC however is not yet known. We therefore conducted a database search, based on 
the characteristics known from the FC receptor in plants, in order to identify possible           
FC receptors in human cells. This resulted in a list of 14 ion channels, 10 transporters and      
4 ATPases, of which only the TASK ion channels were already known to interact with 14-3-3 
proteins. We therefore analyzed the effect of FC on the TASK/14-3-3-interaction. We showed 
that TASK proteins (TASK1 and TASK3) are only able to interact with 14-3-3 proteins when 
the penultimate serine is phosphorylated. FC enhances this interaction up to 7 times. 
Expression analysis showed that TASK1 (and possibly TASK5) are expressed in OVCAR3 
cells. Functionally, we identified an ion channel in OVCAR3 cells that possesses TASK-like 
characteristics. In one batch of untreated OVCAR3 cells FC inhibits most of this TASK 
current, in a 14-3-3 dependent manner. In IFN  treated cells FC inhibits the TASK current as 
well as an extra K
+
 current. Based on the current characteristics, the TRPV3 cation channel 
seems a likely candidate for this second FC regulated ion channel in IFN  treated cells. 
However, TRPV3 expression analysis showed that the channel is hardly expressed in 
OVCAR3 cells, and it is also not able to interact with 14-3-3 proteins, rendering it a less 
likely candidate. 
The presence of FC sensitive ion channel(s) in cancer cells explains the apoptosis induction 
by IFN /FC treatment. And although the FC effects were clear and seem reliable, we have 
not been able to reproduce them independently in another OVCAR3 batch. We can therefore 
only conclude that the TASK channels are likely candidates for FC in vivo, but more 
experiments are needed to verify this as well as the involvement of a second channel upon 
IFN  treatment. 
 
TASK K
+
 channels as Fusicoccin target in ovarian cancer cells 
 
 
 
75 
 
Introduction 
 
K
+
 channels are a diverse class of ion channels expressed in different cell types. They play 
important roles in many cellular processes, ranging from various neurological processes to 
cell growth/survival and even apoptosis. In many tumors K
+
 channels, like EAG (ether à go-
go) and KCNK9 (TASK3, a TWIK-Related Acid-Sensitive K
+
 channel), are over-expressed 
and affect proliferation and cell cycle progression (Yao and Kwan, 1999; Fiske, Fomin, et al., 
2006; Zhanping, Xiaoyu, et al., 2007; Ouadid-Ahidouch and Ahidouch, 2008). K
+
 channels 
can be divided into several groups based on their regulation and physiological properties, like 
Ca
2+
 activated channels (KCa channels) which open in response to changes in the cellular   
Ca
2+
 concentration, the voltage-gated channels (Kv channels) which are predominantly found 
in excitable cells and respond to changes in the membrane potential, and the 2-pore domain 
K
+
 channels (K2P channels) which are all made up of 2 pore domains and 4 transmembrane 
domains (Fiske, Fomin, et al., 2006; Zhanping, Xiaoyu, et al., 2007; Enyedi and Czirjak, 
2010). The K2P channels are known to be responsible for the background or leak K
+
 current. 
The K2P channels can be sub-divided into 6 groups (TWIK, TREK, TASK, TALK, THIK 
and TRESK) based on sequence similarity and functional resemblance (Enyedi and Czirjak, 
2010). The TASK (TWIK related acid sensitive K
+
 channel) channels generate pH sensitive 
whole cell K
+
 currents (Duprat, Lesage, et al., 1997; Bayliss, Sirois, et al., 2003; Enyedi and 
Czirjak, 2010). Up to now, TASK1, TASK3, and TASK5 have been identified, while only 
TASK1 and TASK3 have been characterized as it has so far not been possible to functionally 
express TASK5. The activity of TASK1 and TASK3 is regulated by changes in the 
extracellular pH within the physiological range. The pK of TASK1 is ~7.3-7.5, while TASK3 
is inhibited by slightly more acidic pH with a pK of ~6.5-6.7 (Duprat, Lesage, et al., 1997; 
Bayliss, Sirois, et al., 2003). Besides their pH sensitivity, these TASK channels are also 
blocked by divalent cations, anandamide and/or ruthenium red, while they are activated by 
volatile anesthetics, like halothane and isoflurane
68
[68]. Furthermore, the TASK channels are 
regulated by the interaction with various proteins. Their forward transport, for instance, from 
the endoplasmatic reticulum (ER) to the plasma membrane is controlled by the binding of     
-COP and 14-3-3 proteins (O'Kelly, Butler, et al., 2002; Rajan, Preisig-Muller, et al., 2002; 
Zuzarte, Heusser, et al., 2009). The binding of -COP to a dibasic motif (KR) present in the 
N-terminus and a tribasic motif (KRR) in the C-terminus of the TASK protein causes          
ER retention, while the interaction of their C-terminal tip with 14-3-3 proteins facilitates the 
C H A P T E R    4 
 
 
 
76 
 
forward transport to the plasma membrane. This 14-3-3 binding is dependent on the 
phosphorylation of the penultimate serine, and can override the ER retention by -COP 
proteins (O'Kelly, Butler, et al., 2002; Zuzarte, Heusser, et al., 2009). 
14-3-3 proteins are a family of homologous proteins that are present in all eukaryotic 
organisms. There are 7 mammalian isoforms (β, , ε, γ, σ, θ/τ and ζ), which all form homo- 
and/or heterodimers (Obsilova, Silhan, et al., 2008). Each monomer contains an amphipathic 
binding groove that can interact with a target protein (Yaffe, 2002; Aitken, 2006). So far, over 
300 human target proteins have been identified (Meek, Lane, et al., 2004; Pozuelo Rubio, 
Geraghty, et al., 2004). Most targets interact through an internal mode-I (R/KXXpS/pTXP) or 
mode-II (R/KXXXpS/pTXP) biding motif, while the TASK/14-3-3 interaction is an example 
of a C-terminal mode-III (pS/pTX1-2-COOH) interaction (Aitken, 2006; Coblitz, Wu, et al., 
2006; Johnson, Crowther, et al., 2010). When a target interacts by means of a mode-III motif 
there is a cavity left in the 14-3-3 binding groove. This cavity can be filled up by small 
molecules, like Fusicoccin (FC) (Wurtele, Jelich-Ottmann, et al., 2003; Ottmann, Marco, et 
al., 2007). FC is a small molecule produced by the fungus Fusicoccum amygdali Del. (Ballio, 
Chain, et al., 1964). In plants, FC stabilizes a complex between the plasma membrane         
H
+
-ATPase and a 14-3-3 protein (Korthout and De Boer, 1994), resulting in the irreversible 
activation of the H
+
-ATPase. Moreover, FC also inhibits an outward rectifying K
+
 channel in 
barley radicles (Van den Wijngaard, Sinnige, et al., 2005). This inhibition is independent of 
the FC induced H
+
-ATPase activation, but again 14-3-3 proteins are involved. 
Besides affecting plants, FC also disturbs the left-right asymmetry very early during 
Xenopus leavis development (Bunney, De Boer, et al., 2003), and more recently we showed 
that FC combined with the cytokine interferon alpha (IFNα) induces apoptosis in various 
cancer cell lines (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). In this process, 
IFN-α primes the tumor cells for the apoptosis induction by FC. The exact working 
mechanism of FC or the FC receptor in the cancer cells is not yet known. Human cells lack a 
close homolog of the plant H
+
-ATPse and the K
+
 channel or other FC targets have not been 
identified yet. However, there are strong indications for the involvement of 14-3-3 proteins in 
these FC receptor complexes as well. Besides this, ion channels are plausible FC receptor 
candidates in human cells. They are known to be deregulated in many cancers and have been 
linked to apoptosis as well (Pei, Wiser, et al., 2003; Patel and Lazdunski, 2004; Kunzelmann, 
2005; Franco, Bortner, et al., 2006), and could therefore constitute the FC target in the 
IFNα/FC treatment (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). 
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In the present study we therefore tried to identify the FC receptor using a targeted 
approach. We conducted a database search based on the receptor characteristics known from 
the [FC/H
+
-ATPase/14-3-3]-complex in plants, and verified some of the possible                 
FC receptors. The TASK channels were likely candidates as they were already known to 
interact with 14-3-3 proteins (Rajan, Preisig-Muller, et al., 2002). We showed that the 
TASK/14-3-3 interaction is phosphorylation dependent and can be enhanced by FC. 
Functionally, at least TASK1 is expressed in OVCAR3 cells, and we found evidence that FC 
inhibits the channel in a 14-3-3 dependent manner. Besides TASK, FC also seems to inhibit 
another K
+
 conducting channel in IFN  treated cells. We could not establish the identity of 
this channel yet, but its presence explains the priming effect of IFN  in the tumor cell 
treatment as a reduced K
+
 current has been linked to apoptosis before. 
Although the inhibitory effect of FC is clear and the data seems reliable we have not been 
able to reproduce the ion channel inhibition independently in another batch of OVCAR3 cells, 
and we therefore have to be careful with the conclusions. 
 
 
 
Results 
 
Identification of potential FC receptors 
Fusicoccin has been shown to selectively inhibit the growth of various cancer cell lines when 
combined with or applied after the cytokine IFNα (De Vries-van Leeuwen, Kortekaas-
Thijssen, et al., 2010). The cellular target of FC mediating this growth inhibition is not yet 
known. We therefore conducted a database search, based on the characteristics known from 
the FC receptor in plants, in order to identify a group of possible FC receptors in human 
cancer cells. We selected for proteins annotated as channel, pore, transporter, or ATPase, that 
have an S or T at the penultimate and V, L or I at the ultimate position in the protein (Wurtele, 
Jelich-Ottmann, et al., 2003). This resulted in a list of 15 ion channels, 10 transporters and     
4 ATPases (Table 1). Most of these are putative new 14-3-3 interactors (and FC receptors), 
although TASK1 and TASK3 channels are already known to interact with 14-3-3 proteins by 
their C-terminal tip (Rajan, Preisig-Muller, et al., 2002; Zuzarte, Heusser, et al., 2009). This 
interaction is necessary for their targeting to the plasma membrane since interaction with    
14-3-3 proteins facilitates their forward transport from the ER to the plasma membrane. In 
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view of this known interaction, we first analyzed the effect of FC on the TASK/14-3-3-
interaction. 
 
 
 
 
 
Table 1. Putative FC receptors in human cells, fitting the receptor requirements as known from       
the FC receptor in plants (channel, pore, transporter or ATPase, with S or T at the penultimate and  
V, L or I at the ultimate position. 
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FC enhances the pTASK1/14-3-3 interaction 
To analyze the effect of FC on the TASK/14-3-3 interaction we performed competitive 
anisotropy measurements. We analyzed the competition between a C-terminal TASK1 peptide 
(last 16 amino acids) and the FAM-SWpTY peptide for binding to all 14-3-3 isoforms, in the 
presence and absence of FC. The FAM-SWpTY peptide has only been shown to interact with 
14-3-3ζ before (Coblitz, Shikano, et al., 2005; Wu, Coblitz, et al., 2006). We therefore first 
analyzed if this peptide interacts with the other 14-3-3 isoforms as well. Figure 1A shows that 
the FAM-SWpTY peptide interacts with all human 14-3-3 isoforms. There are differences in 
affinity (Table 2) with 14-3-3σ showing the weakest binding (Kd 0.82 μM) and 14-3-3  the 
strongest interaction (Kd 0.08 μM). 
 
 
 
 
 
 
Since all 14-3-3 isoforms interact with the FAM-SWpTY peptide we continued with the 
competitive anisotropy measurements. Various concentrations of the TASK1 peptide, 
phosphorylated at the penultimate serine (pTASK1), were included in the anisotropy 
measurements. The pTASK1 peptide interacts strongly with all 14-3-3 isoforms except       
14-3-3σ, as the anisotropy signal decreases to the background level by the addition of only    
1-4 μM pTASK1 (Figure 1B). From this assay we calculated apparent affinities (Ki values) 
ranging from 0.10 μM to 1.12 μM for most 14-3-3 isoforms; only the affinity for 14-3-3σ was 
lower, yielding a Ki of 3.93 μM (Table 2). When FC is added the binding of the pTASK1 
peptide is slightly enhanced, 1.2 to 2.2 times, for all isoforms. This effect of FC is relatively 
small, but nonetheless it demonstrates that FC is able to enhance the pTASK1/14-3-3 
interaction. 
Table 2. Binding affinity of FAM-SWpTY and pTASK1 (with and without FC) for all human     
14-3-3 isoforms (Kd and Ki in M, ± S.E.). 
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TASK1/14-3-3 interaction is dependent on the phosphorylation of the penultimate 
serine 
Figure 2A shows that a non-phosphorylated peptide (dTASK1) is no longer able to interact 
with any of the 14-3-3 isoforms, nor is FC able to enhance/induce the interaction. This 
indicates that the TASK1/14-3-3 interaction is dependent on the phosphorylation of the 
penultimate serine, and that FC only enhances the affinity after the interaction between 
pTASK1 and the 14-3-3 protein has been established. The phosphorylation dependence of the 
14-3-3 interaction was confirmed by changing the phosphorylation status of the pTASK1 and 
dTASK1 peptides (dephosphorylating pTASK1 by calf intestinal alkaline phosphatase (CIP), 
and phosphorylating dTASK1 by protein kinase G (PKG)) before including them in 
anisotropy measurements (data not shown). 
Figure 1. (A) The FAM-SWpTY peptide interacts with all 14-3-3 isoforms. Average interactions 
of 3 independent experiments are shown for 14-3-3 , 14-3-3ε and 14-3-3σ (± S.E.). Anisotropy 
values are corrected for the background anisotropy of FAM-SWpTY alone. (B) The 
phosphorylated TASK1 (pTASK1) peptide interacts with all 14-3-3 isoforms in competitive 
anisotropy measurements, and FC enhances the affinity of this interaction. The FAM-SWpTY 
interaction with Hs-14-3-3 was measured in the presence of various concentrations of pTASK1 in 
the absence (●) or presence of 10 M FC (▼). Average interactions of 3 independent experiments 
are shown for 14-3-3 , 14-3-3ε and 14-3-3σ (± S.E.). Anisotropy values are corrected for the 
background anisotropy of FAM-SWpTY. 
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The enhancing effect of FC, as well as the phosphorylation dependence of the interaction, 
were not only observed in the competitive anisotropy measurements but were also confirmed 
by a dot blot-overlay. For this various concentrations of the pTASK1, dTASK1 or the 
modified TASK1 peptides were spotted on a nitrocellulose membrane, and incubated with a 
14-3-3 protein in the presence and absence of FC (Figure 2B). This showed that the 14-3-3 
protein only interacts with the phosphorylated TASK1 peptide (either pTASK1 or facilitated 
by a PKG treatment) and that FC again only enhances the interaction of the phosphorylated 
TASK1 peptide. Here FC enhances the TASK1/14-3-3 affinity up to 7-fold, indicating that the 
FC effect in the competitive anisotropy measurements is most likely underestimated, due to 
setup of the experiment and the small pTASK1 concentration range in which FC can enhance 
the TASK1/14-3-3 interaction. 
 
 
 
 
 
Figure 2. (A) The TASK1/14-3-3 interaction is dependent on the phosphorylation of the 
penultimate S of TASK1. A non-phosphorylated TASK1 peptide (dTASK1, ■) does not interact 
with 14-3-3 proteins, nor is FC able to enhance the interaction (dTASK1 + FC, ♦). This in contrast 
to the pTASK1 (●) interaction, which is enhanced by FC (pTASK1 + FC, ). Representative 
example for 14-3-3ε is shown (± S.D.); background corrected for the anisotropy of FAM-SWpTY 
alone. (B) Dot blot-overlay confirms the phosphorylation dependence of the TASK1/14-3-3 
interaction, and the enhancing effect of FC. Various concentrations of a TASK1 peptide were 
spotted on a nitrocellulose membrane and incubated with Xl 14-3-3ζ in the presence and absence 
of 10 μM FC. The TASK1 peptides were phosphorylated (1. pTASK1 and 4. dTASK1 (PKG)) or 
non-phosphorylated (2. pTASK1 (CIP) and 3. dTASK1) and at their penultimate S. 
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The complete intracellular C-terminal domain of TASK1 and TASK3 interact with 
14-3-3 proteins in a phosphorylation dependent manner 
According to literature a larger part of the TASK1 protein is able to interact with 14-3-3 
proteins as well (Rajan, Preisig-Muller, et al., 2002; Zuzarte, Heusser, et al., 2009). To test if 
this interaction is also dependent on the phosphorylation of the penultimate serine, a yeast 
two-hybrid based interaction test was performed. In this assay the interaction between the 
complete intracellular C-terminal domain of TASK1 and all 7 human 14-3-3 was examined. 
Besides TASK1 we also studied the interaction of the complete intracellular C-terminal 
domain of TASK3 with all 14-3-3 isoforms and of TASK1 and TASK3 mutants, in which the 
penultimate serine is mutated to alanine (S→A). The TDO growth shows that the complete 
intracellular C-terminal domain of both TASK1 and TASK3 are able to interact with all      
14-3-3 isoforms, except for 14-3-3  (Figure 3), as was expected from literature (Rajan, 
Preisig-Muller, et al., 2002). However, the S→A mutants are not able to interact with any of 
the 14-3-3 isoforms. This indicates that also in the yeast two-hybrid assay the interaction is 
dependent on the presence of the (phosphorylatable) penultimate serine. 
 
 
 
 
TASK1 (and TASK5) are expressed in OVCAR3 cells 
To see if the TASK channels are also targeted by FC in vivo and if they are involved in the 
growth inhibitory effect of the IFNα/FC treatment in cancer cells, we first analyzed their 
expression in OVCAR3 cells. Quantitative PCR (qPCR) measurements show that TASK1 and 
Figure 3. The intracellular C-terminal domain of TASK1 and TASK3 interact with all human   
14-3-3 isoforms except 14-3-3σ, when a S is present at the penultimate position (wt). Yeast cells 
transformed with TASK1 (wt or S
393
A) or TASK3 (wt or S
373
A) and a 14-3-3 isoform (or empty 
vector) were spotted on a DDO plate to check for colony viability and a TDO plate to check for 
interaction. 
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TASK5 are expressed in OVCAR3 cells, while the TASK3 transcript is hardly detectable 
(Figure 4A). There is, however, no significant difference in the expression level of any of the 
channels upon IFNα, FC or IFNα/FC treatment. 
Besides studying the gene expression level we also analyzed the protein level of TASK1 
and TASK3. The microsomal fraction of control and treated OVCAR3 cells was isolated and 
analyzed for the presence of TASK proteins using specific antibodies. This confirmed the 
presence of TASK1 while no specific band for TASK3 could be detected (Figure 4B). Again, 
no clear affect on the amount of protein could be detected upon treatment with IFN , FC or 
IFNα/FC. These results indicate that TASK1, and possibly TASK5, can be targets of FC in 
the OVCAR3 cells. 
 
 
 
 
TASK channels are functionally expressed in OVCAR3 cells 
Subsequently, we analyzed the activity and characteristics of the TASK channels in OVCAR3 
cells by whole cell patch clamp experiments. TASK channels are known to be outward 
rectifying K
+
 channels that are inhibited by extracellular Ca
2+
 and Mg
2+
 concentrations 
([Ca
2+
/Mg
2+
]) in the mM range and are amongst others sensitive to pH changes within the 
Figure 4. (A) The TASK1 and TASK5 genes are expressed in OVCAR3 cells, while the TASK3 
transcript is hardly detectable. No changes in the expression level are observed upon treatment for 
any of the TASK genes. OVCAR3 cells were treated for 3 days after which the TASK expression 
was measured by qPCR. Average mean normalized expression percentages of 3 independent 
experiments are shown (± S.E.), using β-actin as reference gene. (B) The TASK1 protein is also 
detectable in OVCAR3 cells; this in contrast to TASK3. Treatment does not affect the protein 
level. Western blot analysis was performed on the microsomal fraction of 3 day (un)treated 
OVCAR3 cells. 
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physiological range (Lopes, Gallagher, et al., 2000; Rajan, Wischmeyer, et al., 2000; Talley 
and Bayliss, 2002). TASK1 is blocked below pH 7.4 and TASK3 below pH 6.2, whereas 
these pH values can vary in dependence of the K
+
 concentration in the buffers (Morton, 
O'Connell, et al., 2003). In our patch clamp experiments we first identified the total K
+
 current 
in OVCAR3 cells and analyzed if there was a TASK component within this current that is 
activated by lowering the [Ca
2+
/Mg
2+
] from 2 and 1 mM respectively to 0.1 mM and reduced 
by a more acidic pH of 6.2. The results show that OVCAR3 cells contain a K
+
 current that 
meets the TASK characteristics (Figure 5). About half of the low [Ca
2+
/Mg
2+
] activated 
current is subsequently inhibited by the low pH (6.2) buffer and we therefore designated this 
current as TASK current. 
 
 
 
Figure 5. (A) Whole cell current traces of the K
+
 current in OVCAR3 cells, with standard buffer, low 
[Ca
2+
/Mg
2+
] buffer and low pH (6.2) buffer; representative example is shown. The low [Ca
2+
/Mg
2+
] 
buffer increases the K
+
 current, which can subsequently be partially blocked by the low pH (6.2) 
buffer. (Holding potential: -77 mV; Step protocol: -97 mV to +69 mV, with +15 mV increments).  
(B) I/V-plot of the whole cell K
+
 current in (A), showing the normalized currents (pA/pF) of the 
standard buffer (●), low [Ca2+/Mg2+] buffer ( ) and low pH (6.2) buffer (■), as well as the TASK 
current (= low [Ca
2+
/Mg
2+
] current - low pH (6.2) current). 
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FC inhibits TASK (and other K
+
 channels) in OVCAR3 cells, with the help of 14-3-3 
proteins 
The TASK current is present in both control and IFNα treated cells. To assess if FC affects 
this TASK current, FC was added to the low [Ca
2+
/Mg
2+
] buffer. This resulted in a partial 
reduction of the low [Ca
2+
/Mg
2+
] activated current in untreated OVCAR3 cells, comparable to 
the low pH inhibited current (Figure 6A). When FC is added to IFNα treated OVCAR3 cells, 
the FC inhibited current is larger than the pH inhibited current (Figure 6B). From this we 
conclude that FC inhibits TASK channels in control cells, and TASK channels together with 
another K
+
 conducting channel in IFNα treated cells. 
To confirm the involvement of 14-3-3 proteins in the TASK channel inhibition, the same 
patch clamp measurements were performed with R18 added to the patch pipette (intracellular 
side). R18 is a peptide that binds in the 14-3-3 binding groove with high affinity                  
(Kd 70-90 nM) (Wang, Yang, et al., 1999), thereby excluding other proteins from binding to 
14-3-3 proteins. Both control and IFNα treated cells still contain a TASK current in the 
presence of the R18 peptide. However, FC is no longer able to inhibit the K
+
 current in either 
control or IFNα treated cells (Figure 6C). This indicates that 14-3-3 proteins are part of the 
[FC/TASK]-complex in control and IFN  treated cells, as well as part of the second FC 
inhibited channel-complex in the IFN  treated cells. These results are in line with the model 
wherein FC anchors the 14-3-3 proteins to the ion channels and thereby reduces the current 
through these channels. 
 
TRPV3 is most likely not the second FC inhibited channel in OVCAR3 cells 
The presence of an extra FC inhibited ion channel in IFNα treated cells explains the priming 
effect of IFNα observed in the cancer cell treatment (De Vries-van Leeuwen, Kortekaas-
Thijssen, et al., 2010). Based on the list of ion channels that suite our FC receptor 
requirements, and the current characteristics derived from the patch clamp measurements, the 
temperature sensing TRPV3 channel is a likely candidate for being the second FC regulated 
channel. This channel is not known to interact with 14-3-3 proteins, but it conducts K
+
 ions 
besides most other cations and is activated by lowering the extracellular Ca
2+
 concentration 
(Xu, Ramsey, et al., 2002; Xiao, Tang, et al., 2008). To determine if TRPV3 can be the 
second FC regulated ion channel, we first analyzed its expression in OVCAR3 cells by   
qPCR measurements. This showed that the TRPV3 channel is hardly expressed in OVCAR3 
cells (data not shown). Furthermore, a yeast two-hybrid based interaction test showed that the 
C H A P T E R    4 
 
 
 
86 
 
intracellular C-terminal domain of TRPV3 is not able to interact with any of the 14-3-3 
isoforms, neither is a phospho-mimic mutant (TRPV3 (D); Figure 7), making TRPV3 a less 
likely candidate. However, these interaction studies were performed in yeast, which might 
lack the (activated) kinase required for the phosphorylation of the 14-3-3 binding motif. 
 
 
 
Figure 6. (A) I/V-plot of the normalized K
+
 current in untreated OVCAR3 cells, showing a 
TASK current and an almost equal FC inhibited current (= low [Ca
2+
/Mg
2+
] current - 10 µM FC 
current). Standard buffer (●), low [Ca2+/Mg2+] buffer ( ), low [Ca2+/Mg2+] buffer + 10 M FC 
(■), and low pH (6.2) buffer (♦); representative example is shown. (B) I/V-plot of the normalized 
K
+
 current in IFNα treated OVCAR3 cells, showing a TASK current and a larger FC inhibited 
current. Standard buffer (●), low [Ca2+/Mg2+] buffer ( ), low [Ca2+/Mg2+] buffer + 10 M FC (■), 
and low pH (6.2) buffer (♦); representative example is shown. (C) Relative TASK and FC 
inhibited current at +69 mV in untreated and IFN  treated OVCAR3 cells (measured in the 
presence and absence of the R18 peptide). An almost equal TASK current is observed in all cells, 
while the FC inhibited current is enhanced in IFNα treated cells. In the presence of the R18 
peptide FC is no longer able to inhibit a current, in either untreated or IFNα treated cells. Inhibited 
currents are calculated as% of the low [Ca
2+
/Mg
2+
] buffer current at +69 mV; averages are shown 
(± S.E.). (n = number of cells analyzed; n.d. = not determined). 
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Note: Although the FC effects are clear and observed in several OVCAR3 cell independently 
with reliable data for each cell, we have not been able to reproduce them decisively in another 
batch of OVCAR3 cells. We therefore can only conclude with certainty that the TASK 
channels interact with 14-3-3 proteins in a phosphorylation dependent manner, and that FC 
enhances this interaction. Furthermore, TASK1 is expressed in OVCAR3 cells and these cells 
possess a TASK-like current. However, we are not sure if this channel is affected by FC, 
although this seems very likely based on the initially observed FC effects. 
Nonetheless, the TASK channels are still likely candidates for FC in vivo, and the presence 
of a second FC inhibited ion channel in IFNα treated cells does explain the priming effect of 
IFN  in the tumor cell treatment. 
 
 
 
Discussion 
 
The fungal toxin Fusicoccin exerts various effects on plants. This ranges from stomatal 
opening and the regulation of ion transport to cytochrome c leakage from mitochondria and 
seed germination (Marre, 1979; Malerba, Crosti, et al., 2003; Malerba, Crosti, et al., 2004; 
Van den Wijngaard, Sinnige, et al., 2005). With our current knowledge most effects are 
explained, directly or indirectly, by the irreversible activation of the H
+
-ATPase, while others 
like the regulation of the K
+ 
channel in barley embryonic root cells are independent of the   
H
+
-ATPase activation by FC (Van den Wijngaard, Sinnige, et al., 2005). Besides effecting 
plants, FC also affects the left-right patterning early during Xenopus leavis development 
(Bunney, De Boer, et al., 2003) and induces apoptosis in various human cancer cell lines (De 
Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). However, no cellular target for FC 
other than the [FC/H
+
-ATPse/14-3-3]-complex in plants has been identified so far. 
Nevertheless, there are indications for the involvement of 14-3-3 proteins in the other          
FC receptor complexes as well (Van den Wijngaard, Sinnige, et al., 2005; Camoni, Di 
Lucente, et al., 2011). We therefore conducted a database search to identify putative FC 
receptors in human cancer cells, which can potentially form a complex with FC and a 14-3-3 
protein, and identified the TASK K
+
 channels as likely FC targets. 
The rat TASK channels are known to interact with 14-3-3 proteins by their C-terminal tip 
(Rajan, Preisig-Muller, et al., 2002). We confirmed this interaction for the intracellular         
C-terminal domain of human TASK1 and TASK3 channels with almost all human 14-3-3 
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isoforms. No interaction was observed for 14-3-3 , and 14-3-3  (and 14-3-3 ) seems to 
interact slightly weaker than most other isoforms. When the penultimate serine was mutated 
into alanine no interaction was observed with any of the 14-3-3 isoforms. This suggests that 
the TASK/14-3-3 interaction is phosphorylation dependent. This was confirmed by anisotropy 
measurements with the C-terminal TASK1 peptide, which only interacts with 14-3-3 proteins 
when the penultimate serine is phosphorylated. 
 
 
 
The TASK1/14-3-3 interaction is not only phosphorylation dependent, but can also be 
enhanced by FC. When FC is included in the anisotropy measurements the affinity of the 
pTASK1 peptide is enhanced up to 2.2 times, while FC enhances the interaction about 7 times 
in the dot blot-overlay. This difference in the enhancing effect of FC can be explained by the 
difference in the experimental set-up between the anisotropy measurements and the dot blot-
overlay. In the anisotropy measurements the pTASK1 peptide competes with the             
FAM-SWpTY peptide for 14-3-3 binding. As indicated by the phosphorylation dependence of 
the TASK1/14-3-3 binding, FC can only enhance the affinity of the interaction after the 
formation of the pTASK1/14-3-3 complex. In the anisotropy measurements the competitive 
value of pTASK1, which is equal in the presence and absence of FC, determines the initial 
pTASK1/14-3-3 binding and therefore also whether FC can enhance the affinity or not. 
Furthermore, the competitive window of pTASK1 (in μM) is very small, making it difficult to 
resolve the FC effect clearly. The dot blot-overlay does not depend on competition. This assay 
directly monitors the effect of FC on the pTASK1/14-3-3 interaction, and will therefore be 
more accurate. Hence it can be concluded that FC enhances the pTASK1/14-3-3 interaction 
significantly. 
Figure 7. The intracellular C-terminal domain of TRPV3 (wt) does not interact with any of the 
14-3-3 isoforms, nor does the phospho-mimic (TRPV3 (D)). Yeast cells transformed with TRPV3 
(wt or T863D) and a 14-3-3 isoform (or empty vector) were spotted on a DDO plate to check for 
colony viability and a TDO plate to check for interaction. 
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According to literature TASK channels are predominantly expressed in the brain but they 
are found in various other tissues as well, including the ovary (Duprat, Lesage, et al., 1997; 
Rajan, Wischmeyer, et al., 2000; Ashmole, Goodwin, et al., 2001). TASK3 has been linked to 
various cancers, although its oncogenic potential depends on the cellular context (Mu, Chen, 
et al., 2003; Pei, Wiser, et al., 2003; Kim, Cho, et al., 2004; Patel and Lazdunski, 2004).   
Here we observed that only TASK1 and TASK5 are expressed in OVCAR3 cells, and that the 
TASK1 protein can be detected in the microsomal fraction as well. No TASK3 could be 
detected, nor does treatment change the expression level of any of the TASK channels.         
In literature there is some debate about the specificity and the functionality of the 
commercially available TASK1 and TASK3 antibodies (Bayliss, Sirois, et al., 2003). We 
confirmed the lack of specificity, as both antibodies detect many other proteins as well (data 
not shown). However, they seem to be functional as the Western blot results are in line with 
the qPCR data, i.e. only TASK1 is detected in OVCAR3 cells. 
Besides the expression analysis we also tested if the TASK channels are functionally 
expressed in OVCAR3 cells. We analyzed the whole cell K
+
 current and observed that the 
OVCAR3 cells express a K
+
 channel that fits the TASK channel characteristics. This channel 
is both activated upon reducing the extracellular Ca
2+
 and Mg
2+
 concentration and blocked by 
reducing the extracellular pH to 6.2, and was therefore designated as TASK current. The 
activity of this TASK channel is not only hampered by the low extracellular pH, but also by 
the addition of FC to the bath buffer. FC reduces the same amount of K
+
 current as the low pH 
(6.2) buffer in untreated OVCAR3 cells. In IFN  treated cells FC reduces a K
+
 current that is 
even larger than the TASK current. This indicates that FC blocks also a second K
+
 conducting 
channel after IFN  treatment, which explains the apoptosis induction observed upon 
IFN /FC treatment (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). 
The interaction of TASK channels with 14-3-3 proteins is known to facilitate the forward 
transport of the channels from the ER to the plasma membrane (O'Kelly, Butler, et al., 2002; 
Rajan, Preisig-Muller, et al., 2002; Zuzarte, Heusser, et al., 2009), in which 14-3-3 binding 
overrides an ER retention signal. It is however not known if 14-3-3 binding is only necessary 
for the transport or if they also regulate the TASK activity at the plasma membrane. Here we 
show that the TASK channel inhibition by FC is 14-3-3 dependent, as FC is no longer able to 
inhibit the TASK current in the presence of the R18 peptide. This indicates that 14-3-3 
binding at the plasma membrane can influence the TASK channel activity, and is therefore 
most likely not only needed for the forward transport of the channel. 
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A likely candidate for being the second FC inhibited ion channel in IFNα treated OVCAR3 
cells is TRPV3. This channel fits our FC receptor requirements and also possesses the channel 
characteristics we observed, like being inhibited by high extracellular Ca
2+
. Besides this 
deregulated TRPV channels, including TRPV3, have already been linked to cancer 
(Prevarskaya, Zhang, et al., 2007; Hoeft, Linseisen, et al., 2010). The TRPV3 gene expression 
analysis in OVCAR3 cells together with the 14-3-3 interaction study, however, made this 
channel a less likely candidate as it does not seem to be expressed in OVCAR3 cells nor does 
it interact with any of the 14-3-3 proteins. 
Nevertheless ion channels could well be involved in the apoptosis induction upon IFNα/FC 
treatment. They are known to be upregulated in many cancers and have been linked to 
apoptosis as well (Pei, Wiser, et al., 2003; Patel and Lazdunski, 2004; Kunzelmann, 2005; 
Franco, Bortner, et al., 2006). Their inhibition by FC would result in a depolarisation of the 
membrane potential, which is known to induce apoptosis. Their deregulation in cancer cells 
explains the selectivity of the IFNα/FC treatment, making them even more likely candidates 
for being the FC receptor. 
 
 
 
Material and Methods 
 
Reagents. Fusicoccin was obtained from Prof. A. Babakov (Moscow, Russia) and human recombinant 
IFNα from Pierce Biotechnology. 
 
Cell culture and treatment. The OVCAR3 cell line was maintained in DMEM medium (PAA 
Laboratories) supplemented with 10% FBS (PAA Laboratories), 100 units/ml penicillin and 100 μg/ml 
streptomycin (both Lonza). They were grown in a 37°C humidified growth chamber containing        
5% CO2 in air. For treatment the cells were counted and plated out at the desired density. The next day 
the medium was removed and replaced by medium containing the indicated treatment compounds,     
or their solvent as control. The cells were incubated again at 37°C for the indicated times. 
 
Yeast two-hybrid assay. The intracellular C-terminal domains of human TASK1 (a.a. 248-394), 
TASK3 (a.a. 248-374), and TRPV3 (a.a. 760-864) were cloned into the pGADT7 vector (Clontech). 
Point mutations were introduced by which the penultimate T or S was replaced by an A or D. The 
pBD-GAL4 vector (Stratagene) was used to prepare all pBD-14-3-3 constructs. 
The PJ69-4A yeast strain was used for the yeast two-hybrid assay. Yeast transformations were 
performed using the LiAc protocol. Briefly, the PJ69-4A cells were grown o/n in YAPD medium at 
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30°C. A 0.5 ml aliquot was spun down and the cells were mixed with 1 μg DNA (0.5 μg AD and      
0.5 μg BD) and 50 μg linearized salmon sperm DNA (Stratagene). Next, 100 μl 40% PEG-4000/0.2 M 
LiAc was added per tube. The tubes were mixed and incubated for 30 min at 30°C followed by 15 min 
at 42°C, before the cells were plated out on selective SD-LW (DDO) plates. The plates were incubated 
at 30°C for 3-5 days. Some of the grown colonies were dissolved in 50 μl MQ of which 2 μl was 
potted on a DDO plate and 2 μl on a SD-LWH plate containing 7.5 mM 3AT (TDO plate). These 
plates were again incubated at 30°C for 1-3 days, to check for interaction. 
 
Competitive anisotropy measurements. The FAM-SWpTY peptide was a kind gift from Dr. M. Li 
(Baltimore, MD, USA) (Wu, Coblitz, et al., 2006). To determine the affinity of the FAM-SWpTY 
peptide for the human 14-3-3 isoforms 100 nM FAM-SWpTY was mixed with various concentrations 
of GST-Hs-14-3-3 in a final volume of 200 l. In the competitive anisotropy measurements, each 
sample contained 100 nM FAM-SWpTY, GST-Hs-14-3-3 ( M at the 80% of Bmax), 10 M FC or 
MeOH and various concentrations of a TASK1 peptide (containing the last 16 residues) in a final 
volume of 200 l (pTASK1, TASK1 peptide phosphorylated at the penultimate S; dTASK1,          
non-phosphorylated TASK1 peptide). All reaction mixtures were incubated at RT for 2 hours before 
the anisotropy was measured with a Varian Cary Eclips fluorescence spectrophotometer. All 
compounds were diluted in PBS or MeOH, and MeOH controls were taken along when necessary. 
The phosphorylated TASK1 peptide (pTASK1) was dephosphorylated by calf intestinal 
phosphatase (CIP, New England Biolabs), using the recommended buffer. The non-phosphorylated 
peptide (dTASK1) was phosphorylated by PKG-1α (Calbiochem), using a Tris-buffer (20 mM       
Tris-HCl, 10 mM MgCl2, 10 mM DTT, 200 μM ATP, pH 7.4). Both reactions were incubated for      
90 min at 37°C. 
 
Dot blot-overlay. Various concentrations of the TASK1 peptide were spotted on a nitrocellulose 
membrane, which were allowed to air-dry for 10 min before the membrane was incubated for 1 hour in 
4% ELK (Campina) in buffer A (25 mM Tris-HCl, 0.5 M NaCl, pH 7.5). The membrane was 
subsequently incubated with 2 mg/ml BSA in buffer A, to which 5 g/ml Bio-Xl-14-3-3  was added 
after 5 min (in the presence 10 M FC or MeOH). The membrane was incubated at RT for 1 hour 
while shaking, after which the bound complexes very visualized using an avidin-HRP antibody 
(incubated 1 hour at RT) and ECL (Peirce). 
 
Gene expression analysis and Western blotting. Fifty thousand cells/well were seeded in a 6 well 
plate and treated with the indicated compounds in 2 ml/well for 3 days. The total RNA was extracted 
with TRIZOL
®
 Reagent (Invitrogen), a DNAse treatment was performed with DNaseI (RNase free; 
Roche) and the RNA was converted to first strand cDNA using an oligo(dT) primer and 
SuperScript™-II Reverse Transcriptase (Invitrogen); all performed according to the manufacturer’s 
instruction. From this, equal amounts of cDNA were used for the expression analysis with SYBR
©
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Green (Applied Biosystems) using the MJ Opticon Monitor (BioRad). The data were analyzed with 
the qgene96 program (Muller, Janovjak, et al., 2002), using β-actin as reference gene. Primers used: 
TASK1 CAACCTCCCTTCGTGTTGTTTTGC (sense) and GCCTGTCCCTCCTTCTTTCTGTCC 
(anti-sense), TASK3 CTTCCCATCGCCTATTAGCTCCATCTC (sense) and 
GAATGTGCAGTTAGTTCCCCTAAACGG (anti-sense), TASK5 
CCAGGGATTGGAAACGGATGAC (sense) and TTTTGGAAAGGAGGGAGGGGAC (anti-sense), 
TRPV3 AACCTCGGTGTAGAAGCGGAACC (sense) and GACTCCACCATCCCTCAAAGCCT 
(anti-sense), and β-actin AGCATCCCCCAAAGTTCACAATGT (sense) and 
GATGGCAAGGGACTTCCTGTAACAA (anti-sense). 
For the microsomal fraction isolation, (treated) OVCAR3 cells were lysed after an incubation of  
15 min in swelling buffer (50 mM Hepes, 0.25 M sucrose, 1 mM EDTA, 1 mM EGTA, 1.5 mM 
MgCl2, 5 mM DTT, 250 μM Na3VO4, 10 μM Cantharidin, 1 mM PefaBloc SC (Fluka), 1x Protease 
inhibitor mix cocktail (Roche), pH 7.4 KOH) by 30 strokes through a 26G needle. The homogenate 
was centrifuged for 10 min at 800g to remove the cell debris, followed by 60 min at 100,000g to 
obtain the microsomal fraction (pellet) and the cytosolic fraction (supernatant). The isolated protein 
concentration was determined by a Bradford protein assay (BioRad), using BSA for the standard 
curve. Equal protein amounts were loaded on a SDS-PAGE and blotted with a TASK1 (H50) or 
TASK3 (H90) antibody (Santa Cruz). 
 
Whole cell patch clamping. After 2 or 3 days of treatment OVCAR3 cells were transferred to a glass 
coverslip in the recording chamber. They were allowed to settle for 30 min at 37°C before starting the 
perfusion (≈ 1-2 ml/min) at RT. All experiments were performed at RT within 5 hours of isolation. 
Patch pipettes were made from thin wall borosilicate glass without filament (Clark Electromedical 
Instruments), coated with sylgard (Dow Corning), and fire-polished before use. The pipette resistance 
was 1-3 MΩ when filled with internal solution (10 mM Hepes, 4 mM NMDG-gluconate, 140 mM    
K-glutamate, 0.5 mM CaCl2, 1 mM MgCl2, 10 mM EGTA, 3 mM ATP, pH 7.2 (KOH)). The standard 
bath buffer contained: 10 mM Hepes, 150 mM NMDG-gluconate, 5 mM K-glutamate, 2 mM CaCl2,   
1 mM MgCl2, 10 mM glucose, pH 7.4 (KOH). In the low [Ca
2+
/Mg
2+
] buffer the concentration of both 
ions was reduced to 0.1 mM, the loss of Cl was compensated by NMDG-Cl. The low pH (6.2) buffer 
is the low [Ca
2+
/Mg
2+
] buffer at pH 6.2. Whole cell currents were recorded at 10 kHz with an 
Axopatch-200A patch-clamp amplifier (Molecular Devices) using the pClamp-8 software; low-pass 
filter set at 2 kHz. The pipette and membrane capacitances were compensated as much as possible. 
The currents were analyzed using the Clampfit-9 software by averaging the currents recorded in the 
last 65 ms of each pulse. The holding potentials were corrected for the liquid junction potential 
(calculated with JP Calc, pClamp-8). 
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Abstract 
 
Small molecules, like Fusicoccin (FC), influence various cellular processes and diseases by 
affecting protein/protein-interactions. FC is a well-studied fusicoccane that stabilizes the 
protein/protein-interaction between with the C-terminal tip of the plant plasma membrane  
H
+
-ATPase and 14-3-3 proteins, thereby irreversibly activating the H
+
-ATPase. More recently, 
FC has also been shown to selectively induce apoptosis in different cancer cell lines in 
combination with Interferon-  (IFN ) and reduce the ligand induced Estrogen Receptor alpha 
(ER ) activity in MCF7 breast cancer cells, most likely in combination with 14-3-3 proteins. 
However, the FC receptor involved in the apoptosis induction is not known. To identify the 
FC receptor in the human cancer cells a proteomics approach was used, in which FC-coated 
beads (FC-Beads) were used to pull-down the FC receptor from a whole cell lysate from 
MCF7 and OVCAR3 cells. Proteins that form a complex on the FC-Beads together with     
14-3-3 proteins were eluted by means of the R18 peptide, and Western blot analysis showed 
that the FC-Beads selectively bound 14-3-3 proteins. Mass spectrometry analysis identified 
many proteins, amongst which 21 proteins containing a C-terminal tip that should allow for 
FC receptor complex formation. 
None of these 21 proteins has been shown before to interact with 14-3-3 proteins by their 
C-terminal tip. PMCA1 is known to interact with an N-terminal motif, but no C-terminal 
interaction with 14-3-3 proteins could be established. Phosphorylated peptides of PABPC1 
and STAT1 interact with 14-3-3 proteins in a phosphorylation dependent manner and FC 
enhances this interaction. However, no interaction is observed for the C-terminal half of both 
proteins in a yeast two-hybrid assay. More experiments are therefore needed to confirm the 
involvement of PABPC1, STAT1, or any of the other 21 identified proteins as the                
FC receptor. 
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Introduction 
 
Several small molecules (MW ≤ 1000 Da) are currently being developed into drugs for the 
treatment of various diseases. Some of these molecules affect protein/protein-interactions by 
replacing the natural substrate from the substrate-binding pocket and prevent thereby the 
interaction with other proteins. This happens for instance for small molecules that inhibit the 
Bcl-xL/Bcl-2 interaction that plays a crucial role in apoptosis regulation (Baell and Huang, 
2002), as well as for nutlins which prevents the p53/MDM2 interaction and thereby apoptosis 
(Klein and Vassilev, 2004; Vassilev, Vu, et al., 2004). Small molecules that stabilize 
protein/protein-interactions have been identified as well. Examples are rapamycin and 
tacrolimus which act as immunosuppressors (Griffith, Kim, et al., 1995; Choi, Jie, et al., 
1996), or paclitaxel/taxol a stabilizer of microtubule polymers which is widely used as an 
anticancer drug (Schiff and Horwitz, 1980). Because small molecules can influence various 
important cellular processes they are of interest in drug design studies (Koehler, 2010). 
Database screens have identified several protein/protein-interactions that are good candidates 
for modulation as well as small molecules that could potentially influence interactions (Block, 
Weskamp, et al., 2007; Davis and Sali, 2010). 
A number of molecules belonging to the so-called Fusicoccane family, recently identified 
as stabilizers of specific protein/protein-interactions, may have great potential as small 
molecule drugs. Fusicoccanes are molecules with a dicyclopenta[a,d]cyclooctane skeleton   
(5-8-5 core ring structure) to which various side groups and sugar moieties are linked 
(Muromtsev, Voblikova, et al., 1994). They are found throughout nature and are produced by 
fungi, liverworts, algae and even insects and higher plants (Muromtsev, Voblikova, et al., 
1994). The best characterized fusicoccane is Fusicoccin-A (FC). FC was first described by 
Ballio et al. in 1964 (Ballio, Chain, et al., 1964) and is produced by the fungus Phomopsis 
amygdali from which more than 19 Fusicoccin derivatives have been isolated up to now 
(Muromtsev, Voblikova, et al., 1994; Sassa, Tajima, et al., 2002; Tajima, Nukina, et al., 
2004). The fungus infects peach and almond trees and secretes FC into the leaves, resulting in 
uncontrolled water loss. FC stabilizes the protein/protein-interaction between the C-terminal 
tip of the plasma membrane H
+
-ATPase and 14-3-3 proteins (Korthout and De Boer, 1994; 
Baunsgaard, Fuglsang, et al., 1998; Wurtele, Jelich-Ottmann, et al., 2003; Ottmann, Marco, et 
al., 2007). This irreversibly activates the H
+
-ATPase, widely opens the stomata, and 
eventually causes wilting of the tree. Besides stabilizing the H
+
-ATPase/14-3-3-interaction, 
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FC also induces an apoptotic like cell death in sycamore cells (Malerba, Cerana, et al., 2003; 
Malerba, Crosti, et al., 2003), inhibits the catalase activity (Beffagna and Lutzu, 2007; 
Beffagna and Riva, 2011), reduces the hydrogen peroxide and nitric oxide production in guard 
cells (She, Huang, et al., 2010; She, Li, et al., 2010) and inhibits an outward rectifying         
K
+
 channel in barley radicles (Van den Wijngaard, Sinnige, et al., 2005). A major unanswered 
question with respect to these FC effects remains whether they are all caused by the activation 
of the only identified FC target to date, viz. the H
+
-ATPase, or if FC also affects other targets. 
FC not only affects plants, but more recently, has also been shown to selectively induce 
apoptosis in human cancer cells of different origins (De Vries-van Leeuwen, Kortekaas-
Thijssen, et al., 2010). In this, the efficacy of FC can be enhanced by combining it with the 
cytokine IFNα. In addition, FC randomizes the left-right organ asymmetry in developing 
Xenopus leavis oocytes (Bunney, De Boer, et al., 2003), and hampers the ligand induced 
estrogen receptor α (ER ) activity in MCF7 breast cancer cells [unpublished data, Chapter 6 
of this thesis]. Except for the [H
+
-ATPase/14-3-3]-complex in plants no other FC receptor has 
been confirmed, although there are strong indications for the involvement of 14-3-3 proteins 
in other FC effects as well (Bunney, De Boer, et al., 2003; Van den Wijngaard, Sinnige, et al., 
2005). 
14-3-3 proteins are a family of homologous proteins that are present in all eukaryotic 
organisms. There are 7 mammalian isoforms (β, , ε, γ, σ, θ/τ and ζ), which all form homo- 
and/or heterodimers (Obsilova, Silhan, et al., 2008) and have so far been described to interact 
with over 300 human target proteins (Jin, Smith, et al., 2004; Meek, Lane, et al., 2004; 
Pozuelo Rubio, Geraghty, et al., 2004; Ge, Li, et al., 2010). Most of these proteins interact 
through a phosphorylated internal mode-I (R/KXXpS/pTXP) or mode-II (R/KXXXpS/pTXP) 
binding motif, while others interact by a mode-III motif (pS/pTX1-2-COOH) located at the 
extreme C-terminus of a protein (Aitken, 2006; Coblitz, Wu, et al., 2006; Johnson, Crowther, 
et al., 2010). The binding of 14-3-3 can exert different effects on target proteins (Fu, 
Subramanian, et al., 2000; Hermeking, 2003; Wilker and Yaffe, 2004). It can attenuate their 
function by influencing their localization (Obsilova, Vecer, et al., 2005; Obsilova, Silhan, et 
al., 2008), change the activity of enzymes, or act as a scaffold (Fu, Subramanian, et al., 2000; 
Agarwal-Mawal, Qureshi, et al., 2003). When a 14-3-3 target interacts by means of a mode-III 
motif there is a cavity left in the 14-3-3 binding groove. This cavity can be filled up by small 
molecules, like FC and Pyrrolidone 1 (Wurtele, Jelich-Ottmann, et al., 2003; Ottmann, Marco, 
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et al., 2007; Rose, Erdmann, et al., 2010), which thereby influence the 14-3-3/target-
interaction and the effect of 14-3-3 binding on the target protein. 
 
 
 
Figure 1. Fusicoccin is coupled to biotin and magnetic beads in a two step coupling process.    
(A) In the first step of the coupling process FC is oxidized. The oxidation reaction changes the 
terminal vinylic carbon of the sugar moiety (encircled) into a reactive aldehyde, generating      
FC-aldehyde (FC-Ald). (B) In the second step FC-Ald is coupled to biotin-XX-hydrazide 
generating FC-Bio (left), or magnetic hydrazide-beads to generate FC-Beads (right). 
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To obtain a better understanding of the working mechanism of FC in cancer cells and to 
identify new targetable protein/protein interactions for cancer therapy, we searched for the FC 
receptor in human cancer cell lysates. For this, FC was biotinylated FC (FC-Bio) or coupled 
to magnetic beads (FC-Beads) and used in protein pull-down assays to identify proteins that 
specifically interact with the FC molecule. The results show that 14-3-3 proteins interact with 
FC-Beads only when the binding groove is not blocked, what indicates that they are involved 
in the FC receptor complex as expected. Furthermore, several potential FC receptor 
candidates have been identified whose cellular function can explain the apoptosis induction 
caused by FC in the cancer cells, but their involvement in the FC receptor complex still needs 
to be confirmed. 
 
 
 
Results 
 
FC-Bio and FC-Beads production 
FC has various affects on human cancer cells, amongst which is apoptosis induction in 
OVCAR3 cells (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). To identify the FC 
receptor in tumor cells we decided to perform pull-downs with FC in cancer cell lysates, 
followed by mass spectrometry analysis to identify the receptor. For this, two forms of 
coupled FC were prepared: i) biotinylated FC (FC-Bio) and ii) FC coupled to magnetic beads 
(FC-Beads), in a two-step process (Figure 1). In the first step, the vinylic carbon located at the 
extreme of the sugar moiety was changed into a reactive aldehyde by an oxidation reaction 
(Figure 1A), generating FC-aldehyde (FC-Ald). FC-Ald was purified over a Sep-Pak C18 
cartridge and subsequently coupled to biotin-XX-hydrazide to generate FC-Bio or magnetic 
hydrazide-beads to generate FC-Beads in the second step (Figure 1B). Biotin-XX-hydrazide 
has a relatively long linker (XX) between the biotin group and the hydrazide residue, what 
should allow the biotin part of FC-Bio to bind in the deep pocket of streptavidin without 
causing sterical hindrance for protein binding to the FC-moiety. With the FC-Beads, the FC 
molecule is coupled almost directly to the bead surface rendering the FC molecule available 
for receptor formation with the FC-Beads as well. 
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Establishing the functionality of FC-Bio and the FC-Beads 
Before starting the pull-down in the human cancer cell lysate to identify the FC receptor, the 
functionality of FC-Bio and the FC-Beads was tested. We analyzed their ability to form the 
[FC/H
+
-ATPase/14-3-3]-complex with recombinant GST-14-3-3ε and a H+-ATPase peptide 
(YpTV-peptide), derived from the C-terminus of the barley H
+
-ATPase. Silver staining 
showed that GST-14-3-3ε interacts a-specifically with the streptavidin and FC-Beads    
(Figure 2A), as all ‘Beads’ lanes show a strong GST-14-3-3ε band. However, the FC-Beads 
allow for the specific elution of a considerable amount of GST-14-3-3ε with the R18 peptide, 
a peptide that strongly interacts with the 14-3-3 binding groove (Kd 70-90 nM) (Wang, Yang, 
et al., 1999). The specificity of the interaction was further demonstrated by including an 
excess of free FC or R18 during incubation to prevent receptor complex formation (+ FC resp. 
+ R18 in Figure 2A, FC-Beads). From FC-Bio coupled to streptavidin beads no or very little 
GST-14-3-3ε could be eluted by the R18 peptide (Figure 2A, FC-Bio; see also supplementary 
info) and therefore we focussed on the FC-Beads. 
 
Figure 2. The [FC/H
+
-ATPase/14-3-3]-complex can be eluted specifically from FC-Beads by 
R18. (A) FC-Beads and Streptavidin beads were incubated with GST-14-3-3ε and the          
YpTV-peptide, together with the indicated compounds. Silver staining shows that GST-14-3-3ε 
binds non-specifically to the beads and only from the FC-Beads 14-3-3 proteins are eluted by 
R18. (B) FC-Beads bind endogenous 14-3-3 proteins (27 and 29 kD). FC-Beads were incubated 
with a cytosolic OVCAR3 lysate in the presence of the YpTV-peptide or NIP-1. Silver staining 
shows that endogenous 14-3-3 is specifically eluted off the beads by R18 only when the      
YpTV-peptide is present. (C) Western blotting on the pull-down in (B) confirms the specificity of 
the endogenous 14-3-3 interaction with the FC-Beads when the YpTV-peptide is present, and 
shows that only part of the [FC/H
+
-ATPase/14-3-3]-complex is eluted by R18. 
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To test the FC-Beads for their capacity to bind endogenous 14-3-3 proteins from a cell 
lysate, a pull-down was performed with the YpTV-peptide added to a cytosolic OVCAR3 
lysate; or non-interacting peptide 1 (NIP-1) as negative control. Figure 2B shows that 
endogenous 14-3-3 proteins are only eluted by R18 only when the YpTV-peptide was 
included in the cell lysate. The negative control (NIP-1) shows no non-specifically bound or 
eluted 14-3-3. These results were confirmed by Western blot analysis (Figure 2C). In 
conclusion these experiments show that the FC-Beads are functional and fulfil our criteria: an 
FC receptor complex made up by human 14-3-3 protein and the plant ATPase peptide can 
bind to the FC-Beads and R18 specifically elutes the 14-3-3 proteins. 
 
Analysing the R18 elution efficiency and effect of different detergents 
Before starting the pull-down experiments with the FC-Beads in the human cancer cell lysate 
to identify the FC receptor, some tests were performed to assess the efficiency of the R18 
elution and to determine which detergents can be used to prepare the cell lysate. For this we 
used an assay that measured the amount of fluorescent FAM-YpTV-peptide remaining in 
solution or eluted from the FC-Beads by R18. To assess the efficiency of the R18 elution 
other elution methods (SDS, urea and boiling the beads in buffer) were tested as well, since it 
was shown before that SDS and urea break the FC receptor complex of plants (De Boer, 
Watson, et al., 1989) and boiling should denature the complex and release the receptor 
components. Figure 3A shows that the beads coated with FC (FC-Beads) strongly reduce the 
amount of free FAM-YpTV-peptide (81% reduction) and that R18 elutes about 35% of the 
bound peptide. A subsequent wash with 0.1% SDS (left) or 8M Urea (right) elutes the 
remaining FAM-YpTV-peptide. No fluorescence is eluted from non-coated empty beads, 
indicating that the binding of the short peptide to the FC-coated beads is very specific. These 
fluorescent peptide experiments show that the elution efficiency of 100 µM R18 is only 35%. 
Although 0.1% SDS and 8M urea are more efficient, we will not use these compounds for 
elution since they lack specificity and release non-specifically bound proteins as well (data 
not shown). 
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Because a whole cell lysate prepared with detergent was to be used to isolate the             
FC receptor complex from we tested the compatibility of four detergents with FC-complex 
formation. De Boer et al. showed that in plants some detergents did not solubilize the receptor 
Figure 3. R18 selectively elutes part of the [FC/H
+
-ATPase/14-3-3]-complex, and NP-40 is efficient 
in cell lysis and does not hamper complex formation. (A) The [FC/H
+
-ATPase/14-3-3]-complex is 
specifically formed on FC-Beads, and can be broken by the R18 peptide as well as SDS and Urea. 
FAM-YpTV was incubated with FC-Beads or Empty-Beads in the presence of GST-14-3-3. 
Fluorescent measurements of the supernatant and the elutions show that part of the                  
[FC/H
+
-ATPase/14-3-3]-complex is eluted by R18, while 0.1% SDS and 8M Urea both elute the 
remaining complex off the FC-Beads. (B) NP-40 and Octyl Glucoside (OG) do not hamper the 
[FC/H
+
-ATPase/14-3-3]-complex formation, while high (≥ 0.5%) Triton-X100 and SDS do. FAM-
YpTV was incubated with GST-14-3-3ε, 10 μM FC and various concentrations of Triton-X100 (●), 
NP-40 ( ), OG (■) or SDS (♦), after which the complex formation was analyzed by measuring the 
anisotropy. (C) NP-40 lysis OVCAR3 cell lysis much more efficient than OG. OVCAR3 cells were 
lysed with buffer containing 1% OG or NP-40, from which the indicated amount of protein was 
analyzed by silver staining. (D) The [FC/H
+
-ATPase/14-3-3]-complex formation on FC-Beads is not 
hampered by 0.75% NP-40. FC-Beads were incubated with GST-14-3-3ε and FAM-YpTV in the 
presence and absence of 0.75% NP-40, before the complex formation was analyzed by fluorescent 
measurements. 
C H A P T E R    5 
 
 
 
108 
 
(sufficiently) while others reduced the receptor complex formation (De Boer, Watson, et al., 
1989). To analyze the effect of octyl glucoside (OG) and some generally used detergents for 
cell lysis (NP-40, Triton-X100 and SDS) complex formation was studied by competitive 
anisotropy measurements (Figure 3B). Neither NP-40 nor OG had a negative effect on 
complex formation, whereas Triton-X100 at high concentrations (≥ 0.5%) slightly reduced 
complex formation, and SDS completely abrogated complex formation already at very low 
concentrations (≥ 0.01%). Since OG is not very efficient in the lysis of cancer cells (Figure 
3C) and as NP-40 also allows for the complex to be formed on FC-Beads (Figure 3D), we 
decided to use NP-40 for the preparation of the whole cell lysate of the cancer cells. 
 
 
 
Figure 4. FC receptor isolation from MCF7 and OVCAR3 whole cell lysates. (A) 14-3-3 proteins 
specifically bind to FC-Beads in the absence of R18. FC-Beads were incubated with a whole cell 
lysate of MCF7 or OVCAR3 cells (with and without a 2 day IFN  treatment), in the presence of 
NIP-2 or R18. Western blotting against 14-3-3 indicates that both proteins specifically interact 
with the NIP-2/FC-Beads. (B) Coomassie staining on the elutions (OVCAR3 NIP-2 pull-down) 
and the FC-Beads (MCF7 and OVCAR3 pull-down) of (A) show that multiple proteins interact 
with the FC-Beads and can be eluted, while no apparent specific protein band is detected in the 
NIP-2 pull-down or the R18 elution only. 
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FC receptor isolation from MCF7 and OVCAR3 cell lysates 
Whole cell lysates of MCF7 and OVCAR3 (control or 2 day IFN  treated) cells were 
prepared in the presence of phosphatase inhibitors. ATP was added during the incubation with 
the FC-Beads to enhance target phosphorylation, since 14-3-3 proteins are assumed to be part 
of the FC receptor complex, and because many 14-3-3 interactions are phosphorylation 
dependent. After the FC receptor pull-down we first analyzed by Western blotting whether 
14-3-3 proteins were bound to the FC-Beads when the NIP-2 or R18 peptide were present 
during the incubation. Figure 4A shows that the presence of R18 effectively blocks the 
binding of endogenous 14-3-3 to the FC-Beads, both from the MCF7 cell lysate as well as the 
OVCAR3 control lysate. Only from the OVCAR3 cell lysate treated with IFN  a small 
amount of 14-3-3 was still bound in the presence of R18. However, from this lysate more   
14-3-3 was also bound to the FC-Beads in the presence of NIP-2 than from the other lysates. 
 
 
 
 
 
 
Table 1. Proteins identified in the mock and R18 elution of the OVCAR3 (contr.) NIP-2/FC-Bead 
pull-down. Number of assigned spectra are shown, and the proteins are sorted according to their ratio 
of assigned spectra (R18 elution divided over mock elution). Proteins with a putative C-terminal tip 
for FC receptor complex formation are indicated in bold (tip motif indicated between brackets). 
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Table 1 continued. 
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Table 1 continued. 
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Next, the samples were run on SDS-PAGE and stained with coomassie (Figure 4B). No 
obvious differentially stained bands were observed on the FC-Beads (also not when the gel 
was silver stained, data not shown) nor was there a clear differential banding pattern between 
the mock elution as compared to the R18 elution of the OVCAR3 (control) FC-Bead         
pull-down, performed with NIP-2 present during the incubation. Proteins present in the mock 
and R18 elution of the OVCAR3 (control) pull-down and in the strip of the MCF7 cells  
(NIP-2 versus R18) were identified by nano-LC/MS-MS analysis. 
In the OVCAR3 elutions 135 proteins were identified in total (Table 1), with 33% more 
peptides identified in the R18 elution as compared to the mock elution. In both elutions five 
different 14-3-3 isoforms (β, ε, γ, θ and ζ) were identified with an almost equal peptide count; 
the latter is not consistent with the selective binding of OVCAR3 14-3-3 proteins to the     
FC-Beads as shown in Figure 4A. A putative FC receptor protein should fulfil two criteria:    
i) it should be more abundant in the R18 elution than the mock elution, and ii) it should have a 
Table 1 continued. 
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C-terminal tip that allows for FC/14-3-3-receptor complex formation (Wurtele, Jelich-
Ottmann, et al., 2003; Ottmann, Marco, et al., 2007). Tip compositions that allow for the 
formation of a stable plant FC receptor contain a valine (V), leucine (L) or isoleucine (I) as 
ultimate amino acid and a penultimate threonine (T) or serine (S) that can be phosphorylated 
(Ottmann, Marco, et al., 2007). Of the identified proteins 15 were unique for the R18 elution 
and another 10 proteins were at least 3-fold more abundant in the R18 elution than the mock 
elution (based on the ratio of the peptide counts in both elutions). Furthermore, 4 of the 
identified proteins have a C-terminal tip according to our FC receptor criteria ([T/S][V/I/L]), 
of which 3 proteins fulfilled both criteria, as they are also more abundant in the R18 elution 
(Table 3). Isoform 1 of Polypyrimidine tract-binding protein 1 (PTBP1) is three times more 
abundant, and another protein of interest is Polyadenylate-binding protein 1 (PABPC1). 
Although the PABPC1 peptide ratio is 1.36, it has a high number of assigned spectra in the 
R18 elution and it has been identified before in several 14-3-3 pull-down studies (Jin, Smith, 
et al., 2004; Pozuelo Rubio, Geraghty, et al., 2004; Ge, Li, et al., 2010). 
 
 
 
 
 
 
Table 2. Proteins identified on the FC-Beads of the MCF7 pull-down. Number of assigned spectra 
are shown, and the proteins are sorted according to their ratio of assigned spectra (NIP-2/FC-Bead 
spectra divided over the R18/FC-Bead spectra). Proteins with a putative C-terminal tip for FC 
receptor complex formation are indicated in bold (tip motif indicated between brackets). 
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The MCF7 FC-Bead analysis indentified 776 proteins (Table 2) of which 104 proteins 
(13%) were unique for the NIP-2 sample, whereas only 3% of the identified proteins were 
unique in the sample where R18 was present to block endogenous 14-3-3 protein. So, due to 
the presence of functional 14-3-3 proteins the FC-Beads interact with more unique proteins. 
Twenty-one identified proteins fulfil the criteria for the FC receptor as formulated above 
(Table 3), of which 2 are selective for the NIP-2 sample (Ribosome-binding protein 1 and 
Cancerous Inhibitor of PP2A (CIP2A)) and 4 other proteins are at least three times enriched: 
Sodium-dependent multivitamin transporter, Rab3 GTPase-activating protein, Coatomer 
subunit beta and Exocyst complex component 4. Again PABPC1 is found (ratio: 1.24), and 
two other proteins of interest are the Plasma membrane calcium-transporting ATPase 1 
Table 2 continued. 
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(PMCA1, ratio: 2.0; PMCA1 belongs to the same family of P-type pumps as the plant         
FC receptor), and isoform alpha of Signal transducer and activator of transcription 1 (STAT1, 
ratio: 1.3; STAT1 is an IFN signalling intermediate). 
 
Analysis of putative FC receptor proteins 
Some of the proteins listed above (bold in Table 3) have been identified in 14-3-3 interactome 
studies (De Vries-van Leeuwen and et al.; Jin, Smith, et al., 2004; Meek, Lane, et al., 2004; 
Pozuelo Rubio, Geraghty, et al., 2004; Ge, Li, et al., 2010). The interaction of these proteins 
with 14-3-3 has however not been confirmed nor is the 14-3-3 binding site known. We 
selected 3 proteins for a further analysis of their C-terminal interaction with 14-3-3 proteins 
and a putative role for FC. This are i) PMCA1, because PMCA1 as well as PMCA3 and 
PMCA4 (but not PMCA2) has been shown to interact with 14-3-3 proteins by an N-terminal 
motif (Rimessi, Coletto, et al., 2005; Linde, Di Leva, et al., 2008) and because this protein 
belongs to the family of P-type pumps, ii) PABPC1, because this proteins has been identified 
before in two independent FC-Bead pull-downs in a cytosolic OVCAR3 lysate (De Vries-van 
Leeuwen, unpubl. res.) as well as in several 14-3-3 interactome studies (Jin, Smith, et al., 
2004; Meek, Lane, et al., 2004; Pozuelo Rubio, Geraghty, et al., 2004; Ge, Li, et al., 2010) 
and iii) STAT1, because STAT1 plays a role in IFN signalling and IFN  acts in synergy with 
FC against several cancer cell lines (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). 
A yeast two-hybrid assay was performed with the intracellular C-terminal domain of 
PMCA1, PMCA2 and PMCA4 in the activation domain against all human 14-3-3 isoforms in 
the binding domain (Figure 5A). No interaction was observed and therefore we consider it  
unlikely that PMCA1 is the FC receptor. For PABPC1 and STAT1 phosphorylated C-terminal 
peptides (last 16 amino acids) were generated for competitive anisotropy measurements using 
recombinant 14-3-3 . Both peptides have a very low affinity for 14-3-3ε but the addition of 
FC strongly enhances the affinity (Ki) of the PABPC1 and STAT1 peptides to 3.4 and 1.3 μM 
respectively (Figure 5B). Similar results have been obtained for other 14-3-3 isoforms (data 
not shown). This FC enhanced affinity between the PABPC1 and STAT1 peptides and 14-3-3 
is fully dependent upon the phosphorylation of the penultimate threonine, as the FC effect is 
lost when the peptides are dephosphorylated by a phosphatase treatment (Figure 5C). Next, a 
yeast two-hybrid assay was performed with the C-terminal half of PABPC1 and STAT1 
against all 14-3-3 isoforms. However, no interaction was observed between these C-terminal 
proteins and any of the 14-3-3 isoforms (Figure 5D). There are several explanations for why 
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no interaction was observed in the yeast two-hybrid assay for which more experiments are 
needed, but due to a lack of time we had to leave it with this at this moment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Proteins identified in the OVCAR3 (contr.) and MCF7 FC-Bead pull-down that possess       
a C-terminal tip that should allow for FC receptor complex formation. Proteins identified before      
as 14-3-3 interactors are indicated in bold. 
(1) Linde, Di Leva, et al., 2008; (2) Jin, Smith, et al., 2004; (3) Pozuelo Rubio, Geraghty, et al., 2004; 
(4) Ge, Li, et al., 2010; (5) De Vries-van Leeuwen, et al., [unpublished data]. 
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Discussion 
 
In this study a proteomics approach was used to search for the FC receptor in human cancer 
cells. This is important for our understanding of the molecular mechanism responsible for the 
apoptosis induction caused by FC in several cancer cell lines (De Vries-van Leeuwen, 
Kortekaas-Thijssen, et al., 2010), and to get more insight in protein/protein-interactions that 
small molecules can target in general. In plants, the FC receptor was identified by a pull-down 
with FC coupled to an agarose resin and with biotinylated FC (FC-Bio) (De Boer, Watson, et 
al., 1989; Korthout, Van der Hoeven, et al., 1994). The identification of 14-3-3 proteins as 
part of the FC receptor was done with FC-Bio, incubated with a plasma membrane extract and 
a subsequent isolation on a monomeric avidin column (Korthout and De Boer, 1994). Further 
studies have shown that FC on its own exhibits a low affinity for 14-3-3 proteins, but in the 
trimeric receptor complex, which also includes the C-terminal tip of the plant plasma 
membrane H
+
-ATPase, FC enhances the complex affinity about 100-fold (Wurtele, Jelich-
Ottmann, et al., 2003). Although the FC receptor complex isolation from plants worked well 
with FC-Bio (Korthout, Van der Hoeven, et al., 1994), here no 14-3-3 proteins could be 
specifically bound and eluted with FC-Bio. The functionality of both the FC-part and the 
Figure 5. Putative FC receptor verification. (A) PMCA proteins do not interact with any of       
the 14-3-3 isoforms by their intracellular C-terminal domain. Yeast cells transformed with         
the intracellular C-terminus of PMCA1, 2 or 4 and a 14-3-3 isoform (or empty vector) were 
spotted on a DDO plate to check for colony viability and a TDO plate to check for interaction.  
(B) Phosphorylated PABPC1 and STAT1 peptides interact with 14-3-3ε in competitive anisotropy 
measurements, and FC enhances the interaction affinity. The FAM-SWpTY interaction with  
GST-14-3-3ε and various concentrations of a phosphorylated PABPC1 peptide (pPABPC1) was 
determined in the presence ( ) and absence (●) of 10 M FC, or various concentrations of            
a phosphorylated STAT1 peptide (pSTAT1) in the presence (♦) and absence (■) of 10 M FC. 
(C) Dephosphorylated PABPC1 (dPABPC1) or STAT1 (dSTAT1) do not interact with 14-3-3ε, 
nor can FC induce/enhace the affinity. Competitive anisotropy measurements with 14-3-3ε and  
32 M dPABPC1 in the presence ( ) and absence (●) of 10 M FC, or 32 M dSTAT1 in the 
presence (♦) and absence (■) of 10 M FC indicate that the interaction of both peptides is 
dependent on the phosphorylation of the penultimate T. (D) The C-terminal halves of PABPC1 
and STAT1 proteins do not interact with any of the 14-3-3 isoforms in a yeast two-hybrid. Yeast 
cells transformed with PABPC1 or STAT1 and a 14-3-3 isoform were spotted on a DDO plate to 
check for colony viability and a TDO plate to check for interaction. 
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biotin-part of FC-Bio were confirmed separately, while the FC-Bio molecule as a whole was 
not functional without any apparent reason. 
In contrast, FC coupled to magnetic beads (FC-Beads) was functional and interacts 
specifically with recombinant as well as endogenous 14-3-3 proteins. Western blot analysis 
demonstrated the presence of endogenous 14-3-3 proteins on FC-Beads incubated with a 
MCF7 or OVCAR3 cell extract, and the addition of R18 prevented this binding. However, in 
contrast to the FC-affinity purification with plant plasma membranes (Korthout and De Boer, 
1994), many proteins were found both on the FC-Beads and in the R18 elutions. This 
difference might be due to the fact that purified plasma membranes were used for the plant 
receptor identification, whereas here whole cell lysates were used. It should also be kept in 
mind that the identification of the plant FC receptor initially only yielded the 14-3-3 proteins 
(Korthout and De Boer, 1994; Marra, Fullone, et al., 1994; Oecking, Eckerskorn, et al., 1994). 
Only 5 years later it was shown that the second protein component of the FC receptor, the  
H
+
-ATPase, was not identified in the gel because only a proteolytic C-terminal fragment of 
the ATPase remained as part of the receptor complex (Oecking and Hagemann, 1999). 
The mass spectrometry analysis of the strips of the MCF7 cell lysate incubated FC-Beads 
and the elutions of the OVCAR3 lysate incubated FC-Beads showed some notable 
differences. E.g. the total assigned spectra were 21 and 33% higher in the MCF7/NIP-2      
FC-Beads and OVCAR3/R18 elution than their respective controls. Uniquely identified 
proteins in the MCF7/NIP-2 strip represent 13% of all identified proteins, whereas this is only 
3% in the MCF7/R18 strip. The same holds for the OVCAR3 R18 elution versus the mock 
elution, with 11% and 2% respectively. It is not clear how to interpret these differences, but 
there seems to be a correlation with the function of 14-3-3 proteins and their selective 
identification by Western blot analysis. 
From the list of proteins identified by mass spectrometry analysis only a few proteins fulfil 
our criteria as formulated for the FC receptor (peptide enrichment and specific C-terminal 
amino acids). The most interesting proteins are: 1) Polypyrimidine tract-binding protein 1 
(PTB1; peptide count 3-fold enriched in OVCAR3 pull-down, TI at the C-terminus),             
2) Ribosome-binding protein 1 (RRBP1; 4 unique peptides, SV at the C-terminus) and          
3) Cancerous inhibitor of protein phosphatase 2A (CIP2A; 2 unique peptides and SI at the    
C-teminus). The cellular functions of PTB1 and CIP2A are well documented and based on 
these functions we will speculate as to what the consequences of deregulation by FC can be 
for these proteins. 
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 PTB1: PTB1 is an RNA-interacting protein with an important function in RNA maturation 
and translation. PTB1 interacts with pyrimidine-rich sequences in pre-mRNAs, preferentially 
UCUU or CUCUCU stretches, to regulate alternative splicing and the production of multiple 
mRNAs from a single transcript (Perez, McAfee, et al., 1997; Petoukhov, Monie, et al., 2006). 
Most silenced exons are flanked by PTB1 binding sites, and their silencing is suggested to be 
regulated by the formation of a RNA-loop upon the multimerization of bound PTB1 proteins 
(Wagner and Garcia-Blanco, 2001). In addition to regulating alternative splicing, PTB1 has 
also been implicated in the regulation of mRNA localisation, stability and the initiation of 
translation (Le Sommer, Lesimple, et al., 2005; Petoukhov, Monie, et al., 2006; Auweter, 
Oberstrass, et al., 2007). Furthermore, active PTB1 has been shown to enhance the expression 
of apoptotic genes in differentiating cardiomyocytes and increases their susceptibility to 
caspase-dependent apoptosis (Zhang, Bahi, et al., 2009). PTB1 binding by 14-3-3 and FC 
could prevent the interaction of PTB1 to pyrimidine-rich mRNA sequences thereby 
deregulating alternative mRNA splicing and gene expression in general. 
 CIP2A: CIP2A is an oncoprotein that inhibits the activity of the serine/threonine 
phosphatase PP2A in human malignancies towards the oncogenic transcription factor c-Myc 
(Junttila, Puustinen, et al., 2007; Basile and Czerninski, 2010). S62 phosphorylation stabilizes 
the c-Myc protein and S62 dephosphorylation by PP2A is critical for the tumor suppressive 
activity of PP2A. Furthermore, PP2A functions as a trimeric protein complex, consisting of a 
catalytic subunit (PP2Ac or C), a scaffold subunit (PR65 or A), and one of the regulatory B 
subunits, and it is noteworthy that besides CIP2A two of these PP2A subunits were also 
identified on the FC-Beads from the MCF7 cell lysate: #49 (PP2A 56 kDa regulatory subunit 
delta, ratio: selective) and #206 (PP2A 65 kDa regulatory subunit A alpha, ratio: 2.50). 
Besides this, CIP2A has been associated with enhanced clinical aggressiveness and the 
promotion of malignant cell growth of several human cancers including breast cancer, lung 
cancer, and colon cancer (Junttila, Puustinen, et al., 2007; Come, Laine, et al., 2009; Dong, 
Wang, et al., 2011), and increased CIP2A expression has been linked to a reduced affectivity 
of several chemotherapeutic drugs (Chen, Liu, et al., 2010; Choi, Park, et al., 2011). 
Phosphorylated peptides have also been detected of the C-terminal CIP2A tip (Beausoleil, 
Villen, et al., 2006; Daub, Olsen, et al., 2008), which are theoretically be required for 14-3-3 
and FC binding. So, when CIP2A is the FC receptor the interaction with 14-3-3 and FC most 
likely prevents the inhibitory action of CIP2A, resulting in active PP2A, dephosphorylated    
c-Myc and thereby a reduced proliferation and enhanced sensitivity for chemotherapeutic 
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drugs. However, all this is still speculation and we will continue to address the question 
whether there is an interaction between PTB1 or CIP2A and 14-3-3 proteins that can be 
stabilized by FC. 
Although several promising FC receptor targets have been identified, that could explain the 
apoptosis induction caused by FC in cancer cells, more experiments are still needed to 
confirm their interaction with 14-3-3 proteins and their involvement in the FC receptor 
complex as well as the effect that FC binding has on the receptor, which will clarify the 
working mechanism of FC in tumor cell treatment. 
 
 
 
Material and methods 
 
Reagents. Fusicoccin was obtained from Prof. A. Babakov (Moscow, Russia) and human recombinant 
IFNα from Pierce Biotechnology. 
 
Cell culture and treatment. The OVCAR3 and MCF7 cell lines were maintained in DMEM medium 
(PAA Laboratories) supplemented with 10% FBS (PAA Laboratories), 100 units/ml penicillin and  
100 μg/ml streptomycin (both Lonza). They were grown in a 37°C humidified growth chamber 
containing 5% CO2 in air. 
 
FC-Bio and FC-Beads production. FC-Bio and FC-Beads were obtained by coupling FC to biotin-
XX-hydrazide (B2600, Molecular Probes) or magnetic hydrazide-beads (Chemicell) in a 2 step 
coupling process (Figure 1). First FC was oxidized to FC-aldehyde (FC-Ald), based on a protocol 
described by Feyerabend and Weiler (Feyerabend and Weiler, 1987). 7.34 μmol FC (5 mg) was 
dissolved in 1 ml tetrahydrofuran (THF) to which 54 μmol NaIO4 and 7.35 μmol OsO4 were added in a 
final volume of 2 ml (with HPLC grade H2O). The mixture was stirred overnight at RT in the dark. 
The next day the THF was evaporated by N2-gas, and the FC-Ald was purified over a Sep-Pak C18 
cartridge (Millipore Waters) and eluted with MeOH. The purity and quantity of the FC-Ald was 
determined by HPLC analysis, before it was coupled to biotin-XX-hydrazide to generate FC-Bio or 
magnetic hydrazide-beads to generate FC-Beads. The FC-Ald (final concentration 0.94 μmol          
FC-Ald/ml) was mixed with a 3x excess of biotin-XX-hydrazide (dissolved in DMSO at 18.5 mg/ml) 
or a 0.3x excess of hydrazide-beads (washed 2x with PBS before coupling) in coupling buffer (100 
mM NaAc, 0.02% NaN3, pH 5.0 acetic acid). After stirring for 1 hour at RT in the dark, 62.5 μl 
NaCNBH3 (10 mg/ml) was added per ml coupling buffer and the solution was stirred overnight at 4°C 
in the dark. The next day, the FC-Bio was purified on the HPLC and collected. The collected fractions 
were pooled and concentrated over a Sep-Pak C18 cartridge. The FC-Bio was stored in MeOH and the 
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concentration was determined by HPLC analysis. The FC-Beads were washed 3 times with PBS and 
the remaining hydrazide sites were blocked by incubating the beads with 0.1 M D-glyceraldehyde in 
PBS (1 ml/50 mg beads) for 1 hour at RT while rotating. The beads were subsequently washed          
10 times with PBS and stored in MeOH at 50 mg/ml. 
 
HPLC analysis. Small samples of FC dissolved in THF, and FC-Ald before and after coupling were 
analyzed on the HPLC to see if the chemical reactions and the coupling were successful. The samples 
were run isocratically (65% MeOH at 1 ml/min) on a Luna-5u-C18-(2)-100A column (250 x 4.6mm,  
5 µm, Phenomenex) and the absorbance was measured at 203 nm. With these settings FC eluted after 
about 14.5 min and FC-Ald after about 8.2 min. FC-Bio was purified over a LiChrosorb-10U-PR-8-
100 C8 column (250 x 4.6mm, 5 µm, Phenomenex), from which it eluted after about 16 min when 
running isocratically with 55% MeOH at 1.5 ml/min, and after about 7.6 min when using the Luna-5u-
C18-(2)-100A column isocratically with 65% MeOH at 1 ml/min. The FC-Ald and FC-Bio 
concentrations were determined by comparing the peak surface area to an FC standard curve, obtained 
by running known FC concentrations using the same column and running conditions. 
 
Functionality assessment of FC-Bio and FC-Beads. The functionality of FC-Bio and the FC-Beads 
was analyzed by pull-down assays, (competitive) anisotropy measurements and fluorescence 
measurements. Pull-down assay: FC-Bio together with streptavidin beads (or resin when indicated) or 
FC-Beads were mixed with human GST-14-3-3 or cytosolic OVCAR3 lysate and a peptide derived 
from the barley H
+
-ATPase (YpTV-peptide, sequence: Biotin-VKLKGLDIDTINQNYpTV) or a    
non-interacting peptide (NIP; NIP-1 sequence: CSLSTFRGLMKRRSSV, and NIP-2 sequence: 
ERYMGICMRKQYNNFVPVCLRS-amide). When indicated a 14-3-3 binding peptide (R18; 
sequence: PHCVPRDLSWLDLEANMCLP, with 14-3-3 interaction motif in bold (Wang, Yang, et 
al., 1999)), or an excess of FC were included as well. The samples were mixed and incubated for       
1-2 hours at RT while rotating and washed with PBS. Elutions were performed for 10 min at RT with 
50 μl PBS containing the indicated peptide/compound or nothing, after which the beads/resin was 
stripped by boiling in 50 μl SDS loading buffer. Equal volumes of the elutions and strips were loaded 
on a SDS-PAGE and stained with coomassie or silver to analyze the bound proteins or by Western 
blotting to confirm the association of 14-3-3 proteins. Anisotropy: Anisotropy measurements 
performed with FAM-YpTV (sequence: FAM-INQNYpTV) contained 100 nM FAM-YpTV, 1 M 
human GST-14-3-3ε, 10 M FC and various concentrations of the indicated detergents in a final 
volume of 200 l. In the competitive anisotropy measurements 100 nM FAM-SWpTY (sequence: 
FAM-RGRSWpTY, kind gift from Dr. M. Li (Baltimore, MD, USA) (Wu, Coblitz, et al., 2006)), was 
mixed with 0.65 M human GST-14-3-3ε, 20 μM YpTV-peptide, and various concentrations of FC or 
FC-Bio in a final volume of 200 l. All samples were incubated for 1-2 hours at RT before their 
anisotropy was measured with a Varian Cary Eclips fluorescence spectrophotometer. All compounds 
were diluted in PBS or MeOH and MeOH controls were taken along when necessary. Anisotropy 
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values are corrected for the background anisotropy of the FAM-peptide alone (without 14-3-3 protein) 
and for the effect of detergent on the FAM-YpTV background anisotropy. Fluorescence: The FAM-
YpTV-peptide was also used to determine the FC-Bead efficiency by fluorescence measurements. In 
this, 2 pmol FAM-YpTV was mixed with 1 μM barley His-14-3-3C and 2 mg FC-Beads or Empty-
Beads (non-coated magnetic beads), and 0.75% NP-40 when indicated, in a final volume of 200 μl 
PBS. The mixture was incubated for 45 min at RT in the dark while rotating. Next, the beads were 
washed with 1 ml PBS, and subsequently various elutions (50-200 μl each) were performed by 
incubating the beads for 20 min at RT in the dark. The fluorescence of all samples, including the wash 
steps, was measured with a Varian Cary Eclips fluorescence spectrophotometer (excitation 470 nm 
and emission 525 nm). 
 
Protein pull-down to identify the FC receptor. The MCF7 or OVCAR3 cells were seeded at    
250,000 cells/plate in 10 cm dishes 3 days before the experiment. When the cells were IFN  treated, 
the medium was removed after 24 hours and replaced by medium containing 400 Units/ml IFN  or its 
solvent. At the day of the pull-down, the cells were washed 2x with cold PBS (supplemented with       
1 mM CaCl2 and 0.5 mM MgCl2), and lysed with 0.75 ml/plate NP-40 based lysis (50 mM Tris-HCl, 
1% NP-40, 100 mM NaCl, 5 mM EDTA, 2 mM MgCl2, 10% Glycerol, 1 mM PefaBloc SC (Fluka),  
10 μM Cantharidin, 1x Protease inhibitor mix cocktail (Roche), and 1x PhosSTOP (Roche), pH 7.4). 
The isolated protein concentration was determined with the BCA protein assay (Pierce) according to 
the manufacturer’s description using BSA for the standard curve. Equal amounts of protein (2.2 mg) 
were mixed with 10 mg FC-Beads and 100 M NIP-2 or R18 and incubated for 1-1.5 h at RT while 
rotating. The beads were washed four times with lysis buffer, before a mock elution was performed 
with 100 M NIP-2 followed by an elution with 100 M R18. Both elutions (100 l each) were 
incubated for 20 min at RT while rotating. Next the beads were resuspended in 100 l SDS sample 
buffer. All bound-eluted proteins were analyzed by SDS-PAGE followed by coomassie/silver staining 
and Western blotting for 14-3-3 proteins. 
 
Mass spectrometry analysis (nano-LC/MS-MS). The proteins in the elutions and on the beads were 
separated by SDS-PAGE and stained with coomassie. The SDS-PAGE gel was cut into slices, which 
were further cut into small gel cubes (2 mm
2
) for in-gel digestion. The gel cubes were washed with   
50 mM ammonium bicarbonate (50-ABC) followed by 50-ABC in 50% acetonitrile (50-ABC/ACN). 
This wash cycle was repeated two times, and next the proteins were reduced for 1 hour at 37°C with 
10 mM dithiothreitol (DTT) in 50-ABC followed by an alkylation step with 55 mM iodoacetamide in 
50-ABC for 45 min at RT in the dark. After this the samples were washed twice as described before 
and dried completely in a speedvac. The gel cubes were rehydrated with 50-ABC containing          
6.25 ng/μl trypsin (Sequence grade modified trypsin; Promega) for 10 min and covered with 50-ABC 
to keep the cubes immersed during digestion. The samples were digested overnight (12-16 hours) at 
25°C. The next day the peptides were extracted with 1% formic acid (FA), followed by two 
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extractions with 5% FA in 50% ACN. All extractions were pooled and stored at -20°C. Prior to 
analysis the volume of each sample was reduced to 50 μl in the speedvac and of this a small amount 
was used for nano-LC/MS-MS analysis. The number of assigned spectra (and their ratio) is shown for 
each protein identified with at least 2 peptides (peptide confidence ≥ 95%) and a ≥ 99% protein 
certainty. 
 
Yeast two-hybrid assay. The intracellular C-terminal domains of human PMCA-1b (amino acids (a.a.) 
1095-1220), PMCA-2b (a.a. 1073-1198), and PMCA-4b (a.a. 1081-1205) were cloned into the pAD 
vector (Stratagene). The C-terminal domains of human PABPC1 (a.a. 371-636), and STAT1 (a.a. 317-
750) were cloned into the pGADT7 vector (Clontech). The pBD-GAL4 vector (Stratagene) was used 
to prepare all pBD-14-3-3 constructs. 
The PJ69-4A yeast strain was used for the yeast two-hybrid assay. Yeast transformations were 
performed using the LiAc protocol. Briefly, the PJ69-4A cells were grown o/n in YAPD medium at 
30°C. A 0.5 ml aliquot was spun down and the cells were mixed with 1 μg DNA (0.5 μg AD and      
0.5 μg BD) and 50 μg linearized salmon sperm DNA (Stratagene). Next, 100 μl 40% PEG-4000/0.2 M 
LiAc was added per tube. The tubes were mixed and incubated for 30 min at 30°C followed by 15 min 
at 42°C, before the cells were plates out on selective SD-LW (DDO) plates. The plates were incubated 
at 30°C for 3-5 days. Some of the grown colonies were dissolved in 50 μl MQ of which 2 μl was 
potted on a DDO plate and 2 μl on a SD-LWH plate containing 7.5 mM 3AT (TDO plate). These 
plates were again incubated at 30°C for 1-3 days, to check for interaction. 
 
Competitive anisotropy measurements (PABPC1 and STAT1). For the competitive anisotropy 
measurements on PABPC1 and STAT1 each sample contained 100 nM FAM-SWpTY, GST-14-3-3 
( M at the 80% of Bmax), various concentrations of a PABPC1 or STAT1 peptide (containing the last 
16 amino acids with the penultimate T being phosphorylated; pPABPC1 or pSTAT1), and 10 M FC 
or MeOH in a final volume of 200 l. All reaction mixtures were incubated at RT for 2 hours before 
the anisotropy was measured with a Varian Cary Eclips fluorescence spectrophotometer. All 
compounds were diluted in PBS or MeOH, and MeOH controls were taken along when necessary, and 
the anisotropy values are again corrected for the background anisotropy of the FAM-peptide alone 
(without 14-3-3 protein). The pPABPC1 and pSTAT1 peptides were dephosphorylated (dPABPC1 and 
dSTAT1) by incubating them for 90 min at 37°C in the presence of calf intestinal alkaline phosphatase 
(CIP, New England Biolabs), using the recommended buffer. 
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Why FC-Bio is not functional 
 
Figure 2 indicates that the [FC/H
+
-ATPase/14-3-3]-complex is not formed with FC-Bio on 
streptavidin beads. One explanation for this is that the FC-Ald was not coupled correctly to 
the biotin-XX-hydrazide. FC-Bio was therefore analyzed by mass spectrometry (MALDI 
analysis), and this showed that the molecule had the expected mass (data not shown). 
Subsequently, the functionality of the FC-part and the biotin-part were assessed separately. 
The FC-part of FC-Bio was analyzed by competitive anisotropy measurements. We analyzed 
the competition between the FAM-SWpTY peptide binding to GST-14-3-3  and the      
YpTV-peptide in combination with increasing concentrations of FC or FC-Bio (Figure S1A). 
This shows that FC and FC-Bio are equally effective which indicates that the FC-moiety of 
FC-Bio is functional. The functionality of the biotin-part of FC-Bio was derived from its 
ability to bind to streptavidin beads. Equal amounts of FC-Bio were injected into the HPLC 
column before and after an incubation with streptavidin beads (Figure S1B). The latter sample 
lacked FC-Bio, indicating that the biotin-part of FC-Bio does interact with streptavidin beads 
and is functional. 
To establish the functionality of the FC-Bio molecule as a whole another anisotropy test 
was performed (Figure S1C). In this, the binding of FAM-SWpTY to GST-14-3-3  was 
competed by the addition of R18 or the YpTV-peptide together with FC or FC-Bio. As 
expected, the FAM-SWpTY is competed out of the 14-3-3 binding groove by all additions. 
However, when FC-Bio was pre-incubated with streptavidin beads no competition was 
observed in the supernatant (Sup FC-Bio-beads). This indicates that the FC-Bio is coated on 
the beads, generating FC-Bio-beads. When these FC-Bio-beads were subsequently incubated 
with GST-14-3-3  in the presence of the YpTV-peptide, in order to form the                
[FC/H
+
-ATPase/14-3-3]-complex and reduce the amount of free GST-14-3-3 , the anisotropy 
signal remained high when this supernatant was used (Figure S1C, FC-Bio-beads versus 
Biotin-beads), demonstrating that the [FC/H
+
-ATPase/14-3-3]-complex formation failed. 
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Figure S1. (A) FC-Bio enhances the H
+
-ATPase/14-3-3 interaction, like FC. Competitive anisotropy 
measurements on the FAM-SWpTY/14-3-3 interaction with the YpTV-peptide in the presence of 
various concentrations of FC (●) or FC-Bio ( ). Both compounds displace the FAM-SWpTY from 
the 14-3-3 binding groove, and display a similar affinity (Ki) of 1.3 μM. (B) FC-Bio interacts with 
streptavidin beads. Equal amounts of FC-Bio (29 pmol) were analyzed on the HPLC before and after 
an incubation with streptavidin beads (FC-Bio retention time 7.7 min). (C) Both the FC-part and 
biotin-part of FC-Bio are functional, while the FC-Bio molecule is not. Competitive anisotropy 
measurements indicate that FAM-SWpTY interacts with GST-14-3-3ε, which can be abolished by 
the addition of R18 or the YpTV-peptide in combination with FC or FC-Bio. When FC-Bio is first 
incubated with streptavidin beads no competition is observed for the supernatant (Sup FC-Bio-
beads), while these FC-Bio coated beads do not reduce the amount of 14-3-3 when incubated with 
GST-14-3-3ε and the YpTV-peptide as compared to biotin blocked beads (FC-Bio-beads vs Biotin-
beads). (D) The [FC-Bio/H
+
-ATPase/14-3-3]-complex is not bound by streptavidin resin. FC-Bio 
was incubated with GST-14-3-3ε and the YpTV-peptide before and after a coating of FC-Bio on 
streptavidin resin. Silver staining shows that hardly any GST-14-3-3ε is specifically eluted by R18 
from the streptavidin resin, not when FC-Bio was first coated on the resin (FC-Bio coated resin vs 
Blocked resin) nor when the [FC/H
+
-ATPase/14-3-3]-complex was formed before the addition of 
streptavidin resin (Complex + resin vs Complex + blocked resin). 
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As a final test on the functionality of FC-Bio, the GST-14-3-3  pull-down was repeated 
with streptavidin resin instead of magnetic beads, as a streptavidin resin was used before 
together with FC-Bio to isolate the FC receptor from plants (Korthout, Van der Hoeven et al., 
1994). This pull-down confirmed previous results and showed that the 14-3-3 protein cannot 
be eluted by R18 (Figure S1D). Furthermore, no receptor complex is specifically bound by 
the streptavidin resin. Not when the resin is pre-incubated with FC-Bio (FC-Bio coated resin 
vs Blocked resin), nor when the complex was first assembled before the addition of resin 
(Complex + resin vs Complex + blocked resin). 
Although it is not clear why the FC-Bio molecule as a whole is not functional, whereas the 
two separate moieties are, we conclude that FC-Bio cannot be used to isolate the FC receptor 
from the cancer cell extract. 
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Abstract 
 
The estrogen receptor alpha (ERα) is a nuclear receptor that is involved in the onset and 
progression of many breast cancers. A reduction of ERα activity with anti-estrogens like 
tamoxifen is currently the main therapeutic strategy for ERα positive breast cancers. In this 
study we report a novel mechanism of ERα down-regulation. We show that the extreme       
C-terminal tip of ERα interacts with 14-3-3 proteins, involving a mode-III 14-3-3 binding 
motif. ERα/14-3-3 interaction is enhanced by 17 -estradiol binding and is absent when the 
penultimate threonine (T
594
) is mutated into an alanine. This T
594
A mutation, which prevents 
14-3-3 binding, enhances the estradiol induced ERα dimerization as well as the transcriptional 
activity of the receptor. Moreover, the small molecule ligand Fusicoccin (FC) stabilizes the 
interaction between the phospho-(pT
594
)-peptide derived from the ERα C-terminus and 14-3-3 
proteins, binds endogenous ERα and 14-3-3 from MCF7 cells and reduces the 17 -estradiol 
induced ERα activity in vivo. Our study thereby provides the mechanism underlying the role 
of the F-domain in regulating receptor dimerization, and offers a novel treatment option for 
ERα-positive breast cancer using FC as small-molecule ligand that, in contrast to anti-
estrogens, inhibits the ERα activity through binding outside the ligand binding domain (LBD), 
without an apparent effect on cofactor binding. 
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Introduction 
 
The proliferation of various tumors from reproductive organs, like breast and uterus, is 
regulated by estrogens that bind to the estrogen receptor alpha (ER ) expressed in the tumor 
cells (Ikeda and Inoue, 2004). Current therapeutic strategies to treat ER  positive breast 
cancer rely on the reduction of ER  transcriptional activity by anti-estrogens like tamoxifen 
(TAM). However, in many tumors TAM acquires agonistic properties and enhances 
proliferation by transactivating ER  (Zwart, Griekspoor, et al., 2007). Therefore, a better 
understanding of ER  regulation is necessary for the development of new therapeutic 
strategies. 
ERα is made up of six regions, denoted A to F (Peters and Khan, 1999). Region A/B 
possesses the ligand independent transcriptional activation function (AF-1), which is promoter 
and cell type dependent. The DNA binding domain (DBD) is located in region C. Region E 
contains the main dimerization domain, but also the hormone or ligand binding domain 
(LBD) and the ligand dependent transcriptional activation function (AF-2). ER  activity is 
furthermore regulated by ligand binding, dimerization and phosphorylation (Wang, Peters, et 
al., 1995; Powell, Wang, et al., 2010). Various phosphorylation sites have been identified, 
some of which are regulated by ligand binding while second messenger pathways, like the 
MAPK pathway, are involved in the phosphorylation of others (Lannigan, 2003). In general, 
phosphorylation affects the ER  activity by influencing cofactor binding, ligand binding and 
the stability of the ER  protein. The proteasomal degradation of ER  upon activation by  
17 -estradiol (E2) is stimulated by phosphorylation through CDK11
p58
 (Wang, Zong, et al., 
2009), while Akt stabilizes ER  by the phosphorylation of S
167
 (Park, Song, et al., 2008). The 
dimerization of ER  is regulated by ligand binding and the F-domain. The binding of ligands, 
like E2 and TAM, to the LBD induces a conformational change in the C-terminal tail of ER  
(helix 12 and the F-domain), and exposes amongst others the cofactor binding site and the 
dimerization domain, and changes the position of the F-domain (Ikeda and Inoue, 2004; 
Dahlman-Wright, Cavailles, et al., 2006; Powell, Wang, et al., 2010). The F-domain 
negatively controls receptor dimerization through an as yet undefined mechanism, as shown 
by several mutational studies (Wang, Peters, et al., 1995; Peters and Khan, 1999; Skafar and 
Koide, 2006; Yang, Singleton, et al., 2008). Although the F-domain is highly divergent 
amongst species, the last two amino acids of the C-terminus are conserved. 
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Since ER ’s function is critically influenced by numerous protein-protein interactions 
(PPIs), ER  is an attractive target for modulation by small-molecule modulators of PPIs. 
However, no such compound has been reported thus far. Recently, we reported that the  
small-molecule ligand Fusicoccin (FC) induces apoptosis in cancer cell lines from different 
origin, in synergy with the cytokine interferon alpha (IFNα) (De Vries-van Leeuwen, 
Kortekaas-Thijssen, et al., 2010). FC is the product of a fungus that infects peach and almond 
trees and acts as a PPI stabilizer of the plasma membrane ATPase and 14-3-3 proteins 
(Korthout and De Boer, 1994; Wurtele, Jelich-Ottmann, et al., 2003). 14-3-3 proteins are a 
family of adapter proteins present in all eukaryotic organisms. There are seven human 
isoforms (β, , ε, γ, σ, θ/τ and ζ), which can form homo- and/or heterodimers (Obsilova, 
Silhan, et al., 2008). Each monomer contains an amphipathic binding groove that can interact 
with a target protein (Yaffe, 2002; Aitken, 2006), of which over 300 have been identified in 
human cells (Meek, Lane, et al., 2004; Pozuelo Rubio, Geraghty, et al., 2004). In view of their 
involvement in vital cellular processes (signal transduction, metabolism, protein trafficking, 
cell-cycle progression and apoptosis), 14-3-3 proteins have gained a key position in cell 
biology, as well as in disease development such as tumorigenesis (Morrison, 2009). FC owes 
its specificity to the unique mode of interaction between 14-3-3 proteins and the plant 
ATPase: the ultimate ATPase C-terminus only partially fills the 14-3-3 binding groove, 
leaving a cavity that fits the FC molecule (Wurtele, Jelich-Ottmann, et al., 2003). Unlike other 
so-called mode-III binding targets identified thereafter in animal cells, the ATPase does not 
have an arginine (R) or lysine (K) at the -3 or -4 position relative to the phosphorylated S or T 
(Coblitz, Wu, et al., 2006). We hypothesize that the molecular mode of action of FC in tumor 
cells is analogous to the way it stabilizes the 14-3-3/ATPase interaction in plant cells. 
In the present study we examined the effect of FC treatment on breast cancer cells (MCF7) 
and the putative role of ER  in FC’s mode of action. We report that the ER  C-terminus 
interacts with 14-3-3 proteins through a mode-III binding motif and that FC stabilizes the 
ER /14-3-3 interaction. Furthermore, we show that 14-3-3 and FC binding negatively affect 
ER  dimerization and thereby the activity of the receptor. With this, we present a new 
regulatory mechanism of ER  involving 14-3-3 proteins and the small-molecule stabilizer 
Fusicoccin. 
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Results 
 
E2 induced MCF7 growth stimulation is reduced by Fusicoccin treatment 
Treatment of various tumor cell lines with FC in combination with IFNα effectively reduces 
cell growth through the induction of apoptosis (De Vries-van Leeuwen, Kortekaas-Thijssen, 
et al., 2010). However, when we treated MCF7 breast cancer cells grown in standard medium 
with FC, IFNα or a combination of both, only FC induced a small growth reduction        
(13%; data not shown). One difference between MCF7 and the other tumor cells tested, is that 
ERα expression level in MCF7 cells is high and that their cell growth is strongly stimulated 
by estrogens, like E2. To analyze if FC affects the E2 stimulated growth of MCF7 cells, we 
replaced the standard medium containing phenol red (a pH indicator known to act as a weak 
estrogen (Berthois, Katzenellenbogen, et al., 1986)), by phenol red free DMEM supplemented 
with 10% charcoal-treated FBS. Because serum E2 levels are rather in the pM range than in 
the frequently used nM range (Yaffe, Barnes, et al., 2007) we exposed the cells to                
E2 concentrations ranging from 0.1 pM to 10 nM, in the absence and presence of 10 μM FC 
(Figure 1). This shows that the E2-stimulated MCF7 growth is sensitive to FC in the          
sub-saturating E2 concentration range (0.1 and 10 pM), with a maximum growth inhibition of 
around 45%. In view of the interference of FC with the E2 stimulated growth, we next 
focussed on the possibility that ER  plays a role in the observed FC effect. 
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The C-terminal ERα F-domain interacts with 14-3-3 proteins in a ligand dependent 
manner 
The last two amino acids of the plant ATPase (TV) are essential for the interaction with      
14-3-3 proteins and FC, where phosphorylation of the penultimate threonine (T) enhances the 
affinity for 14-3-3 and the last valine (V) provides a contact site for stabilization by FC 
(Wurtele, Jelich-Ottmann, et al., 2003). The same two amino acids are also present at the     
C-terminal ERα F-domain (Suppl. Figure S1). To analyze the ERα/14-3-3 interaction a yeast 
two-hybrid based test was performed with the C-terminal half of ERα (ERα-LBD302-595) and 
all human 14-3-3 isoforms. Yeast cells transformed with ERα-LBD and each of the 14-3-3 
isoforms grew well on triple drop-out (TDO) plates (Figure 2A), providing the first indication 
that the ERα-LBD interacts with all 14-3-3 isoforms. Considering the putative role of the 
penultimate T in the ER /14-3-3 interaction, a point-mutation was made in T
594: ERαT594A. 
We hypothesized that if phosphorylation of T
594
 is important for 14-3-3 interaction,          
ERα-LBDT594A should show a reduced interaction with 14-3-3. Indeed, yeast cells 
transformed with the ERα-LBDT594A mutant, in combination with any of the 14-3-3 isoforms, 
were no longer able to grow on TDO plates (Figure 2A). From this we conclude that the       
C-terminal tip of the ERα protein is involved in the 14-3-3 interaction with a central role for 
T
594
. 
Figure 1. FC reduces the E2 induced MCF7 growth stimulation at sub-saturating         
E2 levels. MCF7 cells were treated with various E2 concentrations for 4 days in the 
presence ( ) and absence (●) of 10 μM FC. MCF7 cell growth increases with the        
E2 concentration till saturation at around 100 pM E2, while FC reduces the E2 
stimulated growth at sub-optimal E2 concentrations. 
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Figure 2. ER  interacts with 14-3-3, which can be enhanced by ligands and Fusicoccin. (A) The 
ERα-LBD interacts with all 7 human 14-3-3 isoforms, while no interaction is observed for     
ER -LBD
T594A. Yeast cells transformed with the ERα-LBD (wt or T594A) and a 14-3-3 isoform, or 
empty BD vector, were spotted on a DDO plate to check for colony growth and a TDO plate       
to check for protein interaction. (B) Ligand binding (E2 or 4OH-TAM) enhances the wt         
ERα-LBD/14-3-3  interaction. The interaction strength of the ERα-LBD (wt or T594A) interaction 
with 14-3-3  was determined with a -gal assay, in the presence or absence of E2 or 4OH-TAM 
(1 M each). (C) The pERα peptide interacts with 14-3-3, and FC enhances the interaction 
affinity for most isoforms. The FAM-SWpTY interaction with all 14-3-3 isoforms was measured 
in the presence ( ) and absence (●) of 10 M FC and various concentrations of the pER  peptide. 
Representative interactions are shown for 14-3-3 , 14-3-3β and 14-3-3 . (D) The ER /14-3-3 
interaction is dependent on the phosphorylation of the penultimate T in ER  (T
594
). Competitive 
anisotropy measurements were performed with 14-3-3  and a dephosphorylated ER  peptide 
(dER ) in the presence ( ) and absence (●) of 10 M FC, or pER  in the presence (♦) and 
absence (■) of 10 M FC. 
C H A P T E R    6 
 
 
 
158 
 
Binding of ligands to the LBD domain of ER  changes the conformation of the C-terminus 
of ERα (Ikeda and Inoue, 2004; Dahlman-Wright, Cavailles, et al., 2006; Powell, Wang, et 
al., 2010). To find out whether this ligand induced conformational change affects the 
interaction with 14-3-3, we performed a -galactosidase (β-gal) assay as a more quantitative 
reporter assay for the interaction. As shown in Figure 2B, both E2 and 4OH-TAM enhance 
the ERα-LBD/14-3-3θ interaction, while again ERα-LBDT594A does not interact with 14-3-3  
at all. Similar results have been obtained with other 14-3-3 isoforms (Suppl. Figure S2), and 
the ERα/14-3-3 interaction was not only observed with ERα-LBD, but also with full length 
ERα (Suppl. Figure S3). 
 
 
 
 
 
 
Fusicoccin enhances the affinity of the ERα/14-3-3 interaction 
The crystal structure of the [ATPase/14-3-3/FC]-complex shows that FC contacts two 
residues of the ATPase: the ultimate valine and a histidine at position 930. We modelled the 
ERα C-terminus on the crystal structure of the [ATPase/14-3-3/FC]-complex and this shows 
that it is theoretically possible to form an [ERα/14-3-3/FC]-complex without sterical 
hindrance and that FC contacts both V
595
 and H
567 of ERα (Suppl. Figure S1A). To provide 
experimental support for the hypothesis that FC stabilizes the ERα/14-3-3 interaction, a 
competitive anisotropy assay was performed, as described before (Wu, Coblitz, et al., 2006; 
De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). As competing peptide we used the 
phosphorylated ERα peptide (pERα) containing the last 16 amino acids of ERα with the 
penultimate T
594
 phosphorylated. Figure 2C shows a concentration dependent decrease in the 
anisotropy signal upon the addition of the pERα peptide for three 14-3-3 isoforms. Similar 
results were obtained for all other 14-3-3 isoforms (Table 1 and Suppl. Figure S4). This 
indicates that all 14-3-3 isoforms accommodate pERα with a Ki between 1.0 and 3.2 M. 
Table 1. Affinity (Ki) of the pER  peptide for all human 14-3-3 isoforms in the presence 
and absence of FC, and the affinity increase caused by FC. 
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Moreover, FC (10 μM) enhances the pERα/14-3-3 affinity 4- to 12-fold for most 14-3-3 
isoforms, except 14-3-3σ (Figure 2C and Suppl. Figure S4). 
To confirm the phosphorylation dependence of the ERα/14-3-3 interaction, we de-
phosphorylated the ERα peptide (dERα). The dERα peptide cannot compete for 14-3-3 
binding, nor is FC able to increase the affinity (Figure 2D). Based on these results we 
conclude that the C-terminal tip of ERα is involved in the ERα/14-3-3 interaction in a 
phosphorylation dependent manner, and that FC acts as a stabilizing small-molecule. 
 
 
 
 
Endogenous ER  from MCF7 cells interacts with endogenous 14-3-3 proteins and 
Fusicoccin 
Next, we performed pull-down assays with MCF7 cell lysate to confirm the [ERα/14-3-3/FC]-
complex formation with endogenous proteins. Magnetic beads were coated with either           
i) recombinant 14-3-3 protein, ii) FC or iii) ERα-LBD. To demonstrate the specificity of 
interaction, we added R18 (a peptide with high affinity for the 14-3-3 binding groove (Wang, 
Yang, et al., 1999)) or NIP (a non-interacting peptide) to the cell lysate. As shown in Figure 
3A, endogenous ER  interacts with 14-3-3 coated beads in the presence of NIP, while with 
R18 present the amount of ERα protein on the beads is at least three-fold lower. A similar 
Figure 3. Endogenous ER  binds 14-3-3, and can form the [ER /14-3-3/FC]-complex.            
(A) Endogenous ERα from MCF7 cells interacts with recombinant 14-3-3 proteins. A MCF7 cell 
lysate was incubated with recombinant 14-3-3 coated beads in the presence of the non-interacting 
peptide (NIP) or the 14-3-3 blocking R18 peptide. ER  binding to the beads was visualized by 
Western blotting. (B) Endogenous ER  and 14-3-3 proteins from MCF7 cells bind to FC coated 
beads. MCF7 cell lysate was incubated with FC coated beads in the presence of the                  
non-interacting peptide (NIP) or the 14-3-3 blocking R18 peptide. The bound ER  and 14-3-3 
proteins on the beads were visualized by Western blotting. (C) Endogenous 14-3-3 proteins from 
MCF7 cells interact with GST-ERα-LBD. A MCF7 cell lysate was incubated with recombinant 
GST-ERα-LBD coated beads in the presence of the non-interacting peptide (NIP), the 14-3-3 
blocking R18 peptide and FC as indicated. 14-3-3 binding to the beads was visualized by Western 
blotting. 
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experiment with FC-coated beads (performed after confirming the functionality of the FC 
molecule when coupled to the beads (Suppl. Figure S5)) established that the FC-beads bind 
both endogenous 14-3-3 proteins and ER  from the MCF7 cell lysate as well (Figure 3B). 
The R18 peptide strongly reduced the amount of 14-3-3 protein bound to the FC-beads         
(> 95% reduction), while bound ER  was again reduced with around 60%, just as with the 
14-3-3 coated beads. Apparently, there is some non-specific ER  binding to the bead matrix. 
The ERα-LBD pull-down shows specific interaction with endogenous 14-3-3 proteins and, 
importantly, the addition of FC to the cell extract results in a 3.5-fold increase in binding of 
14-3-3 proteins (Figure 3C). 
 
T
594A mutation enhances the transcriptional activity of ERα, while FC reduces the 
E2 induced activation 
To address the importance of the T
594
 residue for the transcriptional activity of ERα and 
sensitivity for FC, we performed ERE-luciferase (ERE-luc) assays in U2OS cells transfected 
with full length ERα or ERαT594A. U2OS cells have no endogenous ERα activity and allow for 
the testing of activating ligands and other compounds, like FC. Without E2 stimulation, the 
basal activity of ERαT594A is already twice as high as that of ERα (Figure 4). As expected,    
E2 enhances the activity of ERα as well as ERαT594A. Importantly, FC blocks over 70% of the 
E2 induced ERα activation, while the T594A mutation diminishes the FC effect with more than 
50% (Figure 4). The residual sensitivity of the ERαT594A mutant for FC is in line with the 
observation by Fuglsang et al. that FC also promotes 14-3-3 binding to the full length 
dephosphorylated plant ATPase, albeit less than to the phosphorylated ATPase (Fuglsang, 
Visconti, et al., 1999). This suggests that FC enhances the 14-3-3 binding to the C-terminal tip 
of ERα, and thereby interferes with the ability of E2 to stimulate the ERα activity.  
 
The T
594
A mutation stimulates ERα dimerization 
There are several possibilities to explain the FC induced reduction in ERα activity: FC affects 
the level of ER  mRNA, the production of ER  protein or the stability of the ER  protein. 
Therefore, we analyzed the ERα expression in MCF7 cells by Q-PCR measurements and the 
amount of ER  protein by Western blotting. ER  mRNA expression is slightly reduced in  
E2 treated cells and even further in cells treated with FC/E2 (Figure 5A). The reduction of 
ERα expression in MCF7 cells after E2 exposure has been well documented (Borras, Hardy, 
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et al., 1994), but the synergistic effect of FC needs further study. Despite the reduced mRNA 
levels, the amount of ER  protein in FC/E2 treated MCF7 cells is the same as in E2 treated 
cells (Figure 5B). The presence of E2 reduces the ER  concentration, as has been reported 
before to be caused by the proteasomal degradation of ER  after the activation by E2 (Laios, 
Journe, et al., 2005). So, the FC induced reduction in ER  activity is not due to changes in 
ER  protein level. 
 
 
 
 
Another possibility is that 14-3-3 binding (enhanced by FC) to the tip of the F-domain 
affects receptor dimerization. Dimerization is necessary for the E2 induced ER  activation 
and the F-domain acts as a negative regulator of receptor dimerization (Yang, Singleton, et 
al., 2008). To analyze the effect of the T
594
A mutation on the ER  dimerization, we 
performed a yeast two-hybrid β-gal assay with ER -LBD or ER -LBDT594A in both the 
pGADT7 and pBD vector. Figure 5C shows that both ER -LBD and ER -LBD
T594A
 dimerize 
weakly without ligands. Upon the addition of ligands the ER -LBD dimerization is enhanced 
around 5-fold by E2 and 16-fold by 4OH-TAM. However, the dimerization of the ER -
LBD
T594A
 mutant is enhanced about 30-fold by either E2 or 4OH-TAM. Similar results have 
been obtained for the dimerization of full length ER  or ER
T594A
 with ER -LBD or ER -
LBD
T594A
 (Suppl. Figure S6). Based on these results and the role of T
594
 in 14-3-3 binding 
Figure 4. Transcriptional activity of ER  is enhanced by the T
594
A mutation, while FC 
hampers the E2 induced activation. The transcriptional activity of ER  (wt and T
594
A) 
was measured with an ERE-luc assay in transfected U2OS cells, in the presence and 
absence of 10 nM E2 and/or 10 M FC. 
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reported above, we postulate a novel level of ER  regulation through 14-3-3 controlled 
receptor dimerization that can be targeted by the small-molecule stabilizer Fusicoccin. 
 
 
 
 
 
Discussion 
 
Although selective ER  modulators (SERMs) are used effectively to treat breast cancer, 
resistance against the SERMs does develop, what results in the relapse of the disease. Since 
SERMs modulate ER  activity by competing for access to the cognate ligand-binding pocket, 
Figure 5. T
594
A mutation stimulates ER  dimerization. (A) E2 and FC/E2 treatment slightly 
reduce the ER  gene expression in MCF7 cells. MCF7 cells were treated for 3 days, after which 
the ER  expression was measured by Q-PCR. Representative mean normalized expression 
(M.N.E.) is shown, using β-actin as reference gene. (B) FC does not affect the ER  protein level 
in MCF7 cells. Cells received the same treatment as in (A), after which a whole cell lysate was 
made and the ER  protein level was determined by Western blotting, using β-actin as loading 
control. Representative blot is shown. (C) The T
594
A mutation enhances the ligand induced ER  
dimerization. The ERα-LBD/ERα-LBD or ERα-LBDT594A/ERα-LBDT594A dimerization was 
determined with a -gal assay, in the presence and absence of ligands (1 M each). 
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there is a new focus on the discovery or design of small molecules that specifically target 
ER  outside the ligand binding pocket and thereby affect the interaction between ER  and 
co-regulators (Koehler, 2010). In this respect, the small molecule protein:protein stabilizer 
Fusicoccin is of interest (Korthout and De Boer, 1994; Wurtele, Jelich-Ottmann, et al., 2003). 
We discovered that FC induces apoptosis of cells from various malignant tissues like lung, 
ovary, prostate, and colon in synergy with the cytokine IFN  (De Vries-van Leeuwen, 
Kortekaas-Thijssen, et al., 2010). However, when we tested the breast cancer line MCF7 there 
was no synergy with IFN , but FC alone reduced the E2 dependent growth of the cells in the 
non-saturating E2 concentration range. To unravel the mechanism of this FC effect at the 
molecular level, we formulated as working hypothesis that FC interferes either with 
intermediates in the estrogen signalling pathway or directly with ER . We started with the 
latter possibility because of an obvious analogy with the plant FC receptor (Korthout and De 
Boer, 1994; Wurtele, Jelich-Ottmann, et al., 2003). 
The FC receptor in plants, the plasma membrane ATPase, is the first 14-3-3 target 
identified that interacts with the ultimate C-terminal tip; now referred to as a mode-III motif 
(Jahn, Fuglsang, et al., 1997; Oecking, Piotrowski, et al., 1997; Ganguly, Weller, et al., 2005). 
The crystal structure of the trimeric [ATPase/14-3-3/FC]-complex revealed that a number of 
amino acids in the ATPase are crucial for the interaction with 14-3-3 and the stabilizing effect 
of FC: the penultimate Thr (phosphorylation of which enhances the ATPase/14-3-3 affinity), 
and the ultimate Val plus a His at position -27 from the tip (H
930 
in the PMA2 protein) that 
contact the FC molecule (Ottmann, Marco, et al., 2007). In analogy with the plant ATPases, 
the C-terminus of human ER  also ends with -TV and has a His at position -29 from the tip. 
Modelling the C-terminal ER  F-domain on the crystal structure of the [ATPase/14-3-3/FC]-
complex supported our idea that ER  can provide the contact sites needed for the interaction 
with both 14-3-3 and FC. The modelling is supported by experimental data that demonstrates 
interaction of endogenous ER  with recombinant 14-3-3 proteins and vice versa, including 
the enhancement by FC. There is one other report on ER  14-3-3 interaction where in vitro 
translated 
35
S-labeled ER  was pulled-down with GST-14–3-3 (Zilliacus, Holter, et al., 
2001). Since the binding of ligands to ER  is known to drive large conformational changes, 
notably affecting the position of helix 12 and the C-terminal F-domain (Ikeda and Inoue, 
2004; Dahlman-Wright, Cavailles, et al., 2006; Powell, Wang, et al., 2010), we conclude that 
the 14-3-3 interaction site is largely inaccessible in the unliganded receptor. 
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T
594
 clearly has a key function in ER /14-3-3 interaction. As expected for a mode III 
binding site, the T
594
A mutation in the yeast two-hybrid assay and dephosphorylation of the 
peptide prevent the ER /14-3-3 interaction. In analogy with the plant FC receptor (Wurtele, 
Jelich-Ottmann, et al., 2003), the mode-III interaction should leave a cavity in the 14-3-3 
binding groove that can be filled by FC. Indeed, FC strongly enhances the affinity between 
the C-terminal ER  peptide and 14-3-3 proteins, FC coated beads specifically bind 
endogenous ER  and 14-3-3 from MCF7 cell lysate, and FC enhances the amount of 
endogenous 14-3-3 interacting with the ER -LBD domain. All these effects of FC are also 
reported for the plant ATPase/14-3-3 complex (Wurtele, Jelich-Ottmann, et al., 2003; Bobik, 
Duby, et al., 2010). 
Interaction with 14-3-3 proteins affects targets in different ways: it can mask nuclear 
localization signals, promote forward trafficking of membrane proteins from the endoplasmic 
reticulum, inhibit or activate enzymatic activity etc. Here, 14-3-3 interaction with the ER    
F-domain prevents receptor dimerization; a comparable effect is observed for the plant 
ATP/14-3-3 interaction, where the intramolecular interaction between the autoinhibitory      
C-terminus and the catalytic domain is prevented by 14-3-3 (Speth, Jaspert, et al., 2010). Also 
Yang et al. concluded that the carboxyl terminal F-domain of ER  imparts internal restraint 
on ER dimerization in the presence of E2 (Yang, Singleton, et al., 2008), but did not provide a 
molecular mechanism. 
A key experiment was the in vivo test: will FC and 14-3-3 binding affect the transcriptional 
activity of ER ? We reasoned that if we treat cells with E2 to activate ER , this induces a 
conformational change in the receptor, exposing the F-domain for 14-3-3 (and FC) binding. 
The ERE-luc reporter assay shows that in the presence of E2, FC strongly reduces the 
transcriptional activity. The importance of T
594
 is emphasized by the enhanced activity of 
ER
T594A
 compared to wt ER . This suggests that 14-3-3 binding to the C-terminal tip of 
ER  reduces the transcriptional activity of the receptor. The difference with the 
phosphorylation dependence of the ERα peptide/14-3-3 interaction as observed in the 
anisotropy measurements, is likely due to the fact that the peptide (16 amino acids) lacks 
additional contact sites, like H
567
, that are present in the full-length ER  protein. Because   
14-3-3 interactions are phosphorylation-dependent, we hypothesize that the 14-3-3 controlled 
ER  dimerization and activation is integrated in phospho-regulatory pathways that are crucial 
for normal growth and development and that often become dysregulated in human disease 
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states such as cancer (Morrison, 2009). Therefore, the next challenge will be the identification 
of the kinase (and phosphatase) that (de)phosphorylate T
594
. Enhancing T
594
 phosphorylation 
in combination with the stabilizing effect of FC may become an alternative therapy to reduce 
the ER  activity in malignant breast cancer cells. 
In view of the above described role of residue T
594
 it is remarkable that several reports 
have been published about a T
594
 polymorphism (Curran, Lea, et al., 2001; Akisik and Dalay, 
2004; Kassi, Vlachoyiannopoulos, et al., 2005; Wu, Sekine, et al., 2005). Although the       
T
594
 polymorphism (ACG [T]  ACA [T]) is a synonymous (silent) mutation that does not 
alter the protein sequence, it has been associated with sporadic breast cancer development 
(Curran, Lea, et al., 2001), migraine (Colson, Lea, et al., 2004) and the development of 
systemic lupus erythematosus at a younger age (Kassi, Vlachoyiannopoulos, et al., 2005). 
Although it is not exactly clear how synonymous mutations work, there is ample evidence that 
they can be harmful, as they have been linked to around 50 genetic diseases. Therefore, it 
seems more than a coincidence, that in the light of the here described function of T
594
 in the 
regulation of the ER  activity a polymorphism is found in amino acid T
594
, and it will be most 
interesting to see if this synonymous mutation is linked to the ERα (de)regulation. 
In conclusion, we have shown that 14-3-3 proteins interact with the ER  receptor through 
a mode-III interaction motif located in the carboxy-terminal F-domain of ER . This 
interaction prevents receptor dimerization, resulting in a reduced transcriptional activity. The 
penultimate threonine (T
594
) has a key function in the 14-3-3/ER  interaction and a mutation 
in this amino acid abolishes the 14-3-3 interaction, increases ligand induced receptor 
dimerization and enhances the transcriptional activity. The small-molecule ligand Fusicoccin 
stabilizes the 14-3-3/ER  interaction and reduces the in vivo transcriptional ER  activity. As 
far as we know, FC is the first small molecule ligand that targets the ER  at a position 
different from the estrogen binding domain and stabilizes the interaction with a regulatory 
protein. Therefore, this small molecule ligand and the whole class of related fusicoccanes 
(Muromtsev, Voblikova, et al., 1994) may provide new therapeutic tools to control the 
function of ER  in malignant tissues at a level different from the classical (anti-)estrogens 
(Koehler, 2010). 
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Material and methods 
 
Reagents. Fusicoccin was obtained from Prof. A. Babakov (Moscow, Russia). -Estradiol and     
4OH-Tamoxifen were purchased from Sigma Aldrich and human recombinant Interferon-α from 
Pierce Biotechnology. FAM-SWpTY peptide was a kind gift from Dr. M. Li (Baltimore, MD, USA) 
(Wu, Coblitz, et al., 2006). 
 
Cells and cell culture. The MCF7 and U2OS cell lines were maintained in DMEM medium         
(PAA Laboratories) supplemented with 10% FBS (PAA Laboratories), 100 units/ml penicillin and  
100 μg/ml streptomycin (both Lonza). During experiments the cells were grown in phenol red-free 
DMEM (PAA Laboratories) supplemented with 10% charcoal-treated FBS (HyClone), 100 units/ml 
penicillin and 100 μg/ml streptomycin, unless indicated differently. Both cell lines were grown in a 
37°C humidified growth chamber containing 5% CO2. 
 
Cell viability assay. Cells were seeded at 2,000 cells/well in a 24 well plate. The next day medium was 
removed and replaced by medium containing the indicated treatment compounds, or their solvents as 
control. After treatment the amount of viable cells was determined with an MTT-assay as described 
before (De Vries-van Leeuwen, Kortekaas-Thijssen, et al., 2010). Average of 2 independent 
experiments is shown (± S.E.). 
 
Yeast two-hybrid, and β-gal staining. Human ERα (full length and LBD [a.a. 302-595]) was cloned 
into the pGADT7 vector (Clontech); both wt and with a T
594
A point mutation. The pBD-GAL4 vector 
(Stratagene) was used to prepare pBD-14-3-3, pBD-ERα-LBD and pBD-ERα-LBDT594A. Yeast 
transformations were performed using the LiAc protocol. Briefly, PJ69-4A cells were grown o/n in 
YAPD medium. A 0.5 ml aliquot was spun down and the cells were mixed with 0.5 μg AD, 0.5 μg BD 
and 50 μg linearized salmon sperm DNA (Stratagene). Next, 100 μl 40% PEG-4000/0.2 M LiAc was 
added per tube, and the tubes were incubated for 30 min at 30°C followed by 15 min at 42°C, before 
the cells were plated out on selective SD-LW (DDO) plates and incubated for 3-5 days at 30°C. Some 
of the grown colonies were dissolved in 50 μl MQ, of which 2 μl was spotted on DDO plates and TDO 
plates (SD-LWH plate containing 7.5 mM 3-AT). These plates were again incubated at 30°C for        
1-3 days, to check for colony viability and interaction. 
To analyze the interaction strength a β-galactosidase ( -gal) assay was performed as described at 
http://labs.fhcrc.org/gottschling/Yeast%20Protocols/Bgal.html. Colonies were only grown o/n in 3 ml 
SD-LW medium (containing the indicated ligands or their solvents), and resuspended in 3 ml Z-buffer 
(see protocol). Average IU are shown of at least 3 independent colonies (± S.E.). 
 
Competitive anisotropy measurements. Each sample contained 100 nM FAM-SWpTY, 1 M      
GST-Hs-14-3-3, various concentrations ERα peptide (pER ; last 16 amino acids of ERα with T594 
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being phosphorylated), and when indicated 10 M FC, in a final volume of 200 l (PBS). Samples 
were incubated for 2 hours at RT before their anisotropy was measured with the Cary Eclips 
fluorescence spectrophotometer (Varian). All anisotropy values are corrected for the background 
anisotropy of FAM-SWpTY alone. 
pERα peptide was dephosphorylated (dER ) by incubating for 90 min at 37°C in the presence of 
calf intestinal alkaline phosphatase (CIP, New England Biolabs), using the recommended buffer. 
 
ERα gene expression and protein level determination. Sixty thousand MCF7 cells/well were seeded 
in a 6 well plate (or 4x 12,000 cells in 24 well plate) and treated with the indicated compounds. The 
total RNA was extracted with TRIZOL
®
 Reagent (Invitrogen), a DNase treatment was performed with 
DNaseI (RNase free; Roche) and the RNA was converted into first strand cDNA using an oligo(dT) 
primer and SuperScript™-II Reverse Transcriptase (Invitrogen); all done according to the 
manufacturer’s instruction. From this, equal amounts of cDNA were used for expression analysis with 
SYBR
©
 Green (Applied Biosystems) using the MJ Opticon Monitor (BioRad). The data was analyzed 
with qgene96 (Muller, Janovjak, et al., 2002), using β-actin as reference gene. Used primers: ERα 
TGGTCAGTGCCTTGTTGGATGCT (sense) and CAGGTTGGTCAGTAAGCCCATCATC (anti-sense), 
and β-actin AGCATCCCCCAAAGTTCACAATGT (sense) and GATGGCAAGGGACTTCCTGTAACAA 
(anti-sense). 
A whole cell lysate was made with NP-40 lysis buffer (50 mM Tris-HCl, 1% NP-40, 100 mM 
NaCl, 5 mM EDTA, 2 mM MgCl2, 10% Glycerol, 1 mM PefaBloc SC (Fluka), 10 μM Cantharidin,  
1x Protease inhibitor mix cocktail (Roche), pH 7.4). The isolated protein concentration was 
determined with the BCA protein assay (Pierce), using BSA for the standard curve. Equal amounts 
were loaded on SDS-PAGE, and probed with an ERα antibody (H184 or HC20, Santa Cruz) or actin 
(I19, Santa Cruz). Both experiments were repeated at least 2 times. Representative examples are 
shown (± S.E.). 
 
Pull-down assay. MCF7 cells were seeded at 250,000 cells/plate in 10 cm dishes 3 days before the 
experiment in standard DMEM. Cells were washed 2x with PBS (supplemented with 1 mM CaCl2 and 
0.5 mM MgCl2), before lysis with 0.75 ml NP-40 lysis buffer/plate. The isolated protein concentration 
was determined with BCA protein assay. Equal amounts of protein were mixed with GST-14-3-3 (mix 
of all seven human isoforms), GST-ERα-LBD or FC-coated beads (FC was coated on magnetic 
hydrazide beads after changing the vinyl group into a reactive aldehyde) and 100 M non-interacting 
peptide (NIP; ERYMGICMRKQYNNFVPVCLRS) or 14-3-3 interacting peptide R18 
(PHCVPRDLSWLDLEANMCLP, 14-3-3 interaction motif in bold (Wang, Yang, et al., 1999)), and 
incubated for 1 hour at RT while rotating. Beads were washed four times with lysis buffer, before a 
mock elution was performed with NIP, followed by a R18 elution. Next the beads were resuspended in 
100 l SDS sample buffer, and the associated endogenous ER  and/or 14-3-3 were detected by 
Western blotting. Each experiment was repeated at least 2 times. Representative examples are shown. 
C H A P T E R    6 
 
 
 
168 
 
 
ERE-luciferase assay. U2OS cells were seeded at 20,000 cells/well in a 24 well plate, 4 hours before 
they were transfected with 10 ng pMSCV-ERα (wt or T594A), 0.2 ug ERE-tk-Luc, and 1 ng       
Renilla-Luc per well, using PEI for 16 hours. Next, transfection medium was removed, cells were 
washed 1x with PBS and treated for 48 hours. After treatment the ERα activity was determined with a 
Dual-Luciferase
®
 Reporter Assay (Promega), according to the manufacturer’s instruction. The 
luminescent intensities were recorded on a Berthold Centro XS3-LB-960 (Berthold technologies). The 
ERE-luciferase signal was first normalized to the Renilla-luciferase signal, this ratio was subsequently 
normalized to the ratio of untreated ERα (wt) transfected cells. Average ratios are shown from             
3 independent experiments (± S.E.). 
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Suppl. Figure S1. C-terminal ERα tip is conserved and can be modelled into a [ERα/14-3-3/FC]-
complex. (A) Modelling of the ER  C-terminal sequence on the crystal structure of the 
[ATPase/14-3-3/FC]-complex (PDB id 2098) shows that it is theoretically possible to form an 
[ERα/14-3-3/FC]-complex without sterical hindrance. In this, ER  (blue ribbon) is able to form 
the same interactions with FC (green stick) and 14-3-3 (red ribbon) as the ATPase. (B) Alignment 
of the last 52 amino acids of human ER  and the ATPase of Nicotiana plumbaginifolia (PMA2) 
and Arabidopsis thaliana (AHA2). The alignment indicates that the three most important amino 
acids for the FC receptor complex formation (V at -1, T at -2 and H at -27/29 position from the  
C-terminal tip) are present in all proteins. (C) Alignment of the C-terminal 81 amino acids of 
ER  from various species, showing that although the overall sequence homology of the F-domain 
is rather low the ultimate tip is conserved. 
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Suppl. Figure S3. Ligand binding to ER  (E2 or 4OH-TAM) enhances the full length 
ERα/14-3-3  interaction, but not ER T594A. The interaction strength of full length ERα 
(wt and T
594
A) with 14-3-3  was determined with a -gal assay, for which the 
transformed yeast cells were grown overnight in the presence and absence of ER  
ligands (1 M each). 
Suppl. Figure S2. Ligands, like E2, enhance the ERα-LBD/14-3-3 interaction. E2        
(1 M) enhances the interaction of various 14-3-3 isoforms with wt ERα-LBD, but not 
with ERα-LBDT594A. 
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Suppl. Figure S4. Anisotropy measurements shows that all 14-3-3 isoforms interact with the pERα 
peptide with Ki-values between 1.0 and 3.2 M. FC increases the affinity 4 to 13 times for all 
isoforms, except 14-3-3σ. 
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Suppl. Figure S6. T
594
A mutation stimulates the ligand induced ER  dimerization of ER -
LBD with full length ER . The interaction strength of the ER -LBD dimerization with full 
length ERα (both wt or T594A) was determined with a -gal assay, for which the transformed 
yeast cells were grown overnight in the presence and absence of ER  ligands (1 M each). 
The wt ER  dimerization is enhanced 1.3-fold by E2 and 5.4-fold by 4OH-TAM, while the 
ER  (T
549
A) dimerization is enhanced about 19-fold by E2 and 9.4-fold by 4OH-TAM. 
Suppl. Figure S5. FC is still functional after coupling to magnetic beads (FC coupled beads). 
(A) Silver staining shows that the FC coupled beads selectively bind endogenous 14-3-3 
proteins (27 and 29 kD) only in the presence of a C-terminal peptide derived from the plant 
ATPase (YpTV), and not in the presence of the non-interacting peptide (NIP), and can be 
eluted of the beads with the 14-3-3 interacting peptide R18. (B) 14-3-3 Western blot confirms 
the specificity of the 14-3-3 interaction to the FC coupled beads, and shows that only part of 
the complex is eluted of the beads with the R18 peptide. 
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Small molecular compounds are currently used to treat various diseases, including cancer. 
Many of these anticancer compounds are derived from living organisms. Etoposide and 
Paclitaxel (taxol), for instance, are both isolated from plants while doxorubicin and bleomycin 
are derived from bacteria. As many tumors become resistent over time, new anticancer drugs 
are still needed. Therefore there is a large interest in the identification of small molecules that 
can be used as cancer therapeutics. A large group of active small molecules that has hardly 
been analyzed belong to the fusicoccane family. Fusicoccanes possess a 
dicyclopenta[a,d]cyclooctane skeleton, 5-8-5 core ring structure, with various side groups 
linked to it and are produced by higher plants, fungi and even animals (insects). Besides 
affecting various biological processes in plants, fusicoccanes also affect animal cells. 
Ophiobolin-A (OPH-A), for instance, affects mammalian cells by the selective inhibition of 
calmodulin, while Cotylenin-A (Cot-A) induces differentiation in myeloid leukaemia cells 
and has an anticancer activity when combined with interferon  (IFN ) or rapamycin (Rap). 
A fusicoccane closely related to Cot-A is Fusicoccin-A (FC). FC has been shown to stabilize 
the protein/protein-interaction between with the C-terminal tip of the plant plasma membrane 
H
+
-ATPase and 14-3-3 proteins, break seed dormancy in plants, and inhibit an outward 
rectifying K
+
 channel in barley radicles. Furthermore, it randomizes the left/right organ 
asymmetry very early during Xenopus laevis development. 
As FC is structurally closely related to Cot-A we studied the anticancer effect of FC in 
chapter 2. We found that FC reduces the number of viable OVCAR3 ovarian carcinoma 
cells. The efficacy of FC can be enhanced by combining it with IFN  but not Rap, or by 
applying it after an IFN  treatment. The IFN /FC treatment is effective against cancer cell 
lines derived from different origins and is far less harmful for HUVEC cells (Human 
Umbilical Vein Endothelial Cells). FC selectively induces apoptosis in cancer cells by 
stimulating the TRAIL pathway. 
The TRAIL pathway does probably not include the primary target of FC. To identify the 
FC receptor and to completely clarify the working mechanism in cancer cells we subsequently 
focussed on what is known about the FC receptor in plants, and used this knowledge in our 
attempt to identify the human FC receptor. In plants, FC stabilizes the plasma membrane    
H
+
-ATPase/14-3-3 interaction. Since mammalian cells do not possess a similar H
+
-ATPase, 
we conducted a database search to identify ion channels, which FC also affects in plants, and 
transporters that have a C-terminal tip similar to the plant H
+
-ATPase. Such a tip should allow 
for the binding of FC in combination with 14-3-3 proteins and a subsequent modulation of the 
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ion channel or transporter could explain the observed anticancer effect. The database search 
identified several transporters and ion channels, of which only the TASK channels (TASK1 
and TASK3) were already known to interact with 14-3-3 proteins by their C-terminal tip. 
Before studying the effect of FC on the TASK channels we first analyzed the ion channels 
present in OVCAR3 cells in general (chapter 3). This showed that OVCAR3 cells mainly 
express K
+
 channels as well as some Na
+
 channels. The large outward K
+
 current is enhanced 
when the extracellular [Ca
2+
/Mg
2+
] is reduced, and blocked by a subsequent reduction of the 
extracellular pH to 6.2. These characteristics indicate that TASK channels are likely present in 
OVCAR3 cells. Besides TASK, other K
+
 conducting channels must be present in OVCAR3 
cells as well, as TASK channels are not known to have the large voltage gated single channel 
openings with a slope conductance of 93 pS (± 1.7) we also observed, and furthermore part of 
the K
+
 current is not affected by the changes in the extracellular [Ca
2+
/Mg
2+
] or pH. 
In chapter 4 we studied the effect of FC on TASK channels and the C-terminal   
TASK/14-3-3 interaction. We confirmed that all human 14-3-3 isoforms interact with the     
C-terminal tip of TASK1 and TASK3 and demonstrated that this interaction is dependent on 
the phosphorylation of the penultimate serine residue. FC enhances the TASK1/14-3-3 
interaction for all isoforms up to 7 times. Expression analysis demonstrated that TASK1 and 
TASK5 are expressed in OVCAR3 cells and the TASK1 protein could also be detected by 
Western blotting. FC and/or IFN  treatment did not change the TASK1 or TASK5 
expression. OVCAR3 cells express K
+
 channels with TASK-like characteristics, as we 
already described in chapter 3. FC seems to inhibit most of the TASK current in untreated 
OVCAR3 cells, while it inhibits the TASK current as well as an extra K
+
 current in IFN  
treated cells; both in a 14-3-3 dependent manner. We have however not been able to 
decisively reproduce these data nor have we identified the second FC inhibited ion channel in 
IFN  treated cells yet. 
Because we could not identify the FC receptor responsible for the apoptosis induction with 
certainty by the ion channel analysis we also performed a more general proteomics approach 
to identify the FC receptor. For this, FC was coated on magnetic beads (FC-Beads), which 
were subsequently used in a pull down assay in chapter 5. The FC-Beads bound endogenous 
14-3-3 proteins selectively from an MCF7 or OVCAR3 whole cell lysate, and mass 
spectrometry analysis identified 21 proteins that were bound to/eluted off the FC-Beads and 
possess a C-terminal tip that should allow for 14-3-3 and FC binding. Of these 21 proteins, 
three potential targets were further analyzed: PMCA1 (a Ca
2+
-ATPase, related to the plant  
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H
+
-ATPase), PABPC1 (polyadenylate-binding protein 1) and STAT1 (signal-transducer and 
activator of transcription 1). PABPC1 is identified in almost all human 14-3-3 interactome 
studies as well as in two independent FC-Bead pull-downs, and STAT1 plays an important 
role in IFN signalling. For PMCA1 we could not observe a C-terminal interaction with any of 
the 14-3-3 isoforms by a yeast two-hybrid assay. C-terminal peptides of both PABPC1 and 
STAT1, however, do interact with 14-3-3 proteins in a phosphorylation dependent manner in 
an anisotropy assay, and FC enhances their affinity. However, no interaction could be 
observed for larger C-terminal fragments of both proteins in a yeast two-hybrid assay, 
although it is not known if these fragments get phosphorylated in yeast. More experiments are 
therefore needed to confirm if PMCA1, PABPC1, STAT1 or any of the other identified 
proteins is the FC receptor in the cancer cells. 
Almost all cancer cell lines we analyzed responded to the IFN /FC treatment, except for 
the MCF7 breast cancer cell line for which we could hardly detect a growth reduction. In 
contrast to the MDA-MB-231 breast cancer cell line, which responds to IFN /FC treatment, 
MCF7 cells have a high estrogen receptor  (ER ) expression. MCF7 cells rely on the 
activation of ER  for their growth and survival and a reduction of the ER  activity with anti-
estrogens like tamoxifen (TAM) is therefore also the main strategy currently used to treat  
ER
+
 breast cancers. In chapter 6 we studied the effect of FC on ER  and report a new ER  
regulatory mechanism, which involves the ER  C-terminus and 14-3-3 proteins. ER  
contains a C-terminal mode-III 14-3-3 binding motif, of which we showed that it interacts 
with 14-3-3 proteins. This interaction is enhanced by ligand binding to ER  and depends on 
the phosphorylation of the penultimate threonine residue of ER , T
594
. FC enhances the 
ER /14-3-3 interaction of the phosphorylated ER  peptide with all 14-3-3 isoforms, except 
14-3-3 . Moreover, the [FC/ER /14-3-3]-complex is also formed by endogenous proteins 
form a MCF7 whole cell lysate, and FC reduces the estradiol (E2) induced MCF7 growth 
stimulation. This is most likely due to a reduced ER  activity caused by the FC treatment     
in vivo. The T
594
A mutation also enhances the ligand induced ER  dimerisation and the 
transcriptional activity in vivo. Combined, these data result in a model in which C-terminal 
14-3-3 binding to the ER  F-domain after T
594
 phosphorylation prevents ER  dimerisation 
which is needed for a full activation of the receptor. We thereby provide the underlying 
mechanism of the C-terminal F-domain in regulating receptor dimerization and activity, and 
S U M M A R Y 
 
 
 
183 
 
offer a novel treatment strategy using FC as small-molecule ligand that inhibits the ERα 
activity through binding outside the ligand binding domain (LBD). 
 
In conclusion, this thesis illustrates the importance and potency of small molecules like 
FC, in modifying protein/protein-interactions and regulating protein activity. Although the 
working mechanism of FC in the different tumor cell lines is still not completely understood it 
appears to selectively modulate several cellular processes and protein/protein-interactions in a 
cell type dependent manner, and reduces thereby the growth and viability of the cancer cells. 
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Voor de behandeling van tumoren worden verschillende kleine organische moleculen 
gebruikt. Veel van deze moleculen zijn afkomstig van levende organismen. Etoposide en 
paclitaxel (taxol) zijn bijvoorbeeld afkomstig uit planten, terwijl doxorubicine en bleomycine 
zijn geïsoleerd uit bacteriën. Omdat veel tumoren resistent worden tegen de bestaande 
medicijnen zijn nieuwe antitumor medicijnen nog steeds nodig en hierdoor is er een grote 
belangstelling voor kleine moleculen met een antitumor werking. Een grote groep moleculen 
die nauwelijks geanalyseerd zijn behoren tot de fusicoccaan familie. Fusicoccanen bezitten 
een dicyclopenta[a,d]cyclooctaan skelet (5-8-5 basis ringstructuur) waar verschillende 
zijgroepen aan zitten. Ze worden onder andere geproduceerd door hogere planten, schimmels 
en zelfs dieren (insecten). Naast het beïnvloeden van verschillende biologische processen in 
planten hebben fusicoccanen ook een effect op dierlijke cellen. Zo beïnvloedt Ophiobolin-A 
(OPH-A) zoogdiercellen door de selectieve remming van calmoduline, en induceert 
Cotylenin-A (Cot-A) differentiatie in myeloïde leukemie cellen en heeft het een antitumor 
werking wanneer het gecombineerd wordt met interferon  (IFN ) of rapamycine (Rap). Een 
fusicoccaan nauw verwant aan Cot-A is Fusicoccine-A (FC). FC stabiliseert de eiwit/eiwit-
interactie tussen het C-terminale uiteinde van de plasmamembraan H
+
-ATPase en 14-3-3 
eiwitten in planten, breekt de kiemrust van zaden en remt een uitwaarts rectificerend           
K
+
-kanaal in gerst wortels. Verder verstoort FC ook de links/rechts orgaan asymmetrie tijdens 
een vroeg stadium van de Xenopus laevis ontwikkeling. 
Omdat FC structureel nauw verwant is aan Cot-A, hebben wij het antitumor effect van FC 
onderzocht in hoofdstuk 2. Hieruit bleek dat FC het aantal levensvatbare OVCAR3 ovarium 
carcinoma cellen vermindert. De effectiviteit van FC kan worden verhoogd door het te 
combineren met IFN  (maar niet Rap) of toe te passen na een IFN  behandeling. De 
IFN /FC behandeling is effectief tegen tumorcellijnen afkomstig van verschillende typen 
tumoren en is nauwelijks schadelijk voor gezonde HUVEC cellen (humane navelstreng 
endotheelcellen). FC induceert apoptose in de tumorcellen door de stimulatie van de TRAIL 
pathway. 
De TRAIL pathway is waarschijnlijk niet het primaire FC target. Om de primaire            
FC receptor te identificeren en het volledige werkingsmechanisme van FC in tumorcellen op 
te helderen, hebben wij ons daarom gericht op wat bekend is over de FC receptor in planten. 
In planten stabiliseert FC de plasmamembraan H
+
-ATPase/14-3-3 interactie. Zoogdiercellen 
beschikken echter niet over een soortgelijke H
+
-ATPase. Daarom hebben wij een database 
search uitgevoerd om ionkanalen (die in planten ook door FC worden beïnvloed) en 
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transporters te identificeren die een C-terminale tip hebben vergelijkbaar met de plant         
H
+
-ATPase. Deze tip zou de binding van FC in combinatie met een 14-3-3 eiwit mogelijk 
moeten maken en een selectieve modulatie van een ionkanaal of transporter zou het antitumor 
effect van de IFN /FC behandeling kunnen verklaren. Verschillende transporters en 
ionkanalen zijn geïdentificeerd in de database search, waarvan de meeste nieuwe potentiële 
targets zijn. Alleen van de TASK kanalen (TASK1 en TASK3) was al een interactie tussen 
hun C-terminale tip en 14-3-3 eiwitten bekend. 
Voordat wij het effect van FC op de TASK kanalen hebben bestudeerd, hebben wij eerst de 
aanwezige ionkanalen in OVCAR3 cellen in het algemeen geanalyseerd (hoofdstuk 3). 
Hieruit bleek dat OVCAR3 cellen voornamelijk K
+
 kanalen bevatten en een klein aantal     
Na
+
 kanalen. De uitwaartse K
+
 stroom wordt vergroot wanneer de extracellulaire Ca
2+
 en 
Mg
2+
 concentratie wordt verlaagd en vervolgens weer geblokkeerd door een verlaging van de 
extracellulaire pH. Deze kenmerken geven aan dat TASK kanalen (waarschijnlijk) aanwezig 
zijn in OVCAR3 cellen. Naast TASK kanalen moeten ook andere K
+
 kanalen aanwezig zijn, 
omdat TASK kanalen niet de grote spannings-afhankelijke openingen hebben met een 
conductantie van 93 pS (± 1.7) en omdat een deel van de K
+
 stroom niet gevoelig is voor een 
veranderingen in de extracellulaire Ca
2+
 en Mg
2+
 concentratie of pH. 
In hoofdstuk 4 hebben wij het effect van FC op TASK kanalen en de C-terminale 
TASK/14-3-3 interactie onderzocht. We hebben bevestigd dat alle 14-3-3 isovormen een 
interactie aangaan met het C-terminale uiteinde van TASK1 en TASK3 en aangetoond dat 
deze interactie afhankelijk is van de fosforylering van het voorlaatste serine residu. Verder 
versterkt FC de TASK1/14-3-3 interactie tot 7 keer voor alle 14-3-3 isovormen. Expressie 
analyse heeft aangetoond dat zowel TASK1 als TASK5 tot expressie komen in OVCAR3 
cellen en van TASK1 kon ook het eiwit worden gedetecteerd met Western blotting. Een FC 
en/of IFN  behandeling resulteerde echter niet in een verandering van de TASK1 of TASK5 
expressie. OVCAR3 cellen hebben K
+
 kanalen met TASK-achtige karakteristieken, zoals 
beschreven in hoofdstuk 3. FC lijkt deze TASK kanalen te remmen in onbehandelde 
OVCAR3 cellen, terwijl FC TASK kanalen en een extra K
+
 kanaal remt in IFN  behandelde 
cellen; beiden op een 14-3-3 afhankelijke manier. Wij zijn echter niet in staat geweest om 
deze data onomstotelijk te reproduceren en ook de identiteit van het tweede FC geremde 
ionkanaal in IFN  behandelde cellen hebben wij niet kunnen achterhalen. 
Omdat wij de FC receptor verantwoordelijk voor de apoptose-inductie niet met zekerheid 
konden identificeren met de ionkanaal analyse, hebben wij ook een algemenere proteomics 
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benadering gevolgd om de FC receptor te identificeren. Hiervoor hebben wij FC gekoppeld 
aan magnetische beads (FC-Beads) en deze beads gebruikt voor een pull down in hoofdstuk 
5. De FC-Beads bonden endogeen 14-3-3 selectief uit een MCF7 of OVCAR3 cellysaat en 
met massaspectrometrie hebben we 21 eiwitten geïdentificeerd die waren gebonden 
aan/geëlueerd van de FC-Beads en beschikken over een C-terminale tip die een interactie met 
14-3-3 en FC mogelijk zou moeten maken. Van deze 21 eiwitten hebben we drie potentiële 
targets verder geanalyseerd: PMCA1 (een Ca
2+
-ATPase, gerelateerd aan de plant H
+
-ATPse), 
PABPC1 (polyadenylate-binding protein 1) en STAT1 (signal-transducer and activator of 
transcription 1). PABPC1 is geïdentificeerd in bijna alle humane 14-3-3 interactoom studies, 
alsmede in 2 onafhankelijke FC-Bead pull-downs en STAT1 speelt een belangrijke rol in IFN 
signalering. Voor de C-terminus van PMCA1 en de 14-3-3 isovormen konden we geen 
interactie aantonen middels een yeast two-hybrid assay. C-terminale peptiden van zowel 
PABPC1 als STAT1 interacteren wel met 14-3-3 eiwitten op een fosforylerings-afhankelijke 
manier in een anisotropie assay en FC verhoogt hun affiniteit. We konden echter geen 
interactie aantonen voor grotere C-terminale fragmenten van beide eiwitten in een yeast    
two-hybrid assay, maar het is ook niet bekend of deze fragmenten worden gefosforyleerd in 
gist. Meer experimenten zijn dan ook nodig om vast te stellen of PMCA1, PABPC1, STAT1 
of een van de andere geïdentificeerde eiwitten de FC receptor is in de tumorcellen. 
Bijna alle tumor cellijnen die wij geanalyseerd hebben reageren op de IFN /FC 
behandeling behalve de MCF7 borsttumor cellijn, bij welke wij nauwelijks een groeireductie 
konden detecteren. In tegenstelling tot de MDA-MB-231 borsttumor cellijn, die wel op de 
IFN /FC behandeling reageert, hebben MCF7 cellen een hoge estrogen receptor  (ER ) 
expressie. MCF7 cellen zijn afhankelijk van de activiteit van ER  voor hun groei en 
overleving en een blokkering van de ER  activiteit met anti-oestrogenen, zoals tamoxifen 
(TAM), is dan ook de belangrijkste therapeutische strategie die momenteel gebruikt wordt 
tegen ER
+
 borsttumoren. In hoofdstuk 6 hebben wij het effect van FC op de ER  bestudeerd 
en rapporteren een nieuw ER  regulerend mechanisme, waarbij de C-terminale tip van ER  
en 14-3-3 eiwitten een belangrijke rol spelen. ER  bevat een C-terminaal mode-III 14-3-3 
bindingsmotief en we hebben aangetoond dat de C-terminus een interactie aangaat met 14-3-3 
eiwitten. Deze interactie wordt versterkt door ligand binding aan ER  en is afhankelijk van de 
fosforylering van de voorlaatste threonine van ER , T
594
. FC verhoogt de ER /14-3-3 
affiniteit van het gefosforyleerde ER  peptide met alle 14-3-3 isovormen, behalve 14-3-3 . 
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Verder wordt het [FC/ER /14-3-3]-complex ook gevormd met endogene MCF7 eiwitten en 
vermindert FC de estradiol (E2) geïnduceerde MCF7 groei. Dit wordt waarschijnlijk 
veroorzaakt door een verminderde ER  activiteit als gevolg van de FC behandeling in vivo. 
De T
594
A mutatie verhoogt ook de ligand geïnduceerde ER  dimerisatie en de transcriptionele 
activiteit van ER  in vivo. Gecombineerd, resulteert deze data in een model waarbij             
C-terminale 14-3-3 binding aan het ER  F-domein, na T
594
 fosforylatie, de ER  dimerisatie 
voorkomt die nodig is voor een volledige activering van de receptor. Hiermee tonen wij het 
onderliggende mechanisme achter de rol van het C-terminale F-domein in de regulatie van 
ER  dimerisatie en activering aan en bieden een nieuwe behandelingsoptie met behulp van 
kleine liganden zoals FC die de ERα activiteit beïnvloeden door binding buiten het ligand 
binding domain (LBD). 
 
Samengevat, toont dit proefschrift het belang en de potentie aan van kleine moleculen 
zoals FC, met betrekking tot de beïnvloeding van eiwit/eiwit-interacties en het reguleren van 
eiwit activiteit. Hoewel het werkingsmechanisme van FC in de diverse tumorcellen nog niet 
geheel duidelijk is, lijkt het selectief en celtype afhankelijk verschillende cellulaire processen 
en eiwit/eiwit-interacties te beïnvloeden waardoor de groei en levensvatbaarheid van 
tumorcellen afneemt. 
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Aangezien ik dit proefschrift en mijn promotieonderzoek uiteraard niet in mijn eentje voor 
elkaar heb gekregen zijn er een aantal mensen die ik wil bedanken. Laat ik beginnen met het 
bedanken van de leden van mijn leescommissie, voor het lezen en het geven van de laatste 
nuttige commentaren en aanpassingen, waardoor ik mijn promotie/verdediging met 
vertrouwen tegemoet ga. 
Dan zijn er nog een aantal mensen die ik persoonlijk wil bedanken. Uiteraard als eerste 
Bert: Bedankt voor deze kans en al je vertrouwen in mij! Ik heb altijd veel vrijheid en 
vertrouwen van je gekregen en de mogelijkheid om veel verschillende leuke dingen te doen. 
Je kon bij jou altijd lekker makkelijk even binnen lopen met data, voor advies, een praatje of 
wat dan ook. Dit alles samen met de altijd leuke discussies over o.a. onderzoek hebben er 
voor gezorgd dat ik een geweldige tijd heb gehad op de VU, waar ik je erg dankbaar voor ben. 
De andere mensen van het lab die achter zijn gebleven, met als eerste Daan die er van 
begin tot eind bij was. Je was een gezellige ('af en toe' chaotische) druktemaker die altijd voor 
leven op het lab wist te zorgen. Altijd enthousiast over resultaten en goed in het actief mee 
denken en voor allerlei discussies, waar dan ook over. Iets wat ik altijd erg gewaardeerd heb 
in je. Verder heel erg bedankt voor al het werk waarmee je me geholpen hebt! Nu alleen nog 
een keer echt (samen met Bert) gaan fietsen! Mijn kamergenoten. Paula: Bedankt voor alle 
cloneringen! Altijd fijn om te weten dat er een back-up is, die het wel kan. Verder uiteraard 
ook voor alle gezelligheid, soesjes en een kijkje in de wonderlijke wereld van Paula; waarin 
o.a. werkbesprekingen nooit langer dan 20 sec p.p. duren en om alles te lachen valt als het 
nodig is. Pedro: Je Nederlands is vast nog goed genoeg, ondanks je gebrekkige oefening nu ik 
weg ben. Jij ook bedankt voor alle gezelligheid en dat je mij het gevoel gaf in sommige 
opzichten onmisbaar te zijn. Selena: Ook al werkte je maar kort 'beneden', ik kende je al wel 
van 'boven'. Je was altijd een gezellige aanvulling met kletsen, o.a. over mannen en hun 
(gebrek aan) logica. Verder was je ook zeer nuttig bij het opstarten van de vibrating probe! De 
andere 'vaste' mensen van het lab. Rinse: Leuk dat je het patch clampen overgenomen hebt! 
Alleen jammer dat je altijd de koffie op maakte als je veel achter je computer zat, maar dat zij 
je vergeven. Jing: Although you had to cope with Daniel on one side and Rinse on the other 
you somehow always seemed to manage. Well done! Thank you for the insight in the Chinese 
kitchen and life in China in general. Keep up the good work in the lab and the control over 
Daniel (as far as that's possible)! 
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Wat de mensen betreft die vóór mij zijn vertrokken, heb ik het genoegen gehad om te 
mogen werken met Petra (die het ouderschap altijd perfect leek te kunnen te combineren met 
onderzoek) en Peter (die altijd nuttig was door zijn duidelijke ideeën over onderzoek in het 
algemeen en hoe wat te doen) die er mede voor gezorgd hebben dat ik me van het begin af aan 
welkom en thuis voelde op het lab. En later ook Roos die 's ochtends altijd tijd had voor een 
gezellig praatje als begin van de dag. 
And furthermore all the students I supervised. I really enjoyed working with you and it was 
nice to experience your enthusiasm (for research). Jan (bedankt voor het samen onderzoek 
ontdekken en het helpen opstarten van mijn project), Chantal (voor het eindeloos doen van 
bindingstudies. Waarbij er elke keer weer wat moois uit leek te komen, maar toch net niet...), 
Jean (despite that you didn't learn Dutch as planned, you did learn plenty of other things! And 
alsways in good spirit.), Pauline (nice to see how much somebody can learn about research, 
and thanks for all the anisotropy measurements), Ilse (bedankt voor het in alle rust helpen 
opzetten van de Y2H), Hoda (nooit geweten dat iemand zoveel geduld kan hebben en zo 
vrolijk en positief kan blijven wat er ook [thuis] gebeurt; wat dat betreft echt een voorbeeld 
voor anderen), Dharjath (Calm, but focussed. You really deserve the PhD position you 
created. I hope that I also contributed something to it.), Simone (lekker enthousiast en een 
goed doorzettingsvermogen), Sjors (ondanks dat je maar half onder mij viel was je toch een 
ideale student. 1 maal iets uitleggen en daarna begeleidde je jezelf zo ongeveer), Zeliha (altijd 
een gezellige kletskous, maar daarnaast ook zeker een enthousiaste harde werker), en als 
laatste Laurens (met wie ik leuk hebben kunnen samenwerken met de vieze schimmels). For 
all of you, thanks for helping out with various parts of my research and that I could be part of 
your education. 
Verder uiteraard ook iedereen van 'boven'. Holger uiteraard als mijn promotor, maar ook 
alle anderen (Dirk, Yves, Marijke, Petra, Henk, Rieky, Annelies, Froukje, Zorica, Lu, en 
Ovidu). Ondanks dat ik jullie niet dagelijks sprak, was het altijd gezellig met verjaardagen, 
borrels, uitjes en de mosselmaaltijd. En natuurlijk ook Anna met wie het regelmatig gezellig 
kletsen was in de trein terug naar Weesp of tijdens een wandeling door de sneeuw naar huis. 
Daarnaast ook Hans (Lodder) die altijd direct klaar stond bij alle problemen en vragen met 
betrekking tot de patch clamp, en zonder wiens hulp en kennis ik waarschijnlijk nooit 1 
meting voor elkaar gekregen had. Laat staan alles wat ik nu gemeten heb, incl. de TEVC 
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metingen. Sander en Connie van de proteomics groep bij het CCA, die veel van mijn samples 
met spoed hebben willen meten. 
En 'last but not least', mijn familie! Omdat zij mij altijd met alles steunen en altijd voor mij 
klaar staan wanneer en waarmee dat ook nodig is. Voor hun liefde en interesse in mij en wat 
ik doe. Mijn zusje (die stiekem toch altijd mijn grote zus zal blijven) daarnaast ook voor alle 
moeite van het doorkijken van mijn proefschrift op domme inconsistenties/foutjes. En in het 
bijzonder natuurlijk Michel. Voor al zijn geduld met mij, o.a. als ik weer eens te laat meldde 
dat ik later thuis kwam en hij daardoor ik de problemen kwam met koken, maar vooral ook 
om wie/wat hij voor mij is. Iemand die mij laat zijn wie ik ben en die er altijd voor me is! 
Voor al deze mensen (en ook iedereen die ik nog vergeten ben), nogmaals heel erg bedankt 
voor alle hulp, vertrouwen en steun in de afgelopen jaren. 
 
Ingrid 
